var title_f9_33_9744="Mobile aortic dissection flap on TEE";
var content_f9_33_9744=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"videoplayer\" h264=\"./images/CARD/67626/teeaodis_conv.mp4?title=Mobile+aortic+dissection+flap+on+TEE\" style=\"width:431px;height:322px\">",
"  </div>",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Mobile aortic dissection flap on transesophageal echocardiography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 262px; height: 300px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The transesophageal echocardiogram shows a large dissection of the aorta. The intimal flap (arrow) is flail, moving widely within the aorta and spontaneous echo contrast can be seen within the false lumen, suggesting turbulent blood flow.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Thomas Binder, MD. University of Vienna.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_33_9744=[""].join("\n");
var outline_f9_33_9744=null;
var title_f9_33_9745="Dexketoprofen: International drug information";
var content_f9_33_9745=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"18\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Dexketoprofen: International drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list fbnlist drugH1Div drugBrandNames\" id=\"F4304148\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     International Brand Names",
"    </span>",
"    <ul>",
"     <li>",
"      Desketo (IT);",
"     </li>",
"     <li>",
"      Enantyum (ES, IT);",
"     </li>",
"     <li>",
"      Ketesse (CH, ES, IT, LU);",
"     </li>",
"     <li>",
"      Quiralam (ES);",
"     </li>",
"     <li>",
"      Sympal (DE)",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1978467\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Analgesic, Nonsteroidal Anti-inflammatory Drug",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block iuse drugH1Div\" id=\"F1978470\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Reported Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Short-term treatment of mild-to-moderate pain, including dysmenorrhoea",
"    </p>",
"   </div>",
"   <div class=\"block idos drugH1Div\" id=\"F1978466\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Range",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Oral:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Children: Not recommended",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Adults: 12.5 mg every 4-6 hours or 25 mg every 8 hours; maximum: 75 mg daily",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justified;\">",
"     Elderly: Maximum dose: 50 mg daily (unless well tolerated)",
"    </p>",
"   </div>",
"   <div class=\"block prod-avail drugH1Div\" id=\"F11821249\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Product Availability",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Product available in various countries; not currently available in the U.S.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F1978469\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tablet, scored: 25 mg",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10364 Version 28.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-115.25.216.6-E05BAE8337-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_33_9745=[""].join("\n");
var outline_f9_33_9745=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F4304148\">",
"      International Brand Names",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978467\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978470\">",
"      Reported Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978466\">",
"      Dosage Range",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F11821249\">",
"      Product Availability",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1978469\">",
"      Dosage Forms",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10364\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_INT/10364|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_33_9746="Patient information: Pinworms (The Basics)";
var content_f9_33_9746=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/83446\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"         Digestive system",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Pinworms (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/pinworms-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H110477881\">",
"      <span class=\"h1\">",
"       What are pinworms?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Pinworms are small worms that can live in people&rsquo;s intestines (",
"      <a class=\"graphic graphic_figure graphicRef66110 \" href=\"UTD.htm?28/27/29107\">",
"       figure 1",
"      </a>",
"      ). They are the most common cause of worm infections in the US. Pinworm infections usually affect school age children.",
"     </p>",
"     <p>",
"      People who have pinworms can have intense itching around their anus. That&rsquo;s because the female worms lay their eggs in the folds of skin around the anus.",
"     </p>",
"     <p>",
"      People catch pinworms when they swallow pinworm eggs. This can happen when someone with a pinworm infection scratches their anus, touches things that other people might touch, and leaves eggs behind. Then, when someone touches the eggs and touches their mouth, they can swallow the eggs without knowing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H110477896\">",
"      <span class=\"h1\">",
"       What are the symptoms of pinworms?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Many people with pinworms don&rsquo;t have any symptoms. When people do have symptoms, the most common symptom is itching around the anus. The itching happens most often at night and can cause trouble sleeping. Some people with a severe case of pinworms might also have belly pain, nausea, and vomiting.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H110477911\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have severe itching around the anus, especially at night, you should see your doctor or nurse.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H110477926\">",
"      <span class=\"h1\">",
"       Is there a test for pinworms?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. After learning about your symptoms, your doctor or nurse will have you do a &ldquo;scotch tape&rdquo; test. This test involves taking a piece of scotch tape and pressing it on the skin around your anus. If you have pinworms, the eggs will stick to the tape. The doctor or nurse will look at the tape under a microscope to see if there are pinworm eggs on the tape. (You can&rsquo;t see the eggs by just looking at the tape.) It is best to apply the tape at night or first thing in the morning before you bathe.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H110477941\">",
"      <span class=\"h1\">",
"       How are pinworms treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Pinworms are treated with medicine. People being treated usually take a pill when they first find out they have pinworms. Then, they take another pill 2 weeks later.",
"     </p>",
"     <p>",
"      If you have pinworms, your doctor or nurse will probably want all the people who live with you to take the medicine. This is because pinworms spread easily between people in the same home.",
"     </p>",
"     <p>",
"      Even after you are treated, the pinworms might still come back.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H110477956\">",
"      <span class=\"h1\">",
"       Is there anything else I should do?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you or anyone in your family has pinworms, you all should:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Keep your fingernails clipped short.",
"       </li>",
"       <li>",
"        Wash your hands often with soap and water.",
"       </li>",
"       <li>",
"        Take a shower or bath every day. (In the morning is best.)",
"       </li>",
"       <li>",
"        Wash your clothes, towels, and bed linens often.",
"       </li>",
"       <li>",
"        Try not to scratch around your anus or between your legs.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      See your doctor or nurse if you start having itching around your anus again.",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?9/33/9746?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 83446 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-F6FDDAB425-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_33_9746=[""].join("\n");
var outline_f9_33_9746=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110477881\">",
"      What are pinworms?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110477896\">",
"      What are the symptoms of pinworms?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110477911\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110477926\">",
"      Is there a test for pinworms?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110477941\">",
"      How are pinworms treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H110477956\">",
"      Is there anything else I should do?",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/83446\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?28/27/29107\">",
"      Digestive system",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_33_9747="Anatomy of the mandible";
var content_f9_33_9747=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F56004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F56004&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 525px\">",
"   <div class=\"ttl\">",
"    Anatomy of the mandible",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 505px; height: 378px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Fractures of the condyle are most common in children younger than 10 years, whereas fractures of the symphysis, body, and ramus are more common in older children. Fractures at multiple sites occur in approximately 40 to 60 percent of cases and are more common among children older than 13 years of age.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_33_9747=[""].join("\n");
var outline_f9_33_9747=null;
var title_f9_33_9748="Pentosan polysulfate sodium: Patient drug information";
var content_f9_33_9748=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Pentosan polysulfate sodium: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36467?source=see_link\">",
"     see \"Pentosan polysulfate sodium: Drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F182887\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Elmiron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F182888\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Elmiron&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10026089\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691608",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to ease pain, swelling, and irritation of the bladder.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10026088\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702710",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to pentosan polysulfate sodium or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10026093\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697237",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have had any problems with a blood thinner called heparin or low platelet counts, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697287",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease or spleen disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697633",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell dentists, surgeons, and other doctors that you use this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697795",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may bleed more easily. Be careful and avoid injury. Use a soft toothbrush and an electric razor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697622",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with your doctor before using products that have aspirin, blood thinners, garlic, ginseng, ginkgo, ibuprofen or like products, pain drugs, or vitamin E.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10026094\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698272",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Upset stomach or throwing up. Many small meals, good mouth care, sucking hard, sugar-free candy, or chewing sugar-free gum may help.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698114",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hair loss. Hair most often grows back when this drug is stopped.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10026096\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698485",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow up with your doctor after using this drug for 3 months.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10026091\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695887",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take on an empty stomach. Take 1 hour before or 2 hours after meals.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695899",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with a full glass of water.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10026092\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10026097\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10026098\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 10964 Version 34.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-EC2EE36D8B-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_33_9748=[""].join("\n");
var outline_f9_33_9748=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182887\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F182888\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026089\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026088\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026093\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026094\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026096\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026091\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026092\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026097\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10026098\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36467?source=related_link\">",
"      Pentosan polysulfate sodium: Drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_33_9749="Insulin injection sites PI";
var content_f9_33_9749=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F74635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F74635&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Where to give an insulin shot",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 607px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The shaded areas can be used for insulin shots. You should change areas so that you do not use the same area each time. Insulin gets into the blood more quickly when injected into the belly, as compared to the arms or legs.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_33_9749=[""].join("\n");
var outline_f9_33_9749=null;
var title_f9_33_9750="Pulmonary manifestations of HIV-associated lymphoma";
var content_f9_33_9750=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Pulmonary manifestations of HIV-associated lymphoma",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/33/9750/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/33/9750/contributors\">",
"     Talmadge E King, Jr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/33/9750/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/33/9750/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/33/9750/contributors\">",
"     Arnold S Freedman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/33/9750/contributors\">",
"     Kevin R Flaherty, MD, MS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/33/9750/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/33/9750/contributors\">",
"     Helen Hollingsworth, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/33/9750/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 1, 2008.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;HIV infection is associated with an increased incidence of lymphoma. Approximately 80 to 90 percent of HIV-associated lymphomas are pathologically intermediate or high grade, and almost all are non-Hodgkin lymphoma (NHL) of B cell origin [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/1\">",
"     1",
"    </a>",
"    ]. Most patients show widespread, rather than nodal disease, frequently involving the central nervous system (CNS), gastrointestinal tract, lungs, bone marrow, and mucocutaneous tissues [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. Burkitt and Hodgkin lymphoma are also associated with HIV infection but are less common [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Rare cases of primary pulmonary lymphoma have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=see_link\">",
"     \"AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link\">",
"     \"HIV infection and malignancy: Management considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Primary effusion lymphoma (PEL) is a rare aggressive tumor seen in HIV infected patients, in association with KS-associated herpes",
"    <span class=\"nowrap\">",
"     virus/human",
"    </span>",
"    herpes virus 8 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/9\">",
"     9",
"    </a>",
"    ]. It has a predisposition to arise in body cavities, such as the pleural space, pericardium, and peritoneum. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=see_link\">",
"     \"AIDS-related lymphomas: Primary effusion lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Prior to the introduction of highly active retroviral therapy (HAART), non-Hodgkin lymphoma (NHL) occurred in 2 to 5 percent of HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. This is the same frequency of lymphoma as seen in other groups of immunosuppressed patients, but represents a",
"    <strong>",
"     marked increase",
"    </strong>",
"    (eg, 100 to 600 fold) over the rate for the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/1,12,13\">",
"     1,12,13",
"    </a>",
"    ]. NHL occurs in all risk groups for HIV infection and at all CD4 counts but is more frequent in those with more severe immunosuppression [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Since the introduction of HAART, the incidence of NHL has declined in the developed world [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/11,14\">",
"     11,14",
"    </a>",
"    ]. One study in Germany found that the incidence post-1985 declined to 3.7 per 1000 patient years [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HIV is also associated with increased incidence or severity of other malignancies that involve the pulmonary system (eg, Kaposi's sarcoma, lung cancer). These are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21623?source=see_link\">",
"     \"Pulmonary involvement in AIDS-related Kaposi sarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ETIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple factors probably contribute to the pathogenesis of lymphoma in HIV-infected patients [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/15\">",
"     15",
"    </a>",
"    ]. Epstein-Barr virus (EBV) appears to be involved in many cases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/16,17\">",
"     16,17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=see_link\">",
"     \"Virology of Epstein-Barr virus\"",
"    </a>",
"    .) It has been suggested that chronic B cell stimulation, induced by EBV or other factors related to HIV, may lead to DNA rearrangements and subsequent abnormalities in oncogene function [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/15,18\">",
"     15,18",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      C-myc expression is a marker for many AIDS-associated lymphomas [",
"      <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/18\">",
"       18",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Serum levels of soluble CD23, a B cell stimulatory factor, have been shown to be markedly elevated in AIDS patients with lymphoma, as compared to those without lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/19\">",
"       19",
"      </a>",
"      ]. Soluble CD44, a cell surface adhesion molecule involved in inflammatory cell function, tumor cell growth and metastasis, has been found to be increased prior to the development of NHL [",
"      <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/20\">",
"       20",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The frequency of clinical pulmonary involvement with NHL ranges from 6 to 31 percent, while autopsy studies show a higher percentage [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/3,21-23\">",
"     3,21-23",
"    </a>",
"    ]. The lung is occasionally the initial site of disease, but more often, it is involved in association with other sites [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/24\">",
"     24",
"    </a>",
"    ]. Patients with NHL typically present with stage B symptoms of fever, weight loss, and night sweats. These systemic symptoms are compatible with the widespread nature of the disease. About 80 to 90 percent have respiratory symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/25\">",
"     25",
"    </a>",
"    ]. Pulmonary involvement by lymphoma has been described in the following sites:",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Parenchyma",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most frequently described radiographic appearances of parenchymal NHL are multiple nodular densities, masses, and diffuse interstitial infiltrates [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/7,8,22,26,27\">",
"     7,8,22,26,27",
"    </a>",
"    ]. The latter presentation can be difficult to distinguish from opportunistic infections. Cavitary masses have also been described [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/6,17\">",
"     6,17",
"    </a>",
"    ]. Pulmonary symptoms are usually nonspecific.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pleura",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pleural effusions are common, occurring in up to 70 percent of patients with parenchymal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. They can occur without parenchymal disease, whereas Kaposi's sarcoma rarely causes an effusion in the absence of parenchymal disease [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/29\">",
"     29",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21623?source=see_link\">",
"     \"Pulmonary involvement in AIDS-related Kaposi sarcoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Lymphoma-related effusions may be unilateral or bilateral and range in size from small to large [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Effusions are exudative and lactic dehydrogenase is frequently elevated [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/25\">",
"     25",
"    </a>",
"    ]. One case of empyema as a presenting manifestation of NHL has been described [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/30\">",
"     30",
"    </a>",
"    ]. Primary effusion lymphoma (PEL) accounts for 4 percent or less of AIDS related lymphomas and is discussed separately [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=see_link\">",
"     \"AIDS-related lymphomas: Primary effusion lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Adenopathy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Involvement of the intrathoracic nodes is reported in 50 to 60 percent of AIDS-associated lymphoma, which is less common than its occurrence with lymphoma in the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/22,25,27,31\">",
"     22,25,27,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Endobronchial lesions",
"    </span>",
"    &nbsp;&mdash;&nbsp;A few cases of endobronchial involvement have been reported; in one patient, the lesion was related to erosion of a node into the airway [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/32,33\">",
"     32,33",
"    </a>",
"    ]. These lesions can occasionally cause life-threatening problems [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the described cases of parenchymal lymphoma have required open lung biopsy for diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/22,24,27\">",
"     22,24,27",
"    </a>",
"    ]. Nuclear scanning may suggest the presence of parenchymal lymphoma, which is avid for both gallium and thallium [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/35\">",
"     35",
"    </a>",
"    ], but for definitive diagnosis, a biopsy is still necessary. Transbronchial and open lung biopsy have reported yields of up to 58 percent and 75 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/25\">",
"     25",
"    </a>",
"    ], and transthoracic needle biopsy was diagnostic in 5 of 10 patients in one series [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/17\">",
"     17",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3642?source=see_link\">",
"     \"Transbronchial needle aspiration\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=see_link\">",
"     \"Evaluation of mediastinal masses\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thoracentesis and pleural biopsy are frequently helpful with lymphomatous effusions; cytology is almost always positive in primary effusion lymphoma [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/2,27,28,36\">",
"     2,27,28,36",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=see_link\">",
"     \"Diagnostic evaluation of a pleural effusion in adults: Initial testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tests such as flow cytometry, immunoglobulin variable heavy chain gene (IGHV) analysis, immunophenotypic analysis, and evidence of Epstein-Barr virus or human herpes virus 8 infection may be helpful. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7242?source=see_link\">",
"     \"AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=see_link\">",
"     \"Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     PROGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The overall outcome remains poor in patients with HIV-associated lymphoma. Most studies show an improvement in response rates and survival in the presence of highly active antiretroviral therapy (HAART) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/37-40\">",
"     37-40",
"    </a>",
"    ]. One study reports a two year survival of 41 percent and another study showed a median survival time of 43.2 months [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/37,38\">",
"     37,38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Poor prognostic factors in these patients included:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      History of AIDS before the diagnosis of lymphoma.",
"     </li>",
"     <li>",
"      Bone marrow involvement.",
"     </li>",
"     <li>",
"      Low Karnofsky performance status (less than 70 percent) (",
"      <a class=\"graphic graphic_table graphicRef58785 \" href=\"UTD.htm?2/11/2236\">",
"       table 1",
"      </a>",
"      ). This includes patients unable to work but who can still care for their personal needs.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A complete response to therapy was seen in only 25 percent of patients with one or more of these poor prognostic factors. However, a complete response only prolonged mean survival from 3.4 to 6.3 months.",
"   </p>",
"   <p>",
"    Some long-term survivors have been reported in patients with NHL and good risk factors. The state of immune suppression at the time of development of lymphoma plays a major role in prognosis, as with other complications of HIV infection.",
"   </p>",
"   <p>",
"    No data are available that specifically address survival of patients with isolated pulmonary lymphoma. However, pulmonary disease alone is rarely a cause of mortality in NHL.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The treatment of the HIV-associated lymphomas, systemic non-Hodgkin lymphoma, Hodgkin lymphoma, Burkitt's lymphoma, and primary effusion lymphoma is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=see_link\">",
"     \"AIDS-related lymphomas: Treatment of systemic lymphoma\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link\">",
"     \"HIV infection and malignancy: Management considerations\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36217?source=see_link\">",
"     \"Treatment of Burkitt leukemia/lymphoma in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=see_link\">",
"     \"AIDS-related lymphomas: Primary effusion lymphoma\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Pleural sclerosis is occasionally required in patients with large and recurring pleural effusions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9750/abstract/28\">",
"     28",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=see_link\">",
"     \"Management of malignant pleural effusions\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1036179\">",
"    <span class=\"h1\">",
"     ACKNOWLEDGMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The editorial staff at UpToDate, Inc. would like to acknowledge Dr. Dorothy White, who contributed to an earlier version of this topic review.",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/1\">",
"      Beral V, Peterman T, Berkelman R, Jaffe H. AIDS-associated non-Hodgkin lymphoma. Lancet 1991; 337:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/2\">",
"      Knowles DM, Chamulak GA, Subar M, et al. Lymphoid neoplasia associated with the acquired immunodeficiency syndrome (AIDS). The New York University Medical Center experience with 105 patients (1981-1986). Ann Intern Med 1988; 108:744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/3\">",
"      Lowenthal DA, Straus DJ, Campbell SW, et al. AIDS-related lymphoid neoplasia. The Memorial Hospital experience. Cancer 1988; 61:2325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/4\">",
"      Kaplan LD, Abrams DI, Feigal E, et al. AIDS-associated non-Hodgkin's lymphoma in San Francisco. JAMA 1989; 261:719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/5\">",
"      Pluda JM, Yarchoan R, Jaffe ES, et al. Development of non-Hodgkin lymphoma in a cohort of patients with severe human immunodeficiency virus (HIV) infection on long-term antiretroviral therapy. Ann Intern Med 1990; 113:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/6\">",
"      Bazot M, Cadranel J, Benayoun S, et al. Primary pulmonary AIDS-related lymphoma: radiographic and CT findings. Chest 1999; 116:1282.",
"     </a>",
"    </li>",
"    <li>",
"     Bazot, M, Canel, J, Benayoun, S, et al. Primary pulmonary AIDS related lymphoma: radiographic and CT findings. Chest 1999: 116:1282.",
"    </li>",
"    <li>",
"     Cortot, AB, Cottin, V, Issartel, B, et al. Pulmonary MALT lymphoma revealing AIDS. Rev Mal Respir 2006: 23:353.",
"    </li>",
"    <li>",
"     Boulanger, E, Gerard, L, Gabarre, J, et al. Prognostic factors and outcome of human herpesvirus 8-associated primary effusion lymphoma in patients with AIDs. J Clin Oncol 2005: 23:4372.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/10\">",
"      DeMario MD, Liebowitz DN. Lymphomas in the immunocompromised patient. Semin Oncol 1998; 25:492.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/11\">",
"      Wolf T, Brodt HR, Fichtlscherer S, et al. Changing incidence and prognostic factors of survival in AIDS-related non-Hodgkin's lymphoma in the era of highly active antiretroviral therapy (HAART). Leuk Lymphoma 2005; 46:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/12\">",
"      Dal Maso L, Franceschi S. Epidemiology of non-Hodgkin lymphomas and other haemolymphopoietic neoplasms in people with AIDS. Lancet Oncol 2003; 4:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/13\">",
"      Cot&eacute; TR, Biggar RJ, Rosenberg PS, et al. Non-Hodgkin's lymphoma among people with AIDS: incidence, presentation and public health burden. AIDS/Cancer Study Group. Int J Cancer 1997; 73:645.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/14\">",
"      Grulich AE, Li Y, McDonald AM, et al. Decreasing rates of Kaposi's sarcoma and non-Hodgkin's lymphoma in the era of potent combination anti-retroviral therapy. AIDS 2001; 15:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/15\">",
"      Herndier BG, Kaplan LD, McGrath MS. Pathogenesis of AIDS lymphomas. AIDS 1994; 8:1025.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/16\">",
"      Hamilton-Dutoit SJ, Pallesen G, Karkov J, et al. Identification of EBV-DNA in tumour cells of AIDS-related lymphomas by in-situ hybridisation. Lancet 1989; 1:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/17\">",
"      Ray P, Antoine M, Mary-Krause M, et al. AIDS-related primary pulmonary lymphoma. Am J Respir Crit Care Med 1998; 158:1221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/18\">",
"      Pelicci PG, Knowles DM 2nd, Arlin ZA, et al. Multiple monoclonal B cell expansions and c-myc oncogene rearrangements in acquired immune deficiency syndrome-related lymphoproliferative disorders. Implications for lymphomagenesis. J Exp Med 1986; 164:2049.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/19\">",
"      Yawetz S, Cumberland WG, van der Meyden M, Mart&iacute;nez-Maza O. Elevated serum levels of soluble CD23 (sCD23) precede the appearance ofacquired immunodeficiency syndrome--associated non-Hodgkin's lymphoma. Blood 1995; 85:1843.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/20\">",
"      Breen EC, Epeldegui M, Boscardin WJ, et al. Elevated levels of soluble CD44 precede the development of AIDS-associated non-Hodgkin's B-cell lymphoma. AIDS 2005; 19:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/21\">",
"      Levine AM, Sullivan-Halley J, Pike MC, et al. Human immunodeficiency virus-related lymphoma. Prognostic factors predictive of survival. Cancer 1991; 68:2466.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/22\">",
"      Polish LB, Cohn DL, Ryder JW, et al. Pulmonary non-Hodgkin's lymphoma in AIDS. Chest 1989; 96:1321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/23\">",
"      Loureiro C, Gill PS, Meyer PR, et al. Autopsy findings in AIDS-related lymphoma. Cancer 1988; 62:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/24\">",
"      Poelzleitner D, Huebsch P, Mayerhofer S, et al. Primary pulmonary lymphoma in a patient with the acquired immune deficiency syndrome. Thorax 1989; 44:438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/25\">",
"      Eisner MD, Kaplan LD, Herndier B, Stulbarg MS. The pulmonary manifestations of AIDS-related non-Hodgkin's lymphoma. Chest 1996; 110:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/26\">",
"      Collins J, M&uuml;ller NL, Leung AN, et al. Epstein-Barr-virus-associated lymphoproliferative disease of the lung: CT and histologic findings. Radiology 1998; 208:749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/27\">",
"      Sider L, Weiss AJ, Smith MD, et al. Varied appearance of AIDS-related lymphoma in the chest. Radiology 1989; 171:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/28\">",
"      Sider L, Horton ES. Pleural effusion as a presentation of AIDS-related lymphoma. Invest Radiol 1989; 24:150.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/29\">",
"      O'Brien RF, Cohn DL. Serosanguineous pleural effusions in AIDS-associated Kaposi's sarcoma. Chest 1989; 96:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/30\">",
"      Forbes AD, Marchioro TL, Schmidt RA, et al. Acquired immunodeficiency syndrome-related lymphoma of the lung presenting as empyema thoracis. Ann Thorac Surg 1994; 57:216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/31\">",
"      Heitzman ER. Pulmonary neoplastic and lymphoproliferative disease in AIDS: a review. Radiology 1990; 177:347.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/32\">",
"      Judson MA, Sahn SA. Endobronchial lesions in HIV-infected individuals. Chest 1994; 105:1314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/33\">",
"      Keys TC, Judson MA, Reed CE, Sahn SA. Endobronchial HIV associated lymphoma. Thorax 1994; 49:525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/34\">",
"      Chaouat A, Fraisse P, Kessler R, et al. A life-threatening tracheal localization of lymphoma in a patient with AIDS. Chest 1993; 103:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/35\">",
"      Lee VW, Fuller JD, O'Brien MJ, et al. Pulmonary Kaposi sarcoma in patients with AIDS: scintigraphic diagnosis with sequential thallium and gallium scanning. Radiology 1991; 180:409.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/36\">",
"      Walts AE, Shintaku IP, Said JW. Diagnosis of malignant lymphoma in effusions from patients with AIDS by gene rearrangement. Am J Clin Pathol 1990; 94:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/37\">",
"      Biggar RJ, Engels EA, Ly S, et al. Survival after cancer diagnosis in persons with AIDS. J Acquir Immune Defic Syndr 2005; 39:293.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/38\">",
"      Lim ST, Karim R, Tulpule A, et al. Prognostic factors in HIV-related diffuse large-cell lymphoma: before versus after highly active antiretroviral therapy. J Clin Oncol 2005; 23:8477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9750/abstract/39\">",
"      Hagemeister FB, Khetan R, Allen P, et al. Stage, serum LDH, and performance status predict disease progression and survival in HIV-associated lymphomas. Ann Oncol 1994; 5 Suppl 2:41.",
"     </a>",
"    </li>",
"    <li>",
"     Noy, A. Update on HIV lymphoma. Curr Oncol Rep 2007: 9:384.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4340 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-115.66.252.144-403C6C9E42-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_33_9750=[""].join("\n");
var outline_f9_33_9750=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ETIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL MANIFESTATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Parenchyma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pleura",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Adenopathy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Endobronchial lesions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      PROGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1036179\">",
"      ACKNOWLEDGMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PULM/4340\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PULM/4340|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/11/2236\" title=\"table 1\">",
"      Karnofsky performance status scale",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/4/7242?source=related_link\">",
"      AIDS-related lymphomas: Clinical manifestations, diagnosis, and staging of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/36/20042?source=related_link\">",
"      AIDS-related lymphomas: Epidemiology, risk factors, and pathobiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/15/30969?source=related_link\">",
"      AIDS-related lymphomas: Primary effusion lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/28/38346?source=related_link\">",
"      AIDS-related lymphomas: Treatment of systemic lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/7/16505?source=related_link\">",
"      Diagnostic evaluation of a pleural effusion in adults: Initial testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/56/35720?source=related_link\">",
"      Epidemiology, clinical manifestations, pathologic features, and diagnosis of Burkitt lymphoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/24/31111?source=related_link\">",
"      Evaluation of mediastinal masses",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/6/13416?source=related_link\">",
"      Management of malignant pleural effusions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/7/21623?source=related_link\">",
"      Pulmonary involvement in AIDS-related Kaposi sarcoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/35/3642?source=related_link\">",
"      Transbronchial needle aspiration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/23/36217?source=related_link\">",
"      Treatment of Burkitt leukemia/lymphoma in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/2/3114?source=related_link\">",
"      Virology of Epstein-Barr virus",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_33_9751="Calculator: Blood pressure percentiles for girls (2 to 17 years)";
var content_f9_33_9751=[" <div id=\"topicText\">",
"  <div id=\"mc3k\">",
"   <form action=\"\" id=\"BloodPressurePercentGirls_form\" name=\"BloodPressurePercentGirls_form\" onkeydown=\"clrResults();\" onkeyup=\"BloodPressurePercentGirls_fx();\" onreset=\"rrclr();\" onsubmit=\"return false;\">",
"    <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"100%\">",
"     <tr>",
"      <td bgcolor=\"#eeeeee\" width=\"1%\">",
"       <br/>",
"      </td>",
"      <td align=\"left\" bgcolor=\"#eeeeee\">",
"       <span class=\"medCalcFontTitleBox\">",
"        Calculator: Blood pressure percentiles for girls (2 to 17 years)",
"       </span>",
"      </td>",
"     </tr>",
"    </table>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_main\">",
"     <center>",
"      <table cellpadding=\"6\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"95%\">",
"       <tr>",
"        <td align=\"right\" width=\"50%\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Input:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table cellpadding=\"3\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Age",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Age_param\" onblur=\"BloodPressurePercentGirls_fx(); minMaxCheck();\" onchange=\"BloodPressurePercentGirls_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Age_unit\" onchange=\"BloodPressurePercentGirls_fx();\" style=\"width:105px;\">",
"              <option value=\"0.0833333333333333|0|mo\">",
"               mo",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|yr\">",
"               yr",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Height",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Height_param\" onblur=\"BloodPressurePercentGirls_fx(); minMaxCheck();\" onchange=\"BloodPressurePercentGirls_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Height_unit\" onchange=\"BloodPressurePercentGirls_fx();\" style=\"width:105px;\">",
"              <option selected=\"selected\" value=\"1|0|cm\">",
"               cm",
"              </option>",
"              <option value=\"2.54|0|in\">",
"               in",
"              </option>",
"              <option value=\"100|0|m\">",
"               m",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Systolic BP",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Systolic_BP_param\" onblur=\"BloodPressurePercentGirls_fx(); minMaxCheck();\" onchange=\"BloodPressurePercentGirls_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Systolic_BP_unit\" onchange=\"BloodPressurePercentGirls_fx();\" style=\"width:105px;\">",
"              <option value=\"10|0|cmHg\">",
"               cmHg",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mmHg\">",
"               mmHg",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\" width=\"42%\">",
"             <span class=\"medCalcFontOneBold\">",
"              Diastolic BP",
"             </span>",
"            </td>",
"            <td align=\"left\" nowrap=\"nowrap\" valign=\"top\" width=\"5%\">",
"             &nbsp;",
"             <input name=\"Diastolic_BP_param\" onblur=\"BloodPressurePercentGirls_fx(); minMaxCheck();\" onchange=\"BloodPressurePercentGirls_fx();\" size=\"6\" type=\"text\" value=\"\"/>",
"            </td>",
"            <td align=\"left\" valign=\"top\" width=\"115\">",
"             <select class=\"medCalcFontSelect\" name=\"Diastolic_BP_unit\" onchange=\"BloodPressurePercentGirls_fx();\" style=\"width:105px;\">",
"              <option value=\"10|0|cmHg\">",
"               cmHg",
"              </option>",
"              <option selected=\"selected\" value=\"1|0|mmHg\">",
"               mmHg",
"              </option>",
"             </select>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"        </td>",
"        <td align=\"left\" bgcolor=\"#eeeeee\">",
"         <center>",
"          <span class=\"medCalcFontIO\">",
"           Results:",
"          </span>",
"          <br/>",
"          &nbsp;",
"          <br/>",
"          <table bgcolor=\"#eeeeee\" cellspacing=\"4\" summary=\"MedCalc 3000 Table\">",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Height Percentile",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Height_Percentile_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"2\">",
"             &nbsp;",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Systolic BP Percentile",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Systolic_BP_Percentile_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              Diastolic BP Percentile",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"Diastolic_BP_Percentile_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"2\">",
"             &nbsp;",
"             <br/>",
"             <center>",
"              <span class=\"medCalcFontIO2\">",
"               Threshold for Stage II hypertension*",
"               <br/>",
"               (defined as 99th percentile plus 5 mmHg)",
"              </span>",
"             </center>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              SBP Threshold",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"SBP_Threshold_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td align=\"right\">",
"             <span class=\"medCalcFontOneBold\">",
"              DBP Threshold",
"             </span>",
"            </td>",
"            <td nowrap=\"nowrap\" valign=\"top\">",
"             &nbsp;",
"             <input name=\"DBP_Threshold_param\" onfocus=\"blur();\" size=\"6\" type=\"text\"/>",
"            </td>",
"           </tr>",
"           <tr>",
"            <td colspan=\"3\">",
"             &nbsp;",
"             <br/>",
"            </td>",
"           </tr>",
"          </table>",
"         </center>",
"         <br/>",
"         &nbsp;",
"         <br/>",
"         <center>",
"          <span class=\"medCalcFontOne\">",
"           <input name=\"reset\" type=\"reset\" value=\"Reset form\"/>",
"          </span>",
"         </center>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"      <tr>",
"       <td bgcolor=\"#eeeeee\" width=\"1%\">",
"        <br/>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <span class=\"medCalcFontTitleBox\">",
"         Systolic BP Percentile Interpretation",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"       <tr id=\"rr1_1\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &lt; 90:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Normal Systolic Blood Pressure",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_2\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &gt;= 90 and &lt; 95:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Prehypertensive Systolic Blood Pressure",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr1_3\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &gt;= 95:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Hypertensive Systolic Blood Pressure",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <table cellpadding=\"4\" cellspacing=\"0\" summary=\"MedCalc 3000 Table\" width=\"70%\">",
"      <tr>",
"       <td bgcolor=\"#eeeeee\" width=\"1%\">",
"        <br/>",
"       </td>",
"       <td align=\"left\" bgcolor=\"#eeeeee\">",
"        <span class=\"medCalcFontTitleBox\">",
"         Diastolic BP Percentile Interpretation",
"        </span>",
"       </td>",
"      </tr>",
"     </table>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <center>",
"      <table border=\"1\" cellpadding=\"4\" cellspacing=\"0\" summary=\"RRTable\">",
"       <tr id=\"rr2_1\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &lt; 90:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Normal Diastolic Blood Pressure",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr2_2\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &gt;= 90 and &lt; 95:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Prehypertensive Diastolic Blood Pressure",
"         </span>",
"        </td>",
"       </tr>",
"       <tr id=\"rr2_3\">",
"        <td align=\"right\" nowrap=\"nowrap\" style=\"border-right: 0px\">",
"         <span class=\"medCalcFontOneBold\">",
"          Percentile &gt;= 95:",
"         </span>",
"        </td>",
"        <td align=\"left\" style=\"border-left: 0px;\">",
"         <span class=\"medCalcFontOne\">",
"          Hypertensive Diastolic Blood Pressure",
"         </span>",
"        </td>",
"       </tr>",
"      </table>",
"     </center>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_hints\">",
"     <span class=\"medCalcFontOne\">",
"      Prehypertension is defined as Systolic and/or Diastolic BP &gt;= 90th percentile but &lt; 95th percentile, OR if BP exceeds 120/80 mmHg even if &lt; 90th percentile.",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      Hypertension is defined as either systolic and/or diastolic BP &gt;= 95th percentile measured upon three or more occasions.",
"The cuff size should be carefully matched to the size of the patient's arm to avoid inaccurate measurements.",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      <font color=\"#aa0000\">",
"       * To facilitate staging of hypertension for this patient, the calculated threshold for stage II hypertension is displayed above.",
"      </font>",
"     </span>",
"     <ul class=\"medCalcFontOne\">",
"      <li>",
"       Stage I hypertension is defined as either Systolic BP or Diastolic BP between the 95th percentile and the 99th percentile plus 5 mmHg.",
"      </li>",
"      <li>",
"       Stage II hypertension is defined as either Systolic BP or Diastolic BP greater than the 99th percentile plus 5 mmHg.",
"      </li>",
"     </ul>",
"     <br/>",
"     &nbsp;",
"     <br/>",
"     <span class=\"medCalcFontOne\">",
"      Children and adolescents whose BP exceeds 120/80 mmHg are considered prehypertensive even if the blood pressure",
"is &lt; 90th percentile",
"      <sup>",
"       1",
"      </sup>",
"      .",
"      <br/>",
"      &nbsp;",
"      <br/>",
"      In this calculator, the subject's blood pressure percentiles are based on age and height percentile.",
"     </span>",
"    </div>",
"    <br/>",
"    &nbsp;",
"    <br/>",
"    <div id=\"calc_refs\">",
"     <span class=\"medCalcFontRef\">",
"      <b>",
"       References",
"      </b>",
"     </span>",
"     <ol>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        National High Blood Pressure Education Program Working Group on High Blood Pressure in Children and Adolescents.  The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents.",
"        <i>",
"         Pediatrics",
"        </i>",
"        . 2004 Aug;114(2 Suppl 4th Report):555-76.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        Percentile conversion from Z-Score is done by table look-up in the standard Normal Table. Percentiles are provided for Z Scores between -3.09 and 3.09.  Values beyond these extremes return percentiles of 0.1 and 99.9 respectively.",
"       </span>",
"      </li>",
"      <li>",
"       <span class=\"medCalcFontRef\">",
"        LMS Parameters for Girls: Height for Age. National health and nutrition survey (NHANES), CDC/National Center for Health Statistics.",
"       </span>",
"      </li>",
"     </ol>",
"    </div>",
"   </form>",
"  </div>",
" </div>",
" <div id=\"topicAgreement\">",
"  Use of UpToDate is subject to the",
"  <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"   Subscription and License Agreement",
"  </a>",
"  .",
" </div>",
" <div id=\"printDisclaimer\">",
"  Information on this page may not appear correctly if printed.",
" </div>",
" <div id=\"disclaimerCalculator\">",
"  <div class=\"medCalcFontTwo\">",
"   <p class=\"header\">",
"    Legal Notices and Disclaimer",
"   </p>",
"   <p>",
"    All information contained in and produced by the MedCalc 3000 system is provided",
"			for educational purposes only. This information should not be used for the diagnosis or treatment",
"			of any health problem or disease.",
"    <b>",
"     THIS INFORMATION IS NOT INTENDED TO REPLACE CLINICAL JUDGMENT OR",
"			GUIDE INDIVIDUAL PATIENT CARE IN ANY MANNER.",
"    </b>",
"    <a class=\"medCalcDisclaimerLink\" href=\"./med-calc-disclaimer\">",
"     Click here for",
"				full notice and disclaimer.",
"    </a>",
"   </p>",
"   <p class=\"copy\">",
"    MedCalc 3000 is Copyright &copy; 1998-2013 Foundation Internet Services",
"   </p>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_33_9751=[" ",
"",
"",
"function log(i){",
"return Math.log(i) * Math.LOG10E;   ",
"}",
"",
"function ln(i){",
"return Math.log(i);",
"}",
"",
"function sq(i){",
"return i * i;",
"}",
"",
"function sqr(i){",
"return Math.sqrt(i);",
"}",
"",
"",
"function power(x,y){",
"return Math.pow(x,y);",
"}",
"",
"function eTo(x){",
"return Math.exp(x);",
"}",
"",
"",
"function fixDP(r, dps) {",
"if (isNaN(r)) return \"NaN\";",
"var msign = '';",
"if (r < 0) msign = '-';",
"x = Math.abs(r);",
"if (x > Math.pow(10, 21)) return msign + x.toString();",
"var m = Math.round(x * Math.pow(10, dps)).toString();",
"if (dps == 0) return msign + m;",
"while (m.length <= dps) m = \"0\" + m;",
"return msign + m.substring(0, m.length - dps) + \".\" + m.substring(m.length - dps);",
"}",
"",
"var currenttimeout;",
"",
"n = new Array;",
"var L = 0;",
"var M = 0;",
"var S = 0;",
"",
"n[0] = 50;",
"n[1] = 50.399;",
"n[2] = 50.798;",
"n[3] = 51.197;",
"n[4] = 51.595;",
"n[5] = 51.994;",
"n[6] = 52.392;",
"n[7] = 52.79;",
"n[8] = 53.188;",
"n[9] = 53.586;",
"n[10] = 53.983;",
"n[11] = 54.38;",
"n[12] = 54.776;",
"n[13] = 55.172;",
"n[14] = 55.567;",
"n[15] = 55.962;",
"n[16] = 56.356;",
"n[17] = 56.749;",
"n[18] = 57.142;",
"n[19] = 57.535;",
"n[20] = 57.926;",
"n[21] = 58.317;",
"n[22] = 58.706;",
"n[23] = 59.095;",
"n[24] = 59.483;",
"n[25] = 59.871;",
"n[26] = 60.257;",
"n[27] = 60.642;",
"n[28] = 61.026;",
"n[29] = 61.409;",
"n[30] = 61.791;",
"n[31] = 62.172;",
"n[32] = 62.552;",
"n[33] = 62.93;",
"n[34] = 63.307;",
"n[35] = 63.683;",
"n[36] = 64.058;",
"n[37] = 64.431;",
"n[38] = 64.803;",
"n[39] = 65.173;",
"n[40] = 65.542;",
"n[41] = 65.91;",
"n[42] = 66.276;",
"n[43] = 66.64;",
"n[44] = 67.003;",
"n[45] = 67.364;",
"n[46] = 67.724;",
"n[47] = 68.082;",
"n[48] = 68.439;",
"n[49] = 68.793;",
"n[50] = 69.146;",
"n[51] = 69.497;",
"n[52] = 69.847;",
"n[53] = 70.194;",
"n[54] = 70.54;",
"n[55] = 70.884;",
"n[56] = 71.226;",
"n[57] = 71.566;",
"n[58] = 71.904;",
"n[59] = 72.24;",
"n[60] = 72.575;",
"n[61] = 72.907;",
"n[62] = 73.237;",
"n[63] = 73.565;",
"n[64] = 73.891;",
"n[65] = 74.215;",
"n[66] = 74.537;",
"n[67] = 74.857;",
"n[68] = 75.175;",
"n[69] = 75.49;",
"n[70] = 75.804;",
"n[71] = 76.115;",
"n[72] = 76.424;",
"n[73] = 76.73;",
"n[74] = 77.035;",
"n[75] = 77.337;",
"n[76] = 77.637;",
"n[77] = 77.935;",
"n[78] = 78.23;",
"n[79] = 78.524;",
"n[80] = 78.814;",
"n[81] = 79.103;",
"n[82] = 79.389;",
"n[83] = 79.673;",
"n[84] = 79.955;",
"n[85] = 80.234;",
"n[86] = 80.511;",
"n[87] = 80.785;",
"n[88] = 81.057;",
"n[89] = 81.327;",
"n[90] = 81.594;",
"n[91] = 81.859;",
"n[92] = 82.121;",
"n[93] = 82.381;",
"n[94] = 82.639;",
"n[95] = 82.894;",
"n[96] = 83.147;",
"n[97] = 83.398;",
"n[98] = 83.646;",
"n[99] = 83.891;",
"n[100] = 84.134;",
"n[101] = 84.375;",
"n[102] = 84.614;",
"n[103] = 84.849;",
"n[104] = 85.083;",
"n[105] = 85.314;",
"n[106] = 85.543;",
"n[107] = 85.769;",
"n[108] = 85.993;",
"n[109] = 86.214;",
"n[110] = 86.433;",
"n[111] = 86.65;",
"n[112] = 86.864;",
"n[113] = 87.076;",
"n[114] = 87.286;",
"n[115] = 87.493;",
"n[116] = 87.698;",
"n[117] = 87.9;",
"n[118] = 88.1;",
"n[119] = 88.298;",
"n[120] = 88.493;",
"n[121] = 88.686;",
"n[122] = 88.877;",
"n[123] = 89.065;",
"n[124] = 89.251;",
"n[125] = 89.435;",
"n[126] = 89.617;",
"n[127] = 89.796;",
"n[128] = 89.973;",
"n[129] = 90.147;",
"n[130] = 90.32;",
"n[131] = 90.49;",
"n[132] = 90.658;",
"n[133] = 90.824;",
"n[134] = 90.988;",
"n[135] = 91.149;",
"n[136] = 91.308;",
"n[137] = 91.466;",
"n[138] = 91.621;",
"n[139] = 91.774;",
"n[140] = 91.924;",
"n[141] = 92.073;",
"n[142] = 92.22;",
"n[143] = 92.364;",
"n[144] = 92.507;",
"n[145] = 92.647;",
"n[146] = 92.785;",
"n[147] = 92.922;",
"n[148] = 93.056;",
"n[149] = 93.189;",
"n[150] = 93.319;",
"n[151] = 93.448;",
"n[152] = 93.574;",
"n[153] = 93.699;",
"n[154] = 93.822;",
"n[155] = 93.943;",
"n[156] = 94.062;",
"n[157] = 94.179;",
"n[158] = 94.295;",
"n[159] = 94.408;",
"n[160] = 94.52;",
"n[161] = 94.63;",
"n[162] = 94.738;",
"n[163] = 94.845;",
"n[164] = 94.95;",
"n[165] = 95.053;",
"n[166] = 95.154;",
"n[167] = 95.254;",
"n[168] = 95.352;",
"n[169] = 95.449;",
"n[170] = 95.543;",
"n[171] = 95.637;",
"n[172] = 95.728;",
"n[173] = 95.818;",
"n[174] = 95.907;",
"n[175] = 95.994;",
"n[176] = 96.08;",
"n[177] = 96.164;",
"n[178] = 96.246;",
"n[179] = 96.327;",
"n[180] = 96.407;",
"n[181] = 96.485;",
"n[182] = 96.562;",
"n[183] = 96.638;",
"n[184] = 96.712;",
"n[185] = 96.784;",
"n[186] = 96.856;",
"n[187] = 96.926;",
"n[188] = 96.995;",
"n[189] = 97.062;",
"n[190] = 97.128;",
"n[191] = 97.193;",
"n[192] = 97.257;",
"n[193] = 97.32;",
"n[194] = 97.381;",
"n[195] = 97.441;",
"n[196] = 97.5;",
"n[197] = 97.558;",
"n[198] = 97.615;",
"n[199] = 97.67;",
"n[200] = 97.725;",
"n[201] = 97.778;",
"n[202] = 97.831;",
"n[203] = 97.882;",
"n[204] = 97.932;",
"n[205] = 97.982;",
"n[206] = 98.03;",
"n[207] = 98.077;",
"n[208] = 98.124;",
"n[209] = 98.169;",
"n[210] = 98.214;",
"n[211] = 98.257;",
"n[212] = 98.3;",
"n[213] = 98.341;",
"n[214] = 98.382;",
"n[215] = 98.422;",
"n[216] = 98.461;",
"n[217] = 98.5;",
"n[218] = 98.537;",
"n[219] = 98.574;",
"n[220] = 98.61;",
"n[221] = 98.645;",
"n[222] = 98.679;",
"n[223] = 98.713;",
"n[224] = 98.745;",
"n[225] = 98.778;",
"n[226] = 98.809;",
"n[227] = 98.84;",
"n[228] = 98.87;",
"n[229] = 98.899;",
"n[230] = 98.928;",
"n[231] = 98.956;",
"n[232] = 98.983;",
"n[233] = 99.01;",
"n[234] = 99.036;",
"n[235] = 99.061;",
"n[236] = 99.086;",
"n[237] = 99.111;",
"n[238] = 99.134;",
"n[239] = 99.158;",
"n[240] = 99.18;",
"n[241] = 99.202;",
"n[242] = 99.224;",
"n[243] = 99.245;",
"n[244] = 99.266;",
"n[245] = 99.286;",
"n[246] = 99.305;",
"n[247] = 99.324;",
"n[248] = 99.343;",
"n[249] = 99.361;",
"n[250] = 99.379;",
"n[251] = 99.396;",
"n[252] = 99.413;",
"n[253] = 99.43;",
"n[254] = 99.446;",
"n[255] = 99.461;",
"n[256] = 99.477;",
"n[257] = 99.492;",
"n[258] = 99.506;",
"n[259] = 99.52;",
"n[260] = 99.534;",
"n[261] = 99.547;",
"n[262] = 99.56;",
"n[263] = 99.573;",
"n[264] = 99.585;",
"n[265] = 99.598;",
"n[266] = 99.609;",
"n[267] = 99.621;",
"n[268] = 99.632;",
"n[269] = 99.643;",
"n[270] = 99.653;",
"n[271] = 99.664;",
"n[272] = 99.674;",
"n[273] = 99.683;",
"n[274] = 99.693;",
"n[275] = 99.702;",
"n[276] = 99.711;",
"n[277] = 99.72;",
"n[278] = 99.728;",
"n[279] = 99.736;",
"n[280] = 99.744;",
"n[281] = 99.752;",
"n[282] = 99.76;",
"n[283] = 99.767;",
"n[284] = 99.774;",
"n[285] = 99.781;",
"n[286] = 99.788;",
"n[287] = 99.795;",
"n[288] = 99.801;",
"n[289] = 99.807;",
"n[290] = 99.813;",
"n[291] = 99.819;",
"n[292] = 99.825;",
"n[293] = 99.831;",
"n[294] = 99.836;",
"n[295] = 99.841;",
"n[296] = 99.846;",
"n[297] = 99.851;",
"n[298] = 99.856;",
"n[299] = 99.861;",
"n[300] = 99.865;",
"n[301] = 99.869;",
"n[302] = 99.874;",
"n[303] = 99.878;",
"n[304] = 99.882;",
"n[305] = 99.886;",
"n[306] = 99.889;",
"n[307] = 99.893;",
"n[308] = 99.896;",
"n[309] = 99.9;",
"",
"function ZtoPercentile(z){",
"with (document.BloodPressurePercentGirls_form){",
"az = Math.abs(z);",
"if (z < -3.09) return 0.1;",
"if (z > 3.09) return 99.9;",
"thispercentile = n[Math.round(az * 100)];",
"if (z >= 0) { return thispercentile }",
"else { return 100 - thispercentile }",
"}}",
"",
"var calctxt = ''; ",
"var xmltxt = ''; ",
"var htmtxt = ''; ",
"",
"",
"",
"function BloodPressurePercentGirls_fx() {",
"",
"currenttimeout = self.setTimeout('minMaxCheck();', 3000);",
"",
"with(document.BloodPressurePercentGirls_form){",
"",
"",
"doCalc = true;",
"if (Age_param.value.indexOf(',') >= 0){ Age_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Age_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Age_unit.options[Age_unit.selectedIndex].value.split('|');",
"Age = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Height_param.value.indexOf(',') >= 0){ Height_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Height_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Height_unit.options[Height_unit.selectedIndex].value.split('|');",
"Height = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Systolic_BP_param.value.indexOf(',') >= 0){ Systolic_BP_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Systolic_BP_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Systolic_BP_unit.options[Systolic_BP_unit.selectedIndex].value.split('|');",
"Systolic_BP = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"if (Diastolic_BP_param.value.indexOf(',') >= 0){ Diastolic_BP_param.value = ''; doCalc = false; alert('Comma character not allowed'); }",
"param_value = parseFloat(Diastolic_BP_param.value);",
"if (isNaN(param_value)){param_value = \"\"; doCalc = false;}",
"unit_parts = Diastolic_BP_unit.options[Diastolic_BP_unit.selectedIndex].value.split('|');",
"Diastolic_BP = param_value * parseFloat(unit_parts[0]) + parseFloat(unit_parts[1]);",
"dp = 0;",
"Age_Months =  Age * 12;",
"",
"if(Age_Months >= 24 && Age_Months < 25){L = 1.051272912; M = 85.3973169; S = 0.040859727;};",
"if(Age_Months >= 25 && Age_Months < 26){L = 1.041951175; M = 86.29026318; S = 0.041142161;};",
"if(Age_Months >= 26 && Age_Months < 27){L = 1.012592236; M = 87.15714182; S = 0.041349399;};",
"if(Age_Months >= 27 && Age_Months < 28){L = 0.970541909; M = 87.9960184; S = 0.041500428;};",
"if(Age_Months >= 28 && Age_Months < 29){L = 0.921129988; M = 88.8055115; S = 0.041610508;};",
"if(Age_Months >= 29 && Age_Months < 30){L = 0.868221392; M = 89.58476689; S = 0.041691761;};",
"if(Age_Months >= 30 && Age_Months < 31){L = 0.81454413; M = 90.33341722; S = 0.04175368;};",
"if(Age_Months >= 31 && Age_Months < 32){L = 0.761957977; M = 91.0515436; S = 0.041803562;};",
"if(Age_Months >= 32 && Age_Months < 33){L = 0.711660228; M = 91.7396352; S = 0.041846882;};",
"if(Age_Months >= 33 && Age_Months < 34){L = 0.664323379; M = 92.39854429; S = 0.041887626;};",
"if(Age_Months >= 34 && Age_Months < 35){L = 0.620285102; M = 93.02945392; S = 0.041928568;};",
"if(Age_Months >= 35 && Age_Months < 36){L = 0.57955631; M = 93.63382278; S = 0.041971514;};",
"if(Age_Months >= 36 && Age_Months < 37){L = 0.54198094; M = 94.21335709; S = 0.042017509;};",
"if(Age_Months >= 37 && Age_Months < 38){L = 0.511429832; M = 94.79643239; S = 0.042104522;};",
"if(Age_Months >= 38 && Age_Months < 39){L = 0.482799937; M = 95.37391918; S = 0.042199507;};",
"if(Age_Months >= 39 && Age_Months < 40){L = 0.455521041; M = 95.94692677; S = 0.042300333;};",
"if(Age_Months >= 40 && Age_Months < 41){L = 0.429150288; M = 96.51644912; S = 0.042405225;};",
"if(Age_Months >= 41 && Age_Months < 42){L = 0.403351725; M = 97.08337211; S = 0.042512706;};",
"if(Age_Months >= 42 && Age_Months < 43){L = 0.377878239; M = 97.6484807; S = 0.042621565;};",
"if(Age_Months >= 43 && Age_Months < 44){L = 0.352555862; M = 98.21246579; S = 0.042730809;};",
"if(Age_Months >= 44 && Age_Months < 45){L = 0.327270297; M = 98.77593069; S = 0.042839638;};",
"if(Age_Months >= 45 && Age_Months < 46){L = 0.301955463; M = 99.33939735; S = 0.042947412;};",
"if(Age_Months >= 46 && Age_Months < 47){L = 0.276583851; M = 99.9033122; S = 0.043053626;};",
"if(Age_Months >= 47 && Age_Months < 48){L = 0.251158446; M = 100.4680516; S = 0.043157889;};",
"if(Age_Months >= 48 && Age_Months < 49){L = 0.225705996; M = 101.033927; S = 0.043259907;};",
"if(Age_Months >= 49 && Age_Months < 50){L = 0.20027145; M = 101.6011898; S = 0.043359463;};",
"if(Age_Months >= 50 && Age_Months < 51){L = 0.174913356; M = 102.1700358; S = 0.043456406;};",
"if(Age_Months >= 51 && Age_Months < 52){L = 0.149700081; M = 102.7406094; S = 0.043550638;};",
"if(Age_Months >= 52 && Age_Months < 53){L = 0.12470671; M = 103.3130077; S = 0.043642107;};",
"if(Age_Months >= 53 && Age_Months < 54){L = 0.100012514; M = 103.8872839; S = 0.043730791;};",
"if(Age_Months >= 54 && Age_Months < 55){L = 0.075698881; M = 104.4634511; S = 0.043816701;};",
"if(Age_Months >= 55 && Age_Months < 56){L = 0.051847635; M = 105.0414853; S = 0.043899867;};",
"if(Age_Months >= 56 && Age_Months < 57){L = 0.02853967; M = 105.6213287; S = 0.043980337;};",
"if(Age_Months >= 57 && Age_Months < 58){L = 0.005853853; M = 106.2028921; S = 0.044058171;};",
"if(Age_Months >= 58 && Age_Months < 59){L = -0.016133871; M = 106.7860583; S = 0.04413344;};",
"if(Age_Months >= 59 && Age_Months < 60){L = -0.037351181; M = 107.3706841; S = 0.044206218;};",
"if(Age_Months >= 60 && Age_Months < 61){L = -0.057729947; M = 107.9566031; S = 0.044276588;};",
"if(Age_Months >= 61 && Age_Months < 62){L = -0.077206672; M = 108.5436278; S = 0.044344632;};",
"if(Age_Months >= 62 && Age_Months < 63){L = -0.09572283; M = 109.1315521; S = 0.044410436;};",
"if(Age_Months >= 63 && Age_Months < 64){L = -0.113225128; M = 109.7201531; S = 0.044474084;};",
"if(Age_Months >= 64 && Age_Months < 65){L = -0.129665689; M = 110.3091934; S = 0.044535662;};",
"if(Age_Months >= 65 && Age_Months < 66){L = -0.145002179; M = 110.8984228; S = 0.044595254;};",
"if(Age_Months >= 66 && Age_Months < 67){L = -0.159197885; M = 111.4875806; S = 0.044652942;};",
"if(Age_Months >= 67 && Age_Months < 68){L = -0.172221748; M = 112.0763967; S = 0.044708809;};",
"if(Age_Months >= 68 && Age_Months < 69){L = -0.184048358; M = 112.6645943; S = 0.044762936;};",
"if(Age_Months >= 69 && Age_Months < 70){L = -0.194660215; M = 113.2518902; S = 0.044815402;};",
"if(Age_Months >= 70 && Age_Months < 71){L = -0.204030559; M = 113.8380006; S = 0.044866288;};",
"if(Age_Months >= 71 && Age_Months < 72){L = -0.212174408; M = 114.4226317; S = 0.044915672;};",
"if(Age_Months >= 72 && Age_Months < 73){L = -0.219069129; M = 115.0054978; S = 0.044963636;};",
"if(Age_Months >= 73 && Age_Months < 74){L = -0.224722166; M = 115.5863089; S = 0.045010259;};",
"if(Age_Months >= 74 && Age_Months < 75){L = -0.229140412; M = 116.1647782; S = 0.045055624;};",
"if(Age_Months >= 75 && Age_Months < 76){L = -0.232335686; M = 116.7406221; S = 0.045099817;};",
"if(Age_Months >= 76 && Age_Months < 77){L = -0.234324563; M = 117.3135622; S = 0.045142924;};",
"if(Age_Months >= 77 && Age_Months < 78){L = -0.235128195; M = 117.8833259; S = 0.045185036;};",
"if(Age_Months >= 78 && Age_Months < 79){L = -0.234772114; M = 118.4496481; S = 0.045226249;};",
"if(Age_Months >= 79 && Age_Months < 80){L = -0.233286033; M = 119.0122722; S = 0.045266662;};",
"if(Age_Months >= 80 && Age_Months < 81){L = -0.230703633; M = 119.5709513; S = 0.045306383;};",
"if(Age_Months >= 81 && Age_Months < 82){L = -0.227062344; M = 120.1254495; S = 0.045345524;};",
"if(Age_Months >= 82 && Age_Months < 83){L = -0.222403111; M = 120.6755427; S = 0.045384203;};",
"if(Age_Months >= 83 && Age_Months < 84){L = -0.216770161; M = 121.22102; S = 0.045422551;};",
"if(Age_Months >= 84 && Age_Months < 85){L = -0.210210748; M = 121.7616844; S = 0.045460702;};",
"if(Age_Months >= 85 && Age_Months < 86){L = -0.202774891; M = 122.2973542; S = 0.045498803;};",
"if(Age_Months >= 86 && Age_Months < 87){L = -0.194515104; M = 122.827864; S = 0.045537012;};",
"if(Age_Months >= 87 && Age_Months < 88){L = -0.185486099; M = 123.3530652; S = 0.045575495;};",
"if(Age_Months >= 88 && Age_Months < 89){L = -0.175744476; M = 123.8728276; S = 0.045614432;};",
"if(Age_Months >= 89 && Age_Months < 90){L = -0.165348396; M = 124.38704; S = 0.045654016;};",
"if(Age_Months >= 90 && Age_Months < 91){L = -0.15435722; M = 124.8956114; S = 0.04569445;};",
"if(Age_Months >= 91 && Age_Months < 92){L = -0.142831123; M = 125.398472; S = 0.045735953;};",
"if(Age_Months >= 92 && Age_Months < 93){L = -0.130830669; M = 125.895574; S = 0.045778759;};",
"if(Age_Months >= 93 && Age_Months < 94){L = -0.118416354; M = 126.3868929; S = 0.045823114;};",
"if(Age_Months >= 94 && Age_Months < 95){L = -0.105648092; M = 126.8724284; S = 0.04586928;};",
"if(Age_Months >= 95 && Age_Months < 96){L = -0.092584657; M = 127.3522056; S = 0.045917535;};",
"if(Age_Months >= 96 && Age_Months < 97){L = -0.079283065; M = 127.8262759; S = 0.045968169;};",
"if(Age_Months >= 97 && Age_Months < 98){L = -0.065797888; M = 128.2947187; S = 0.04602149;};",
"if(Age_Months >= 98 && Age_Months < 99){L = -0.0521805; M = 128.757642; S = 0.046077818;};",
"if(Age_Months >= 99 && Age_Months < 100){L = -0.03847825; M = 129.2151839; S = 0.046137487;};",
"if(Age_Months >= 100 && Age_Months < 101){L = -0.024733545; M = 129.6675143; S = 0.046200842;};",
"if(Age_Months >= 101 && Age_Months < 102){L = -0.010982868; M = 130.1148354; S = 0.04626824;};",
"if(Age_Months >= 102 && Age_Months < 103){L = 0.002744306; M = 130.5573839; S = 0.046340046;};",
"if(Age_Months >= 103 && Age_Months < 104){L = 0.016426655; M = 130.995432; S = 0.046416629;};",
"if(Age_Months >= 104 && Age_Months < 105){L = 0.030052231; M = 131.4292887; S = 0.046498361;};",
"if(Age_Months >= 105 && Age_Months < 106){L = 0.043619747; M = 131.8593015; S = 0.046585611;};",
"if(Age_Months >= 106 && Age_Months < 107){L = 0.05713988; M = 132.2858574; S = 0.046678741;};",
"if(Age_Months >= 107 && Age_Months < 108){L = 0.070636605; M = 132.7093845; S = 0.046778099;};",
"if(Age_Months >= 108 && Age_Months < 109){L = 0.08414848; M = 133.1303527; S = 0.04688401;};",
"if(Age_Months >= 109 && Age_Months < 110){L = 0.097729873; M = 133.5492749; S = 0.046996769;};",
"if(Age_Months >= 110 && Age_Months < 111){L = 0.111452039; M = 133.9667073; S = 0.047116633;};",
"if(Age_Months >= 111 && Age_Months < 112){L = 0.125404005; M = 134.3832499; S = 0.047243801;};",
"if(Age_Months >= 112 && Age_Months < 113){L = 0.13969316; M = 134.7995463; S = 0.047378413;};",
"if(Age_Months >= 113 && Age_Months < 114){L = 0.154445482; M = 135.2162826; S = 0.047520521;};",
"if(Age_Months >= 114 && Age_Months < 115){L = 0.169805275; M = 135.634186; S = 0.047670085;};",
"if(Age_Months >= 115 && Age_Months < 116){L = 0.185934346; M = 136.0540223; S = 0.047826946;};",
"if(Age_Months >= 116 && Age_Months < 117){L = 0.203010488; M = 136.4765925; S = 0.04799081;};",
"if(Age_Months >= 117 && Age_Months < 118){L = 0.2212252; M = 136.9027281; S = 0.048161228;};",
"if(Age_Months >= 118 && Age_Months < 119){L = 0.240780542; M = 137.3332846; S = 0.04833757;};",
"if(Age_Months >= 119 && Age_Months < 120){L = 0.261885086; M = 137.7691339; S = 0.048519011;};",
"if(Age_Months >= 120 && Age_Months < 121){L = 0.284748919; M = 138.2111552; S = 0.048704503;};",
"if(Age_Months >= 121 && Age_Months < 122){L = 0.309577733; M = 138.6602228; S = 0.048892759;};",
"if(Age_Months >= 122 && Age_Months < 123){L = 0.336566048; M = 139.1171933; S = 0.049082239;};",
"if(Age_Months >= 123 && Age_Months < 124){L = 0.365889711; M = 139.5828898; S = 0.049271137;};",
"if(Age_Months >= 124 && Age_Months < 125){L = 0.397699038; M = 140.0580848; S = 0.049457371;};",
"if(Age_Months >= 125 && Age_Months < 126){L = 0.432104409; M = 140.5434787; S = 0.049638596;};",
"if(Age_Months >= 126 && Age_Months < 127){L = 0.46917993; M = 141.0396832; S = 0.049812203;};",
"if(Age_Months >= 127 && Age_Months < 128){L = 0.508943272; M = 141.5471945; S = 0.049975355;};",
"if(Age_Months >= 128 && Age_Months < 129){L = 0.551354277; M = 142.0663731; S = 0.050125012;};",
"if(Age_Months >= 129 && Age_Months < 130){L = 0.596307363; M = 142.59742; S = 0.050257992;};",
"if(Age_Months >= 130 && Age_Months < 131){L = 0.643626542; M = 143.1403553; S = 0.050371024;};",
"if(Age_Months >= 131 && Age_Months < 132){L = 0.693062173; M = 143.6949981; S = 0.050460835;};",
"if(Age_Months >= 132 && Age_Months < 133){L = 0.744289752; M = 144.2609497; S = 0.050524236;};",
"if(Age_Months >= 133 && Age_Months < 134){L = 0.79691098; M = 144.8375809; S = 0.050558224;};",
"if(Age_Months >= 134 && Age_Months < 135){L = 0.85045728; M = 145.4240246; S = 0.050560083;};",
"if(Age_Months >= 135 && Age_Months < 136){L = 0.904395871; M = 146.0191748; S = 0.050527494;};",
"if(Age_Months >= 136 && Age_Months < 137){L = 0.958138449; M = 146.621692; S = 0.050458634;};",
"if(Age_Months >= 137 && Age_Months < 138){L = 1.011054559; M = 147.2300177; S = 0.050352269;};",
"if(Age_Months >= 138 && Age_Months < 139){L = 1.062474568; M = 147.8423918; S = 0.050207825;};",
"if(Age_Months >= 139 && Age_Months < 140){L = 1.111727029; M = 148.4568879; S = 0.050025434;};",
"if(Age_Months >= 140 && Age_Months < 141){L = 1.158135105; M = 149.0714413; S = 0.049805967;};",
"if(Age_Months >= 141 && Age_Months < 142){L = 1.201050821; M = 149.6838943; S = 0.049551023;};",
"if(Age_Months >= 142 && Age_Months < 143){L = 1.239852328; M = 150.2920328; S = 0.049262895;};",
"if(Age_Months >= 143 && Age_Months < 144){L = 1.274006058; M = 150.8936469; S = 0.048944504;};",
"if(Age_Months >= 144 && Age_Months < 145){L = 1.303044695; M = 151.4865636; S = 0.048599314;};",
"if(Age_Months >= 145 && Age_Months < 146){L = 1.326605954; M = 152.0686985; S = 0.048231224;};",
"if(Age_Months >= 146 && Age_Months < 147){L = 1.344443447; M = 152.6380955; S = 0.047844442;};",
"if(Age_Months >= 147 && Age_Months < 148){L = 1.356437773; M = 153.1929631; S = 0.047443362;};",
"if(Age_Months >= 148 && Age_Months < 149){L = 1.362602695; M = 153.7317031; S = 0.04703243;};",
"if(Age_Months >= 149 && Age_Months < 150){L = 1.363085725; M = 154.2529332; S = 0.046616026;};",
"if(Age_Months >= 150 && Age_Months < 151){L = 1.358162799; M = 154.755501; S = 0.046198356;};",
"if(Age_Months >= 151 && Age_Months < 152){L = 1.348227142; M = 155.2384904; S = 0.04578335;};",
"if(Age_Months >= 152 && Age_Months < 153){L = 1.333772923; M = 155.7012216; S = 0.045374597;};",
"if(Age_Months >= 153 && Age_Months < 154){L = 1.315374704; M = 156.1432438; S = 0.044975281;};",
"if(Age_Months >= 154 && Age_Months < 155){L = 1.293664024; M = 156.564323; S = 0.044588148;};",
"if(Age_Months >= 155 && Age_Months < 156){L = 1.269304678; M = 156.9644258; S = 0.044215488;};",
"if(Age_Months >= 156 && Age_Months < 157){L = 1.242968236; M = 157.3436995; S = 0.043859135;};",
"if(Age_Months >= 157 && Age_Months < 158){L = 1.21531127; M = 157.7024507; S = 0.04352048;};",
"if(Age_Months >= 158 && Age_Months < 159){L = 1.186955477; M = 158.0411233; S = 0.043200497;};",
"if(Age_Months >= 159 && Age_Months < 160){L = 1.158471522; M = 158.3602756; S = 0.042899776;};",
"if(Age_Months >= 160 && Age_Months < 161){L = 1.130367088; M = 158.6605588; S = 0.042618565;};",
"if(Age_Months >= 161 && Age_Months < 162){L = 1.103079209; M = 158.9426964; S = 0.042356812;};",
"if(Age_Months >= 162 && Age_Months < 163){L = 1.076970655; M = 159.2074654; S = 0.042114211;};",
"if(Age_Months >= 163 && Age_Months < 164){L = 1.052329922; M = 159.455679; S = 0.041890247;};",
"if(Age_Months >= 164 && Age_Months < 165){L = 1.029374161; M = 159.688172; S = 0.04168424;};",
"if(Age_Months >= 165 && Age_Months < 166){L = 1.008254396; M = 159.9057871; S = 0.041495379;};",
"if(Age_Months >= 166 && Age_Months < 167){L = 0.989062282; M = 160.1093647; S = 0.041322765;};",
"if(Age_Months >= 167 && Age_Months < 168){L = 0.971837799; M = 160.299733; S = 0.041165437;};",
"if(Age_Months >= 168 && Age_Months < 169){L = 0.95657215; M = 160.4776996; S = 0.041022401;};",
"if(Age_Months >= 169 && Age_Months < 170){L = 0.94324228; M = 160.6440526; S = 0.040892651;};",
"if(Age_Months >= 170 && Age_Months < 171){L = 0.931767062; M = 160.7995428; S = 0.040775193;};",
"if(Age_Months >= 171 && Age_Months < 172){L = 0.922058291; M = 160.9448916; S = 0.040669052;};",
"if(Age_Months >= 172 && Age_Months < 173){L = 0.914012643; M = 161.0807857; S = 0.040573288;};",
"if(Age_Months >= 173 && Age_Months < 174){L = 0.907516917; M = 161.2078755; S = 0.040487005;};",
"if(Age_Months >= 174 && Age_Months < 175){L = 0.902452436; M = 161.3267744; S = 0.040409354;};",
"if(Age_Months >= 175 && Age_Months < 176){L = 0.898698641; M = 161.4380593; S = 0.040339537;};",
"if(Age_Months >= 176 && Age_Months < 177){L = 0.896143482; M = 161.5422726; S = 0.040276811;};",
"if(Age_Months >= 177 && Age_Months < 178){L = 0.894659668; M = 161.639917; S = 0.040220488;};",
"if(Age_Months >= 178 && Age_Months < 179){L = 0.89413892; M = 161.7314645; S = 0.040169932;};",
"if(Age_Months >= 179 && Age_Months < 180){L = 0.894475371; M = 161.8173534; S = 0.040124562;};",
"if(Age_Months >= 180 && Age_Months < 181){L = 0.895569834; M = 161.8979913; S = 0.040083845;};",
"if(Age_Months >= 181 && Age_Months < 182){L = 0.897330209; M = 161.9737558; S = 0.040047295;};",
"if(Age_Months >= 182 && Age_Months < 183){L = 0.899671635; M = 162.0449969; S = 0.040014473;};",
"if(Age_Months >= 183 && Age_Months < 184){L = 0.902516442; M = 162.1120386; S = 0.03998498;};",
"if(Age_Months >= 184 && Age_Months < 185){L = 0.905793969; M = 162.17518; S = 0.039958458;};",
"if(Age_Months >= 185 && Age_Months < 186){L = 0.909440266; M = 162.2346979; S = 0.039934584;};",
"if(Age_Months >= 186 && Age_Months < 187){L = 0.913397733; M = 162.2908474; S = 0.039913066;};",
"if(Age_Months >= 187 && Age_Months < 188){L = 0.91761471; M = 162.343864; S = 0.039893644;};",
"if(Age_Months >= 188 && Age_Months < 189){L = 0.922045055; M = 162.3939652; S = 0.039876087;};",
"if(Age_Months >= 189 && Age_Months < 190){L = 0.926647697; M = 162.4413513; S = 0.039860185;};",
"if(Age_Months >= 190 && Age_Months < 191){L = 0.931386217; M = 162.4862071; S = 0.039845754;};",
"if(Age_Months >= 191 && Age_Months < 192){L = 0.93622842; M = 162.5287029; S = 0.039832629;};",
"if(Age_Months >= 192 && Age_Months < 193){L = 0.941145943; M = 162.5689958; S = 0.039820663;};",
"if(Age_Months >= 193 && Age_Months < 194){L = 0.94611388; M = 162.6072309; S = 0.039809725;};",
"if(Age_Months >= 194 && Age_Months < 195){L = 0.95111043; M = 162.6435418; S = 0.0397997;};",
"if(Age_Months >= 195 && Age_Months < 196){L = 0.956116576; M = 162.6780519; S = 0.039790485;};",
"if(Age_Months >= 196 && Age_Months < 197){L = 0.961115792; M = 162.7108751; S = 0.039781991;};",
"if(Age_Months >= 197 && Age_Months < 198){L = 0.966093766; M = 162.7421168; S = 0.039774136;};",
"if(Age_Months >= 198 && Age_Months < 199){L = 0.971038162; M = 162.7718741; S = 0.03976685;};",
"if(Age_Months >= 199 && Age_Months < 200){L = 0.975938391; M = 162.8002371; S = 0.03976007;};",
"if(Age_Months >= 200 && Age_Months < 201){L = 0.980785418; M = 162.8272889; S = 0.039753741;};",
"if(Age_Months >= 201 && Age_Months < 202){L = 0.985571579; M = 162.8531067; S = 0.039747815;};",
"if(Age_Months >= 202 && Age_Months < 203){L = 0.99029042; M = 162.8777619; S = 0.039742249;};",
"if(Age_Months >= 203 && Age_Months < 204){L = 0.994936555; M = 162.9013208; S = 0.039737004;};",
"if(Age_Months >= 204 && Age_Months < 205){L = 0.999505539; M = 162.9238449; S = 0.039732048;};",
"if(Age_Months >= 205 && Age_Months < 206){L = 1.003993753; M = 162.9453912; S = 0.039727352;};",
"if(Age_Months >= 206 && Age_Months < 207){L = 1.0083983; M = 162.9660131; S = 0.03972289;};",
"if(Age_Months >= 207 && Age_Months < 208){L = 1.012716921; M = 162.9857599; S = 0.03971864;};",
"if(Age_Months >= 208 && Age_Months < 209){L = 1.016947912; M = 163.0046776; S = 0.039714581;};",
"if(Age_Months >= 209 && Age_Months < 210){L = 1.021090055; M = 163.0228094; S = 0.039710697;};",
"if(Age_Months >= 210 && Age_Months < 211){L = 1.025142554; M = 163.0401953; S = 0.039706971;};",
"if(Age_Months >= 211 && Age_Months < 212){L = 1.029104983; M = 163.0568727; S = 0.039703391;};",
"if(Age_Months >= 212 && Age_Months < 213){L = 1.032977233; M = 163.0728768; S = 0.039699945;};",
"if(Age_Months >= 213 && Age_Months < 214){L = 1.036759475; M = 163.0882404; S = 0.039696623;};",
"if(Age_Months >= 214 && Age_Months < 215){L = 1.040452117; M = 163.1029943; S = 0.039693415;};",
"if(Age_Months >= 215 && Age_Months < 216){L = 1.044055774; M = 163.1171673; S = 0.039690313;};",
"if(Age_Months >= 216 && Age_Months < 217){L = 1.047571238; M = 163.1307866; S = 0.039687311;};",
"if(Age_Months >= 217 && Age_Months < 218){L = 1.050999451; M = 163.1438776; S = 0.039684402;};",
"if(Age_Months >= 218 && Age_Months < 219){L = 1.054341482; M = 163.1564644; S = 0.039681581;};",
"if(Age_Months >= 219 && Age_Months < 220){L = 1.057598512; M = 163.1685697; S = 0.039678842;};",
"if(Age_Months >= 220 && Age_Months < 221){L = 1.060771808; M = 163.1802146; S = 0.039676182;};",
"if(Age_Months >= 221 && Age_Months < 222){L = 1.063862715; M = 163.1914194; S = 0.039673596;};",
"if(Age_Months >= 222 && Age_Months < 223){L = 1.066872639; M = 163.202203; S = 0.039671082;};",
"if(Age_Months >= 223 && Age_Months < 224){L = 1.069803036; M = 163.2125835; S = 0.039668635;};",
"if(Age_Months >= 224 && Age_Months < 225){L = 1.072655401; M = 163.2225779; S = 0.039666254;};",
"if(Age_Months >= 225 && Age_Months < 226){L = 1.075431258; M = 163.2322024; S = 0.039663936;};",
"if(Age_Months >= 226 && Age_Months < 227){L = 1.078132156; M = 163.2414722; S = 0.039661679;};",
"if(Age_Months >= 227 && Age_Months < 228){L = 1.080759655; M = 163.2504019; S = 0.039659481;};",
"if(Age_Months >= 228 && Age_Months < 229){L = 1.083315329; M = 163.2590052; S = 0.039657339;};",
"if(Age_Months >= 229 && Age_Months < 230){L = 1.085800751; M = 163.2672954; S = 0.039655252;};",
"if(Age_Months >= 230 && Age_Months < 231){L = 1.088217496; M = 163.2752848; S = 0.039653218;};",
"if(Age_Months >= 231 && Age_Months < 232){L = 1.090567133; M = 163.2829854; S = 0.039651237;};",
"if(Age_Months >= 232 && Age_Months < 233){L = 1.092851222; M = 163.2904086; S = 0.039649306;};",
"if(Age_Months >= 233 && Age_Months < 234){L = 1.095071313; M = 163.297565; S = 0.039647424;};",
"if(Age_Months >= 234 && Age_Months < 235){L = 1.097228939; M = 163.304465; S = 0.039645591;};",
"if(Age_Months >= 235 && Age_Months < 236){L = 1.099325619; M = 163.3111185; S = 0.039643804;};",
"if(Age_Months >= 236 && Age_Months < 237){L = 1.101362852; M = 163.3175349; S = 0.039642063;};",
"if(Age_Months >= 237 && Age_Months < 238){L = 1.103342119; M = 163.3237231; S = 0.039640367;};",
"if(Age_Months >= 238 && Age_Months < 239){L = 1.105264876; M = 163.3296918; S = 0.039638715;};",
"if(Age_Months >= 239 && Age_Months < 240){L = 1.107132561; M = 163.3354491; S = 0.039637105;};",
"Height_Z =  (power((Height / M), L) - 1) / (L * S);",
"",
"Height_Percentile =  ZtoPercentile(Height_Z);",
"",
"if (doCalc) Height_Percentile_param.value = fixDP(Height_Percentile, dp);",
"",
"",
"",
"Age_Factor =  Age - 10;",
"",
"Systolic_BP_Avg =  102.01027 + (1.94397 * Age_Factor) + (0.00598 * power(Age_Factor,2)) - (0.00789 * power(Age_Factor,3)) - (0.00059 * power(Age_Factor,4))  + (2.03526 * Height_Z) + (0.02534 * power(Height_Z,2)) - (0.01884 * power(Height_Z,3)) + (0.00121 * power(Height_Z,4));",
"",
"Diastolic_BP_Avg =  60.50510 + (1.01301 * Age_Factor) + (0.01157 * power(Age_Factor,2)) + (0.00424 * power(Age_Factor,3)) - (0.00137 * power(Age_Factor,4))  + (1.16641 * Height_Z) + (0.12795 * power(Height_Z,2)) - (0.03869 * power(Height_Z,3)) - (0.00079 * power(Height_Z,4));",
"",
"Systolic_BP_Z =  (Systolic_BP - Systolic_BP_Avg) / 10.4855;",
"",
"Diastolic_BP_Z =  (Diastolic_BP - Diastolic_BP_Avg) / 10.9573;",
"",
"Systolic_BP_Percentile =  ZtoPercentile(Systolic_BP_Z);",
"",
"if (doCalc) Systolic_BP_Percentile_param.value = fixDP(Systolic_BP_Percentile, dp);",
"",
"",
"",
"Diastolic_BP_Percentile =  ZtoPercentile(Diastolic_BP_Z);",
"",
"if (doCalc) Diastolic_BP_Percentile_param.value = fixDP(Diastolic_BP_Percentile, dp);",
"",
"",
"",
"SBP_Threshold =  (2.326348 * 10.4855) + Systolic_BP_Avg + 5;",
"",
"if (doCalc) SBP_Threshold_param.value = fixDP(SBP_Threshold, dp);",
"",
"",
"",
"DBP_Threshold =  (2.326348 * 10.9573) + Diastolic_BP_Avg + 5;",
"",
"if (doCalc) DBP_Threshold_param.value = fixDP(DBP_Threshold, dp);",
"",
"",
"",
"",
"if (doCalc){",
"",
"rrclr();",
"if (Systolic_BP_Percentile < 90){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((Systolic_BP_Percentile >= 90) && (Systolic_BP_Percentile < 95)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"if (Systolic_BP_Percentile >= 95){ document.getElementById('rr1_3').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"",
"if (doCalc){",
"",
"rrclr();",
"if (Systolic_BP_Percentile < 90){ document.getElementById('rr1_1').bgColor = \"#cccccc\";",
"}",
"if ((Systolic_BP_Percentile >= 90) && (Systolic_BP_Percentile < 95)){ document.getElementById('rr1_2').bgColor = \"#cccccc\";",
"}",
"if (Systolic_BP_Percentile >= 95){ document.getElementById('rr1_3').bgColor = \"#cccccc\";",
"}",
"if (Diastolic_BP_Percentile < 90){ document.getElementById('rr2_1').bgColor = \"#cccccc\";",
"}",
"if ((Diastolic_BP_Percentile >= 90) && (Diastolic_BP_Percentile < 95)){ document.getElementById('rr2_2').bgColor = \"#cccccc\";",
"}",
"if (Diastolic_BP_Percentile >= 95){ document.getElementById('rr2_3').bgColor = \"#cccccc\";",
"}",
"",
"",
"",
"}",
"",
"",
"}",
"",
"}",
"",
"function minMaxCheck(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.BloodPressurePercentGirls_form){",
"",
"if (Age_param.value && Age < 2) {",
"Age = 0;",
"Age_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Age is 2 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Age_param.value && Age > 17.99) {",
"Age_param.value = \"\";",
"clrResults();",
"Age = 0;",
"doCalc = false;",
"alert(\"The maximum value for Age is 17.99 yr.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Height_param.value && Height < 50) {",
"Height = 0;",
"Height_param.value = \"\";",
"clrResults();",
"doCalc = false;",
"alert(\"The minimum value for Height is 50 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"if (Height_param.value && Height > 200) {",
"Height_param.value = \"\";",
"clrResults();",
"Height = 0;",
"doCalc = false;",
"alert(\"The maximum value for Height is 200 cm.\\nIf you are specifying a value with a different unit,\\nchange the unit selector first.\");",
"}",
"",
"",
"}",
"",
"}",
"",
"",
"function clrResults(){",
"",
"if (currenttimeout) self.clearTimeout(currenttimeout);",
"",
"with(document.BloodPressurePercentGirls_form){",
"",
"Height_Percentile_param.value = '';",
"Systolic_BP_Percentile_param.value = '';",
"Diastolic_BP_Percentile_param.value = '';",
"SBP_Threshold_param.value = '';",
"DBP_Threshold_param.value = '';",
"",
"rrclr();",
"",
"}",
"",
"}",
"",
"",
"",
"",
"",
"",
"",
"",
"",
"function rrclr(){",
"document.getElementById('rr1_1').bgColor = \"\";",
"document.getElementById('rr1_2').bgColor = \"\";",
"document.getElementById('rr1_3').bgColor = \"\";",
"document.getElementById('rr2_1').bgColor = \"\";",
"document.getElementById('rr2_2').bgColor = \"\";",
"document.getElementById('rr2_3').bgColor = \"\";",
"}",
"",
"",
""].join("\n");
var outline_f9_33_9751=null;
var title_f9_33_9752="Clinical use of plasma components";
var content_f9_33_9752=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Clinical use of plasma components",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/33/9752/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/33/9752/contributors\">",
"     Arthur J Silvergleid, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/33/9752/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/33/9752/contributors\">",
"     Steven Kleinman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/33/9752/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/33/9752/contributors\">",
"     Jennifer S Tirnauer, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/33/9752/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The preparation of products from human plasma is a major worldwide industry; United States exports of plasma to Western Europe alone are worth more than one billion dollars [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The following definitions apply to these products:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma or blood",
"      <strong>",
"       components",
"      </strong>",
"      , as discussed in this review, are biological products prepared by differential centrifugation of whole blood or plasma in a blood center or hospital laboratory.",
"     </li>",
"     <li>",
"      Plasma",
"      <strong>",
"       derivatives",
"      </strong>",
"      , on the other hand, are prepared by a plasma fractionation process in a large manufacturing facility. Derivatives manufactured from human plasma by these latter techniques (eg, albumin, immune globulins, coagulation protein concentrates, photochemically-treated and other pathogen-reduced products) are discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32039?source=see_link\">",
"       \"Plasma derivatives and recombinant DNA-produced coagulation factors\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Details of the collection and separation of plasma for preparation of components and for further manufacture of plasma derivatives are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11895?source=see_link\">",
"     \"Preparation of blood components\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    This topic review will discuss the general uses and indications for the major plasma products made in blood centers, those we call \"components\" (eg, fresh frozen plasma",
"    <span class=\"nowrap\">",
"     (FFP/FP24),",
"    </span>",
"    cryoprecipitate (cryo), cryo-poor plasma, frozen plasma, thawed plasma, and single donor plasma).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     FRESH FROZEN PLASMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fresh frozen plasma (FFP) is prepared from single units of whole blood or from plasma collected by apheresis techniques. It is frozen at -18 to -30&deg;C within eight hours (FFP) of collection and, when appropriately stored, is usable for one year from the date of collection. Standard FFP units derived from a single unit of whole blood have a volume of about 250 mL; \"jumbo\" units prepared by apheresis may be as large as 800 mL.",
"   </p>",
"   <p>",
"    FFP contains all of the coagulation factors and other proteins present in the original unit of blood, slightly diluted by the citrate-containing anticoagulant solution used to collect the blood.",
"   </p>",
"   <p>",
"    FFP (and FP24, discussed below) is not a concentrate of any of the circulating plasma proteins, and, in general, should not be used to treat coagulation defects caused by known deficiencies of a single factor, or for replacing factors better provided in concentrated form (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/12/198?source=see_link\">",
"     factor VIII concentrates",
"    </a>",
"    for hemophilia A).",
"    <span class=\"nowrap\">",
"     FFP/FP24",
"    </span>",
"    should not be used as a source of albumin or other nutrients, or as a volume expander [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The use of",
"    <span class=\"nowrap\">",
"     FFP/FP24",
"    </span>",
"    is thought to be unnecessarily high in the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/3,4\">",
"     3,4",
"    </a>",
"    ], as well as in other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/5-7\">",
"     5-7",
"    </a>",
"    ], despite the presence of guidelines concerning their use [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/8,9\">",
"     8,9",
"    </a>",
"    ]. Since plasma serves as a source for the further manufacture of plasma derivatives (eg, albumin, gamma globulin, and the coagulation factors), many feel that its use in transfusion should be closely monitored and curtailed wherever possible [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Guidelines for its use in trauma and other emergency settings are under active evaluation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=see_link&amp;anchor=H8#H8\">",
"     \"Massive blood transfusion\", section on 'FFP, platelets, and red cells in trauma patients'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Dose and indications",
"    </span>",
"    &nbsp;&mdash;&nbsp;As a general rule, hemostasis can be achieved when the activity of coagulation factors is at least 25 to 30 percent of normal, in the absence of an inhibitor such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/34/40489?source=see_link\">",
"     heparin",
"    </a>",
"    , and when the level of fibrinogen is at least 75 to 100",
"    <span class=\"nowrap\">",
"     mg/dL",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/12\">",
"     12",
"    </a>",
"    ]. Since the plasma volume in adults is approximately 40",
"    <span class=\"nowrap\">",
"     mL/kg,",
"    </span>",
"    this requires a dose of FFP of approximately 10 to 15",
"    <span class=\"nowrap\">",
"     mL/kg.",
"    </span>",
"    This dose represents approximately three to five units of FFP for most adult patients, representing a significant volume challenge [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The dose may have to be repeated in critically ill patients or in those with massive bleeding, depending upon the patient's clinical response, presence or absence of appropriate shortening of previously abnormal coagulation times, and the half-life of the missing or reduced coagulation factor(s) (",
"    <a class=\"graphic graphic_table graphicRef51595 \" href=\"UTD.htm?9/38/9836\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/14,15\">",
"     14,15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Indications for the use of",
"    <span class=\"nowrap\">",
"     FFP/FP24",
"    </span>",
"    must be carefully followed (",
"    <a class=\"graphic graphic_table graphicRef69637 \" href=\"UTD.htm?13/38/13932\">",
"     table 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      FFP may be needed for inherited factor XI deficiency or as a source of factor V in severe cases of disseminated intravascular coagulation (DIC) when platelet concentrates and cryoprecipitate do not correct the factor V, VIII, and fibrinogen consumption defects.",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       FFP/FP24",
"      </span>",
"      (or, alternatively, prothrombin complex preparations that contain adequate amounts of factor VII [",
"      <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/16\">",
"       16",
"      </a>",
"      ]) may be needed to correct a bleeding condition caused by a deficiency of multiple coagulation factors, such as is seen in",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      overdose, vitamin K deficiency, liver failure, or dilutional coagulopathy following massive transfusion, or for reversing warfarin in preparation for an invasive procedure [",
"      <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/17\">",
"       17",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link&amp;anchor=H6#H6\">",
"       \"Correcting excess anticoagulation after warfarin\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=see_link&amp;anchor=H20#H20\">",
"       \"Endoscopic procedures in patients with disorders of hemostasis\", section on 'Liver failure'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=see_link\">",
"       \"Management of anticoagulants in patients undergoing endoscopic procedures\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=see_link&amp;anchor=H14#H14\">",
"       \"Management of anticoagulation before and after elective surgery\", section on 'Reversing the vitamin K antagonists'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     FFP/FP24",
"    </span>",
"    should not be used as primary therapy for a specific coagulation defect (eg, hemophilia A, hemophilia B, factor VII deficiency) when specific coagulation factor concentrates are available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Minimally elevated INR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Given that the INR of",
"    <span class=\"nowrap\">",
"     FFP/FP24",
"    </span>",
"    units can be as high as 1.3 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/13\">",
"     13",
"    </a>",
"    ], transfusion of",
"    <span class=\"nowrap\">",
"     FFP/FP24",
"    </span>",
"    will have little effect on minimally elevated INRs. Existing guidelines suggest that FFP be considered for this purpose only when the patient's INR is &ge;1.6. However, the ability of FFP to fully or even partially correct an INR &le;1.85, as well as the ability of such testing to predict clinical bleeding, have been called into question [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/13,18-22\">",
"     13,18-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The lack of efficacy of FFP in patients with a minimally prolonged INR was illustrated in a study of the use of FFP in 121 patients with an INR in the range of 1.1 to 1.85 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/20\">",
"     20",
"    </a>",
"    ]. Correction of the INR to normal was achieved in only one patient (0.8 percent) and correction at least halfway to normal in only 15 percent. The median decrease in the PT and INR was 0.2 seconds and 0.07, respectively, and was independent of the number of units of FFP infused (median 2 units; range 1 to 20).",
"   </p>",
"   <p>",
"    Thus, available studies do not support the efficacy of FFP in treating bleeding or as prophylaxis for invasive procedures in patients with a mild coagulopathy (ie, INR &lt;2.0) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/23\">",
"     23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Side effects",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Overview",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of most transfusion-transmitted infections is the same for a standard unit of",
"    <span class=\"nowrap\">",
"     FFP/FP24",
"    </span>",
"    (or cryoprecipitate) as it is for red cells, with the exception of a lower risk of transmitting intracellular viruses such as CMV and HTLV. Because it is basically an acellular blood component, FFP has been a primary focus of research concerning pathogen reduction. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=see_link\">",
"     \"Pathogen inactivation of blood products\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The literature contains conflicting reports on whether the infusion of plasma does or does not increase the risk of infection through a potential immunomodulatory effect [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20242587\">",
"    <span class=\"h3\">",
"     ABO compatibility and presence of alloantibodies",
"    </span>",
"    &nbsp;&mdash;&nbsp;All units collected are subjected to an antibody screen (ie, the donor's serum is run against a red cell pool known to contain virtually all relevant antigens). If the screen is positive (ie, the donor has at least one antibody to a red cell antigen) FFP will not be made from that unit. Therefore, if a unit of FFP is prepared for transfusion, the only red cell alloantibodies that it can have are ABO antibodies. Due to the normal presence of A",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    B alloantibodies in patients with blood types A, B, and O, donor plasma must be either ABO-",
"    <strong>",
"     identical",
"    </strong>",
"    or ABO-",
"    <strong>",
"     compatible",
"    </strong>",
"    with the recipient. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=see_link&amp;anchor=H3#H3\">",
"     \"A primer of red blood cell antigens and antibodies\", section on 'Natural alloantibodies'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      A patient with type A blood can accept plasma from donors who are type A (identical), or type AB (compatible)",
"     </li>",
"     <li>",
"      A patient with type B blood can accept plasma from donors who are type B (identical), or type AB (compatible)",
"     </li>",
"     <li>",
"      A patient with type O blood can accept plasma from donors who are type O (identical), or types A, B, or AB (compatible)",
"     </li>",
"     <li>",
"      A patient with type AB blood can only accept plasma from donors who are type AB (identical)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There are few studies which have addressed the clinical impact of using ABO-compatible plasma rather than ABO-identical plasma:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a matched, retrospective study of trauma patients, the overall complication rate was significantly higher for the 284 subjects receiving ABO-compatible plasma than for the 284 receiving ABO-identical plasma (53.5 versus 40.5 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/26\">",
"       26",
"      </a>",
"      ]. As the volume of ABO-compatible plasma infused increased, a stepwise increase in complications was seen, reaching 70 percent for those receiving more than 6 units of ABO-compatible plasma.",
"     </li>",
"     <li>",
"      In a retrospective cohort study of 86,082 Swedish patients who received their first plasma transfusion between 1990 and 2002, there was an increased mortality associated with exposure to ABO-compatible plasma as compared to ABO-identical plasma, with the excess risk mostly confined to those receiving 5 or more units (RR 1.15; 95% CI 1.02 &ndash; 1.29) [",
"      <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/27\">",
"       27",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    It is difficult to interpret the significance of these retrospective studies, since results could be confounded by many factors, including the relative efficacy of fresher versus thawed plasma. While these data suggest that ABO-identical plasma may result in somewhat better outcomes, the logistical difficulty in providing such components is considerable. Specifically, the need for ABO-identical components would appear to be secondary to the need to rapidly supply adequate amounts of plasma for trauma patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Volume overload",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusion of large amounts of FFP or other blood products may precipitate pulmonary edema, especially in the elderly, small children, and those with preexisting cardiac disease. This can be avoided by reducing the rate of infusion to 1",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    per hour in susceptible patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=see_link&amp;anchor=H2#H2\">",
"     \"Transfusion reactions caused by chemical and physical agents\", section on 'Transfusional volume overload (TACO)'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Febrile and allergic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infusion of plasma can be associated with allergic reactions, fever, and chills. These should be treated symptomatically. Despite the fact that antihistamines",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    are frequently ordered",
"    <strong>",
"     prior",
"    </strong>",
"    to transfusion, there is no evidence to support their effectiveness for the prevention of such reactions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link&amp;anchor=H3#H3\">",
"     \"Immunologic blood transfusion reactions\", section on 'Febrile nonhemolytic reactions'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Anaphylactic reactions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anaphylactic reactions following transfusion of plasma may occur in patients with IgA deficiency and antibodies to IgA [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/28\">",
"     28",
"    </a>",
"    ]. For such patients, IgA-deficient plasma from donors in the national registry is available [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. Very rarely, passive transfer of an allergic phenotype (eg, acquired peanut anaphylaxis from donor IgE antibodies) can occur [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=see_link&amp;anchor=H13#H13\">",
"     \"Immunologic blood transfusion reactions\", section on 'Anaphylactic reactions'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30998?source=see_link&amp;anchor=H24166172#H24166172\">",
"     \"Selective IgA deficiency: Management and prognosis\", section on 'Safe administration of blood products'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2635997\">",
"    <span class=\"h3\">",
"     Transfusion-related acute lung injury (TRALI)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since certain forms of TRALI are felt to be induced by donor antibodies to recipient HLA or neutrophil antigens, a worldwide approach to TRALI prevention involves preparing plasma components for transfusion from either male donors or female donors who have been screened and found not to have antibodies to HLA class 1 or class 2 antigens. This action has, at least in Great Britain, resulted in a substantial drop in reported TRALI cases after plasma transfusions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=see_link\">",
"     \"Transfusion-related acute lung injury (TRALI)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     OTHER PLASMA PRODUCTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fresh frozen plasma (FFP) is a licensed product that must be separated from whole blood and frozen at -18 to -30&ordm;C within eight hours of collection. A number of plasma products that do not meet these criteria (ie, frozen plasma, thawed plasma, single donor plasma) are discussed below.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     FP24 (Frozen plasma)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma frozen within 24 hours of collection (rather than eight hours for FFP) is a licensed product (called frozen plasma, or FP-24) that maintains all the clotting factors at the same levels as in FFP, except that Factor VIII levels are in the range of 65 to 80 percent of normal [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]. Other factor levels may also be slightly reduced [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/32,33,35-37\">",
"     32,33,35-37",
"    </a>",
"    ]. These levels are perfectly acceptable for normal coagulation, especially remembering that the \"normal\" range of factor VIII is roughly 50 to 150 percent of normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Thawed plasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the 1996 edition of Standards for Blood Banks and Transfusion Services, the transfusion expiration time for FFP was extended from no more than 24 hours after thawing to up to five days when stored at refrigerator temperature (ie, 1 to 6&ordm;C), when the thawed plasma is used to treat coagulopathies other than factor VIII deficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/38\">",
"     38",
"    </a>",
"    ]. This component, which after 24 hours of storage must be relabeled as \"thawed plasma,\" and which, as a non-FDA licensed product, cannot be shipped across state lines, is an exceedingly valuable and versatile product. Studies have confirmed earlier observations regarding the stability of clotting factors other than factors V and VIII in thawed plasma that has been stored at refrigerator temperatures for up to five days [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/32,35,39-43\">",
"     32,35,39-43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thawed plasma has the advantage of being available for immediate use; this is particularly important in both emergency department and operating room settings. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=see_link&amp;anchor=H11#H11\">",
"     \"Initial evaluation and management of shock in adult trauma\", section on 'Transfusion of clotting factors'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thawed plasma is indicated, and may be freely substituted for FFP, in the following clinical situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The coagulopathy of liver disease",
"     </li>",
"     <li>",
"      Thrombotic thrombocytopenic purpura",
"     </li>",
"     <li>",
"      Disseminated intravascular coagulation",
"     </li>",
"     <li>",
"      Bleeding in a patient with an elevated INR",
"     </li>",
"     <li>",
"      Reversal of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      effect",
"     </li>",
"     <li>",
"      Massive transfusion protocols",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, thawed plasma should not be used as a predominant source of either Factor V or Factor VIII, and its usefulness in neonates is not yet known. In one study, levels of plasticizers (eg, di(2-ethylhexyl) phthalate, DEHP) leached from the plastic storage bags increased from 22 ppm at the time of thawing to 66 ppm on day 5, suggesting that such long storage of thawed plasma may not be safe for neonates and infants [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As more clinicians become comfortable with the use of thawed plasma as an alternative to FFP, not only will the logistics of managing bleeding patients in the complex settings listed above become greatly simplified, but there will also be the additional benefit of a substantial reduction in the wastage of FFP thawed for use and discarded when not transfused within the first 24 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Single donor plasma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Single donor plasma (plasma frozen within five days of separation from whole blood) can be transfused up to 26 days later or frozen and used within five years. Currently, there is no indication for its use as a transfusable product. It is generally sent to a manufacturing facility for fractionation into albumin and gamma globulin.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21213419\">",
"    <span class=\"h2\">",
"     Solvent/detergent-treated plasma (S/D plasma)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment of pooled plasma prior to freezing with a solvent and a nonionic detergent inactivates a number of viruses with lipid envelopes, including HIV, hepatitis B virus, and hepatitis C virus [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/45\">",
"     45",
"    </a>",
"    ]. Non-lipid-enveloped viruses, such as hepatitis A and parvovirus B19, are not inactivated by this process, nor are prions. The",
"    <span class=\"nowrap\">",
"     solvent/detergent",
"    </span>",
"    <span class=\"nowrap\">",
"     (S/D)",
"    </span>",
"    method is similar to that used to inactivate viruses in immune globulin and coagulation factors. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=see_link&amp;anchor=H5#H5\">",
"     \"Pathogen inactivation of blood products\", section on 'Pathogen inactivation of fresh frozen plasma'",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/25/4500?source=see_link\">",
"     \"Solvent detergent treated fresh frozen plasma: Drug information\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <span class=\"nowrap\">",
"     S/D",
"    </span>",
"    plasma has similar levels of most clotting factors and similar hemostatic properties as standard FFP [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/46\">",
"     46",
"    </a>",
"    ]. Special properties of and indications for its use are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=see_link&amp;anchor=H10#H10\">",
"     \"Pathogen inactivation of blood products\", section on 'Special properties'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=see_link&amp;anchor=H11#H11\">",
"     \"Pathogen inactivation of blood products\", section on 'S/D plasma use in liver transplantation'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     CRYOPRECIPITATE",
"    </span>",
"    &nbsp;&mdash;&nbsp;When FFP is thawed at 4&ordm;C, a precipitate remains, which can be separated by centrifugation; this material is termed cryoprecipitate (cryo). It is a concentrated preparation that contains virtually all of the factor VIII, fibrinogen, fibronectin, factor XIII, and von Willebrand factor (vWF) in fresh frozen plasma, reduced from an initial volume of 250 mL to a final volume of 10 to 20 mL. The remaining material can be refrozen and used as cryo-poor FFP. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Cryoprecipitate-poor plasma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Cryo contains about 200 mg of fibrinogen and 100 units of Factor VIII (80 to 110 international units) per unit and carries the same infectious risk as a unit of FFP. Cryo is used in the treatment of congenital and acquired deficiencies of fibrinogen and Factor XIII [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9752/abstract/2,47\">",
"     2,47",
"    </a>",
"    ]. As examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Ten units of cryo (obtained from 10 units of plasma) contain about 2 g of fibrinogen and will raise the fibrinogen level about 70",
"      <span class=\"nowrap\">",
"       mg/dL",
"      </span>",
"      in a 70 kg recipient (",
"      <a class=\"graphic graphic_table graphicRef69637 \" href=\"UTD.htm?13/38/13932\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Recommended dosages for factor XIII replacement (every 20 to 40 days) are 15 to 20",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      for FFP, 10 to 20",
"      <span class=\"nowrap\">",
"       units/kg",
"      </span>",
"      for factor XIII concentrate, or 1 unit of cryo per 10 kg body weight. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16730?source=see_link&amp;anchor=H26#H26\">",
"       \"Rare (recessively inherited) coagulation disorders\", section on 'Factor XIII deficiency'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Some blood suppliers now provide pre-pooled cryo (one &ldquo;bag&rdquo;) containing the cryo obtained from five (or more) units of FFP. The clinician should check with the local blood bank to determine the exact composition of one &ldquo;bag&rdquo; of cryo in order to determine the correct dosage for a patient.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Because of past experience with viral transmission, cryo should no longer be used for the treatment of hemophilia A. Appropriate factor VIII replacement products are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=see_link&amp;anchor=H9#H9\">",
"     \"Treatment of hemophilia\", section on 'Replacement therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, cryo does contain the large multimers of vWF and may be needed for the treatment of von Willebrand disease when von Willebrand factor replacement is required and there is no other recourse, or in patients with uremic bleeding. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=see_link&amp;anchor=H10#H10\">",
"     \"Treatment of von Willebrand disease\", section on 'Replacement therapy with VWF'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=see_link&amp;anchor=H13#H13\">",
"     \"Platelet dysfunction in uremia\", section on 'Cryoprecipitate'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     CRYOPRECIPITATE-POOR PLASMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cryoprecipitate-poor (\"cryo-poor\") plasma, the plasma remaining after cryoprecipitate has been removed, has been employed as plasma replacement in some patients with thrombotic thrombocytopenic purpura. This subject is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=see_link&amp;anchor=H22#H22\">",
"     \"Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults\", section on 'Cryoprecipitate-poor plasma'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because the vitamin K-dependent factors in plasma are not present in cryoprecipitate, cryo-poor plasma is suitable for use in patients with vitamin K deficiency",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    correction of excessive",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"     warfarin",
"    </a>",
"    anticoagulation (",
"    <a class=\"graphic graphic_table graphicRef69637 \" href=\"UTD.htm?13/38/13932\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of vitamin K\", section on 'Deficiency'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link&amp;anchor=H6#H6\">",
"     \"Correcting excess anticoagulation after warfarin\", section on 'Treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Plasma or blood components are biological products prepared by differential centrifugation of whole blood or plasma in a blood center or hospital laboratory. The major plasma components used in transfusion medicine include fresh frozen plasma",
"      <span class=\"nowrap\">",
"       (FFP/FP24)",
"      </span>",
"      and cryoprecipitate (cryo). General usage guidelines for these products are shown in the table (",
"      <a class=\"graphic graphic_table graphicRef69637 \" href=\"UTD.htm?13/38/13932\">",
"       table 2",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Fresh frozen plasma (FFP), plasma frozen after 24 rather than 8 hours (FP24), and thawed plasma (from FFP or FP24) are indicated for correction of bleeding due to excessive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      , vitamin K deficiency, or a deficiency of multiple coagulation factors (eg, liver disease, disseminated intravascular coagulation), and as components of massive transfusion protocols.",
"     </li>",
"     <li>",
"      FFP is employed in an initial intravenous dose of 10 to 15",
"      <span class=\"nowrap\">",
"       mL/kg",
"      </span>",
"      of body weight. It should not be used as a source of albumin or other nutrients, or as a volume expander. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Dose and indications'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=see_link&amp;anchor=H15#H15\">",
"       \"Correcting excess anticoagulation after warfarin\", section on 'Significant or life-threatening bleeding'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Available studies do not support the efficacy of",
"      <span class=\"nowrap\">",
"       FFP/FP24",
"      </span>",
"      in treating bleeding or as prophylaxis for invasive procedures in patients with a mild coagulopathy (ie, INR &lt;2.0). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Minimally elevated INR'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Cryoprecipitate (cryo) is indicated for replacement of factor XIII or fibrinogen. Cryo can also be used for replacement of von Willebrand factor when it is required in von Willebrand disease and there is no other recourse, or in uremic bleeding. Routinely used doses of cryo for these indications are shown in the table (",
"      <a class=\"graphic graphic_table graphicRef69637 \" href=\"UTD.htm?13/38/13932\">",
"       table 2",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Cryoprecipitate'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of cryo for factor VIII deficiency (Hemophilia A) is outmoded, and has been replaced by",
"      <a class=\"drug drug_general\" href=\"UTD.htm?0/12/198?source=see_link\">",
"       factor VIII concentrates",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/1/23574?source=see_link\">",
"       recombinant human factor VIII",
"      </a>",
"      . (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=see_link&amp;anchor=H9#H9\">",
"       \"Treatment of hemophilia\", section on 'Replacement therapy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Cryo-poor plasma is suitable for the treatment of bleeding in patients with vitamin K deficiency or excessive",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/41/28314?source=see_link\">",
"       warfarin",
"      </a>",
"      anticoagulation as it still contains all of the vitamin K-dependent coagulation factors. Doses of cryo-poor plasma are similar to those employed for FFP. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Cryoprecipitate-poor plasma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Westphal RG. International aspects of blood transfusion. In: Principles of Transfusion Medicine, 2nd ed, Rossi EC, Simon TL, Moss GS, et al. (Eds), Williams and Wilkins, Baltimore 1996. p.917.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/2\">",
"      O'Shaughnessy DF, Atterbury C, Bolton Maggs P, et al. Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant. Br J Haematol 2004; 126:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/3\">",
"      Consensus conference. Fresh-frozen plasma. Indications and risks. JAMA 1985; 253:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/4\">",
"      Dzik W, Rao A. Why do physicians request fresh frozen plasma? Transfusion 2004; 44:1393.",
"     </a>",
"    </li>",
"    <li>",
"     Van Aken WG. The Collection and Use of Human Blood and Plasma in Europe. Council of Europe Press, Strasbourg, 1992.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/6\">",
"      Palo R, Capraro L, Hovilehto S, et al. Population-based audit of fresh-frozen plasma transfusion practices. Transfusion 2006; 46:1921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/7\">",
"      Stanworth SJ, Walsh TS, Prescott RJ, et al. A national study of plasma use in critical care: clinical indications, dose and effect on prothrombin time. Crit Care 2011; 15:R108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/8\">",
"      Lauzier F, Cook D, Griffith L, et al. Fresh frozen plasma transfusion in critically ill patients. Crit Care Med 2007; 35:1655.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/9\">",
"      Roback JD, Caldwell S, Carson J, et al. Evidence-based practice guidelines for plasma transfusion. Transfusion 2010; 50:1227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/10\">",
"      Tavares M, DiQuattro P, Nolette N, et al. Reduction in plasma transfusion after enforcement of transfusion guidelines. Transfusion 2011; 51:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/11\">",
"      Sarode R, Refaai MA, Matevosyan K, et al. Prospective monitoring of plasma and platelet transfusions in a large teaching hospital results in significant cost reduction. Transfusion 2010; 50:487.",
"     </a>",
"    </li>",
"    <li>",
"     Friedman KD, Menitove JE. Preparation and clinical use of plasma and plasma fractions. In: Williams' Hematology, 6th ed, Beutler, E, Lichtman, MA, Coller, BS, et al. (Eds), McGraw-Hill, New York 2001. p.1917.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/13\">",
"      Holland LL, Foster TM, Marlar RA, Brooks JP. Fresh frozen plasma is ineffective for correcting minimally elevated international normalized ratios. Transfusion 2005; 45:1234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/14\">",
"      Hellstern P, Haubelt H. Indications for plasma in massive transfusion. Thromb Res 2002; 107 Suppl 1:S19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/15\">",
"      Chowdary P, Chowdhury P, Saayman AG, et al. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 2004; 125:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/16\">",
"      Holland L, Warkentin TE, Refaai M, et al. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. Transfusion 2009; 49:1171.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/17\">",
"      Ciavarella D, Reed RL, Counts RB, et al. Clotting factor levels and the risk of diffuse microvascular bleeding in the massively transfused patient. Br J Haematol 1987; 67:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/18\">",
"      Segal JB, Dzik WH, Transfusion Medicine/Hemostasis Clinical Trials Network. Paucity of studies to support that abnormal coagulation test results predict bleeding in the setting of invasive procedures: an evidence-based review. Transfusion 2005; 45:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/19\">",
"      Stanworth SJ, Brunskill SJ, Hyde CJ, et al. Is fresh frozen plasma clinically effective? A systematic review of randomized controlled trials. Br J Haematol 2004; 126:139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/20\">",
"      Abdel-Wahab OI, Healy B, Dzik WH. Effect of fresh-frozen plasma transfusion on prothrombin time and bleeding in patients with mild coagulation abnormalities. Transfusion 2006; 46:1279.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/21\">",
"      Holland LL, Brooks JP. Toward rational fresh frozen plasma transfusion: The effect of plasma transfusion on coagulation test results. Am J Clin Pathol 2006; 126:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/22\">",
"      Cheng CK, Sadek I. Fresh-frozen plasma transfusion in patients with mild coagulation abnormalities at a large Canadian transfusion center. Transfusion 2007; 47:748; author reply 749.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/23\">",
"      Triulzi DJ. The art of plasma transfusion therapy. Transfusion 2006; 46:1268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/24\">",
"      Vamvakas EC, Carven JH. Exposure to allogeneic plasma and risk of postoperative pneumonia and/or wound infection in coronary artery bypass graft surgery. Transfusion 2002; 42:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/25\">",
"      Sarani B, Dunkman WJ, Dean L, et al. Transfusion of fresh frozen plasma in critically ill surgical patients is associated with an increased risk of infection. Crit Care Med 2008; 36:1114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/26\">",
"      Inaba K, Branco BC, Rhee P, et al. Impact of ABO-identical vs ABO-compatible nonidentical plasma transfusion in trauma patients. Arch Surg 2010; 145:899.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/27\">",
"      Shanwell A, Andersson TM, Rostgaard K, et al. Post-transfusion mortality among recipients of ABO-compatible but non-identical plasma. Vox Sang 2009; 96:316.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/28\">",
"      Pineda AA, Taswell HF. Transfusion reactions associated with anti-IgA antibodies: report of four cases and review of the literature. Transfusion 1975; 15:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/29\">",
"      Meena-Leist CE, Fleming DR, Heye M, Herzig RH. The transfusion needs of an autologous bone marrow transplant patient with IgA deficiency. Transfusion 1999; 39:457.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/30\">",
"      Rogers RL, Javed TA, Ross RE, et al. Transfusion management of an IgA deficient patient with anti-IgA and incidental correction of IgA deficiency after allogeneic bone marrow transplantation. Am J Hematol 1998; 57:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/31\">",
"      Arnold DM, Blajchman MA, Ditomasso J, et al. Passive transfer of peanut hypersensitivity by fresh frozen plasma. Arch Intern Med 2007; 167:853.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/32\">",
"      Scott E, Puca K, Heraly J, et al. Evaluation and comparison of coagulation factor activity in fresh-frozen plasma and 24-hour plasma at thaw and after 120 hours of 1 to 6&deg;C storage. Transfusion 2009; 49:1584.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/33\">",
"      Alhumaidan H, Cheves T, Holme S, Sweeney J. Stability of coagulation factors in plasma prepared after a 24-hour room temperature hold. Transfusion 2010; 50:1934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/34\">",
"      Cardigan R, Van der Meer PF, Pergande C, et al. Coagulation factor content of plasma produced from whole blood stored for 24 hours at ambient temperature: results from an international multicenter BEST Collaborative study. Transfusion 2011; 51 Suppl 1:50S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/35\">",
"      Yazer MH, Cortese-Hassett A, Triulzi DJ. Coagulation factor levels in plasma frozen within 24 hours of phlebotomy over 5 days of storage at 1 to 6 degrees C. Transfusion 2008; 48:2525.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/36\">",
"      Cardigan R, Lawrie AS, Mackie IJ, Williamson LM. The quality of fresh-frozen plasma produced from whole blood stored at 4 degrees C overnight. Transfusion 2005; 45:1342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/37\">",
"      Katz LM, Kiss JE. Plasma for transfusion in the era of transfusion-related acute lung injury mitigation. Transfusion 2008; 48:393.",
"     </a>",
"    </li>",
"    <li>",
"     Klein HG. Standards for Blood Banks and Transfusion Services, 17th ed, American Association of Blood Banks, Bethesda 1996.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/39\">",
"      Downes KA, Wilson E, Yomtovian R, Sarode R. Serial measurement of clotting factors in thawed plasma stored for 5 days. Transfusion 2001; 41:570.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/40\">",
"      O'Neill EM, Rowley J, Hansson-Wicher M, et al. Effect of 24-hour whole-blood storage on plasma clotting factors. Transfusion 1999; 39:488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/41\">",
"      Smak Gregoor PJ, Harvey MS, Bri&euml;t E, Brand A. Coagulation parameters of CPD fresh-frozen plasma and CPD cryoprecipitate-poor plasma after storage at 4 degrees C for 28 days. Transfusion 1993; 33:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/42\">",
"      von Heymann C, Keller MK, Spies C, et al. Activity of clotting factors in fresh-frozen plasma during storage at 4 degrees C over 6 days. Transfusion 2009; 49:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/43\">",
"      Sheffield WP, Bhakta V, Mastronardi C, et al. Changes in coagulation factor activity and content of di(2-ethylhexyl)phthalate in frozen plasma units during refrigerated storage for up to five days after thawing. Transfusion 2012; 52:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/44\">",
"      Wehrli G, Taylor NE, Haines AL, et al. Instituting a thawed plasma procedure: it just makes sense and saves cents. Transfusion 2009; 49:2625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/45\">",
"      Biesert L, Suhartono H. Solvent/detergent treatment of human plasma--a very robust method for virus inactivation. Validated virus safety of OCTAPLAS. Vox Sang 1998; 74 Suppl 1:207.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/46\">",
"      Inbal A, Epstein O, Blickstein D, et al. Evaluation of solvent/detergent treated plasma in the management of patients with hereditary and acquired coagulation disorders. Blood Coagul Fibrinolysis 1993; 4:599.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9752/abstract/47\">",
"      Callum JL, Karkouti K, Lin Y. Cryoprecipitate: the current state of knowledge. Transfus Med Rev 2009; 23:177.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7920 Version 16.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-61.234.146.186-E927C15C8D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_33_9752=[""].join("\n");
var outline_f9_33_9752=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      FRESH FROZEN PLASMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Dose and indications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Minimally elevated INR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Side effects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Overview",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20242587\">",
"      - ABO compatibility and presence of alloantibodies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Volume overload",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Febrile and allergic reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Anaphylactic reactions",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2635997\">",
"      - Transfusion-related acute lung injury (TRALI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      OTHER PLASMA PRODUCTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      FP24 (Frozen plasma)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Thawed plasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Single donor plasma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21213419\">",
"      Solvent/detergent-treated plasma (S/D plasma)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      CRYOPRECIPITATE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      CRYOPRECIPITATE-POOR PLASMA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"HEME/7920\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"HEME/7920|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/38/9836\" title=\"table 1\">",
"      Properties of coagulation factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?13/38/13932\" title=\"table 2\">",
"      Use of plasma components",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/15/27898?source=related_link\">",
"      A primer of red blood cell antigens and antibodies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/8/30857?source=related_link\">",
"      Correcting excess anticoagulation after warfarin",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/13/31959?source=related_link\">",
"      Endoscopic procedures in patients with disorders of hemostasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/31/11769?source=related_link\">",
"      Immunologic blood transfusion reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29562?source=related_link\">",
"      Initial evaluation and management of shock in adult trauma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/33/21014?source=related_link\">",
"      Management of anticoagulants in patients undergoing endoscopic procedures",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/50/35626?source=related_link\">",
"      Management of anticoagulation before and after elective surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/25/38294?source=related_link\">",
"      Massive blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/37/15960?source=related_link\">",
"      Overview of vitamin K",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/22/38247?source=related_link\">",
"      Pathogen inactivation of blood products",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32039?source=related_link\">",
"      Plasma derivatives and recombinant DNA-produced coagulation factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/30/10727?source=related_link\">",
"      Platelet dysfunction in uremia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/39/11895?source=related_link\">",
"      Preparation of blood components",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/21/16730?source=related_link\">",
"      Rare (recessively inherited) coagulation disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/17/30998?source=related_link\">",
"      Selective IgA deficiency: Management and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?4/25/4500?source=related_link\">",
"      Solvent detergent treated fresh frozen plasma: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/14/42214?source=related_link\">",
"      Transfusion reactions caused by chemical and physical agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=related_link\">",
"      Transfusion-related acute lung injury (TRALI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?41/31/42490?source=related_link\">",
"      Treatment and prognosis of thrombotic thrombocytopenic purpura-hemolytic uremic syndromes in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/34/38442?source=related_link\">",
"      Treatment of hemophilia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/22/21866?source=related_link\">",
"      Treatment of von Willebrand disease",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_33_9753="RA MCP mild erosion";
var content_f9_33_9753=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F85826%7ERADIOL%2F85827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F85826%7ERADIOL%2F85827&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 617px\">",
"   <div class=\"ttl\">",
"    Plain radiograph of mild metacarpophalangeal joint erosion rheumatoid arthritis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 597px; height: 398px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAGOAlUDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6D8e+MbPwXp1nd31nfXgu7oWkUVmIy+8xvJk73UY2xt39K4qX45aVEuZPDXiUD/dtP/kipf2hv+QL4Y/7DP8A7Z3VcH4F8Daf4s0jxFqmua7qthbabetDttfIEaRLbQyljviZs5kbv0xxQB0037RvhmFtsmheJFP/AFytj/7XqP8A4aT8LYz/AGH4k/7823/x+uO+Gnw6+H3xP069vtG1rxhGbSYQyxXZtEkGVyrYWJhtPOOf4TxXglm7SWcLyHLMikn1OKAPqv8A4aV8Kf8AQE8S/wDfm3/+P0h/aX8Jj/mC+JP+/Nv/APH6+V26ZqFs5yOlAH1Yf2mfCQ66L4k/782//wAepD+054RHJ0bxJ/35t/8A49Xyg4456VXcUAfWh/ag8HDro/iT/vxb/wDx6m/8NReDf+gR4l/78W//AMer5Cm5PvUYHpQB9hf8NReDf+gR4k/78W//AMeo/wCGofBv/QH8S/8Afi3/APj1fHpHNGKAPsMftQeDicDR/En/AH4t/wD49Tx+034RI40bxJ/35t//AI9Xx3EP3laUQ46UAfWg/aY8JnpoviT/AL82/wD8ep3/AA0t4UP/ADBPEn/fm3/+P18nqeRxxUqjnmgD6sX9pPwsxwND8SE/9cbb/wCP1pW/x40a5XdD4c8SsD/s2g/ncV8lWw3Sr6Zr0bRh5cC8YI64oA92Hxs00j/kWPEv5Wn/AMkU0fG/Sz08M+JPytP/AJIryXcTDuPekt1wpY0AevL8bNNbp4Y8S/lZ/wDyRS/8Lq07/oV/Ev5Wf/yRXkaDAJHNSZJGMc0Aeqt8b9MUZbwz4kH4Wf8A8kUq/G3TGXcvhjxJt9cWf/yRXkU6ZyPxNSINto2eCTQB6u/xw0tF3N4Z8Sgf7tp/8kVSuf2hfD1sMzeH/Eigf9M7U/ynry29JEXBxxXAeIpP3hUD/wCvQB9Df8NKeFc/8gTxJ/35tv8A4/R/w0t4U/6AniT/AL82/wD8fr5YcZzmoWzkYoA+rP8Ahpfwn/0BPEv/AH5t/wD4/Sf8NL+E/wDoC+JP+/Nv/wDH6+U8D8ab0B9KAPq4/tM+Eh10XxJ/35t//j1NP7TfhEddG8S/9+Lf/wCPV8oN3AqtLQB9an9qDwcOuj+JP+/Fv/8AHqQ/tQ+Df+gR4l/78W//AMer4/fk8c5pv14oA+wv+GofBv8A0CPEn/fi3/8Aj1H/AA1D4N/6A/iX/vxb/wDx6vjzpS4/KgD7C/4ai8G4/wCQR4k/78W//wAer0/UfHGn2Pw+tPF7Wt9LYXUNrPFbxqnnkXDIsa4LBQcyLn5sDnk1+do5619pa/8A8mweGv8Ary0P/wBHWtAGk3xu0xQS3hnxJj6Wn/yRVG5/aE8P22fP8P8AiRf+2dqf5T1wvhnQLTXZfFVzq2p6tZ2OiadDeeXpwg3PuNwX/wBbG2TiFcDIFReGfBfgvxfq+m6c1547sptTsTqNm12bDbNCDjdmJHKn2YCgDtf+Gk/C3/QD8Sf9+rb/AOP0h/aV8Kg86J4kH/bG2/8Aj9fNPiHT00nxLrWmwySyw2OoXNpG8uN7JHM6KWwAM4UZwBWcw57UAfUx/aW8KD/mCeJP+/Nv/wDH6Q/tM+Eh/wAwXxJ/35t//j1fKkntUZzjtQB9Wn9pvwiD/wAgbxL/AN+Lf/49TT+094PHXR/En/fi3/8Aj1fJsg64qrLjBoA+uj+1F4N/6BHiT/vxb/8Ax6j/AIai8G/9AjxJ/wB+Lf8A+PV8e4NGOBQB9hf8NQ+Df+gR4l/78W//AMeo/wCGofBv/QH8S/8Afi3/APj1fHtGOaAPsVf2nPCDdNG8Sf8Afi3/APj1P/4aZ8Jf9AXxJ/35t/8A49XyLbjAFWhge9AH1j/w0t4Ux/yBPEv/AH5t/wD4/Sj9pXwrx/xJPEnP/TG2/wDj9fKS9OlTIOnFAH1laftCeH7s4t/D/iV/+2dqP5z1eHxu0w9PDPiT8rT/AOSK+b/CqYQNj8a7OBi3yjsPSgD10/G/TAcHwz4kz9LT/wCSKX/hdumHp4Z8Sflaf/JFePgGSbpipsfMAO1AHrn/AAurTv8AoV/Ev5Wf/wAkUh+NmmgZPhjxJ+Vn/wDJFeUK3XI496ZIPlz6etAHrCfG7THbavhnxIT9LT/5IpW+NumqSD4Y8Sce1p/8kV5HZpifkDjkmlPIcjrmgD1Kb496JACZfDniRcf7Fqf/AGvVB/2k/CyHDaH4kB/65W3/AMfrxHxE+1ST+GK4eY7nPHU0AfUn/DSvhT/oCeJf+/Nv/wDH6T/hpfwp/wBATxL/AN+bf/4/Xyq3HTmmdeaAPqz/AIaX8J/9AXxJ/wB+bf8A+P0H9pjwmOui+JP+/Nv/APH6+UjwRTWxnPr0oA+rT+014RHXRfEv/fi3/wDj1NP7T/g8ddH8Sf8Afi3/APj1fJsnSqcxoA+vP+GofBv/AECPEn/fi3/+PUf8NQ+Df+gR4k/78W//AMer4979DSHrQB9h/wDDUXg3/oEeJf8Avxb/APx6kb9qPwYoJOkeJMDk/uLf/wCPV8fdajm/1Un+6aAP0/ooooA8p/aF/wCQL4Y/7DP/ALZ3Vcb4Q0DWfFHwn8c6H4dubS1u7/WBBJNcswVYTa2vmY2qSSVyuPc812X7Q/8AyBPDH/YZ/wDbO6rwDXNM06aaSe40+0llb70jwqzHAwMkigD6A8CfDLUPA/xCl1LStUW78P3emRWd1FdbEnEsICxMqxRqhUIAvPPJJzXxvYD/AIl9tj/nkv8AIVc1Cws1uGCWluo9BEo/pUQAUKqqAq8AAYAoAjI/+vUbDnj8alkz2qNiKAIXHbuKrOPUVZeoJeaAKUnJ+nemdz/KnyYyabigAxxzSd6Me/FKKAHRD5xWlGDgd6z4PvitKMfKKAJBnHAqZBUS9BU6DpigC5p6brlB716Jp4HlLkDI4rgdITddpj616Fp6kxqpHX0oAvOh8lcHrUkIAjC4PpUkw2+WuMkjmmp94elAEsSDYecelI4Kk/lViVoyqhFwMYJPrUZjd0yBnHYGgCvKpK5wQD6UBc2zknkEU8/MOOcd6eqAREcYzQBnamcJjOSK831qQvdNmvQ9ZkCRN+przXUX3XEh680AUW70x+e3PapG/WmH1H40ARnA4I6U3HXmnkAnNIR6frQBXaq8pPPpVpwCTniqs1AFST73Sm/jTm602gA7daSl+ooxQAmOPSvtHXhn9mDw1/15aH/6Ota+LvpX2jr/AB+zB4a/68tD/wDR1rQBkfC3TpdX/wCFjabatGk97o1rbxtISFDP9sUE4BOMn0Navw3+FOseHfEHhW+ni0LSo9Gspba8bSpXeTVnZdoabMUYAU/MM7znv3Hkut6bYXb+beWFrcSqu0PLCrkD0yR05NcNr2nadGx8qxtE7fLCo/pQBL47GfHvir/sM3//AKUyVgt605USNAkaKijoqjAFI3TIoAhYDn1qNwQOeM1KTgc9qjb26UAVpKqz9f5VbfpVSagCCjHJpcZoxxQAnbrxRSj+dHegC9bj5RirS8/WoLYfKDVhRyaAJEz6VYjHI4qFOfWrEQ5Hr6UAdr4aQC2Vcc+tdNbjKtj0rA0FSsCAjIxXTQLtt3fmgCKAYkbOcn8qsRrmQ471GvTgY9quQiLyWJyX7CgCJ0xx+VMb5u3SpsFiVQHnkYpmNuVORz0oAitwTMFJ4J5pj8Qvk8ZIqeFP3gPGahu8JE2frQBw/iiXC7fXmuTf71dH4nl3Te1c62CT2oAiIyDxmo8YznpUpHbHNMbkAZoAjPUYPFRv71NgVG/QUAVpCaqTc9quSjHv71Sl60ARn60flSnrn9KTj/69ACDrxTJh+6k/3TUmBnio5/8AUyc/wn+VAH6fUUUUAeVftC/8gXwxgZ/4nP8A7Z3VeG6t345r3P8AaCAOj+Fwen9s/wDtndV4hq44I/yaAPOtTJNy/pmqT5B4FXdU/wCPpz71Ufp70AQt0qFuQSP1qY8NjFRHvQBE3c9Kgk6VO5yM1BKeD1oApuOTTO5HFPPJpO9ACUcUvWk9KAJLcZkH+cVqRD5OlZtsP3mRWoo44oAVR36Gp4xTEqZBigDX0FM3Qb05r0PTBuUcZ/CuH8MRbp9x4xXoWmxEKB3JoAdKDvJ5IFSQQNJkqOSM4p9wrLMQMGpbKcwMegXFAFaRSAMZ9KRJGR8ofY1JIdwyTwaiPAHsMUASWwEjvjkjqKlOTATjGTgVHA3lSA+oqaQtsBIwB0oA5jxG+yFsdu9ecXBy5J55JrvPFcu2J8fSuCkPPXmgCE9fSkYHHqPWnEZye9IR07GgBmOtRk8ZqVhjpTGAOc9KAK8nfPSqs314q2/Oe31qnP0PcUAVsc+1JSnOe+aPagBv0FJjmnY5pMcfjQAnPpX2hr//ACa/4b/68tD/APR1rXxjX2dr4z+zB4aHrZaH/wCjrWgDzHUsbDkYrg/EX3hgD3r0HUlAQ/5xXn/iUfMMdT1NAHPt0z3qInuelTdRUL8HJ+lAET8n3qJ+4qZ+vSoyfTGaAIH71Tm5NXHxgiqcxy2KAIaWlI6ZODR7UAN96UUDpSjqOtAGlbDAHpU+OcdKjtwdozU69eaAHIPerlsuZFHvVdRyO1XrBN9wigdTQB3eigCJF44HNdAwPkgDgHtWXpEOFXp0rclRhArYHWgCqiF2AUcjrmpmjZM5GG6iiJtjhto+lWbycSyblxnHNAFIMQMg89frTnk82VC3yt0+tNYYJ/Q0AZ+buD1oAtIoEu0LyOTWbqRxExPfPStbzC+So7YzWNrT4gOMA0Aeb65Juum9hiskjqMVf1N99zIfeqJGcUANwe+DTD70/Hvz600j8c0AMPHHp2qJ81KfpUUnBxQBWl4Bx09KpSZzV2biqb9eKAGGilHXmg0AN7VHP/qZP901L3qOf/UOP9k0Afp5RRRQB5Z+0D/yCfC+f+gz/wC2d1XimroQhPbp9K9s+P8A/wAgrwtn/oNf+2d1XjerYMbg4FAHmGrLi7bFUG7jv61o6wMXjDtWefagCGTv2qJqnkAzntUJGKAIXPfFQSY2+9TyDnpUMgxkUAU260lOPX1pD3oASkxz2zTsccUhoAltR8/pWov3R61n2gy9aK9Bke1AEidemTVhM7ahTqMVYRehoA6rwlHkHI6n0r0CyTagY9vWuP8ACsG2OME4zXYl8QbSAM+nSgBk5BOTkZpgwV75PGaJOTj2pOuD3oAeyjbyce1JEw+cPyewprnGNtMUjdu79qAFxiVQwzj8a0LhCLZRj3xVMEmZSMc96vXfyWygnkDvQB514vkwu3qSa42QZHX866jxfIPtIXdnFcw2c5/KgBhGAD1pp56U/bx7UjDigCJuTUcnUU/vwRTWH5jmgCBulUrir0nFUZ8bvagCDpRSmkAoAD1pODTqTt0oAbX2froz+zF4ZHrZ6F/6Ota+MfpxX2br5x+zB4aI6/YtD/8AR1rQB51qKEo2Ofr3rz7xMuCD716Pd/6vPqOa898VJtJPv2oA5c+ppj9OakP1pjjIoArngZznFRseOlSsvvUb9KAIGIINVJh81W26ZqpKPm46UARmjHOKdSY96AGkZFKv3wOaMdc06P74xQBp24+Xmp16c9KhiGFxip0AIoAnj5ORWpoi7r5MjgVmRjP1re8NxFrgsOg6UAeg6XF8gHStKcjaFORiq+njyogWxwOtK7cE56mgBqkE8tkU5FyD7nFMGcEfjml6Jk/lQAn3ZAMgjvRPgbtudh6UwnJAPFPZsxDABxQBcsVzExAzgd657xCfLgfPpXS2efIYnoR07Vyfi59ttJyBxigDzq4JaRsetV9pyfSpZTluMY9ajwc8fTpQA0kY4ph6VJjHNRsOfagBjdDULe9TMD3FRPkD6UAVJ+AfSqh9at3GMZPXpVQgYoATqPeg/Tmjvx+VFACVHcf6mT/dP8ql796iuP8AUyf7p/lQB+ndFFFAHln7QPGk+Fv+w0P/AEjuq8g1dQUb1x2r1z9oU7dG8Ln/AKjQ/wDSS6ryfUV3Rn3HWgDyzWQftjcVnHGM1r68u29bnmslhQBEwyeaicY9cVOw5qI9+1AEDjjiq0n61cI7moZ485NAGeRz+NGKcVOSKTFADRSHpTsHNCrz7UAWrBec+9aO3p271BZx7U6VbA5zjgUACrzkVctULyovbNV4x+nStPRovMu1H8qAO70C3IjQHgY5Nbc7A8HovFQaRDsiDHpihyWlIxyew70AIxJbrQJDkY4PtUbZUd89z6UyRxkEctjigCxDlpAAfoMU5gc8ZBHHIqC2kw+4cGrrOLhSV4ZeSD3oALeMtMp5AFX9WXbEQeBtqtZbS64yexNWdZQLGwOSMZzQB5F4mkDai47Dg4rEYc8dfetPW2338xH97FZje1ACN7d6ick5xipXz61E3XA4FAEZxjnrTW55PX2qRh6/yqFjz6H1oAimbjBqhN96r0358VQc5bmgBpo/nR9KKAExzSUp65pCKAD/ABr7L8Qf8mveG/8Ary0P/wBHWtfGfPavsvxESP2XPDhHUWOh/wDo61oA4OdQ1suRgivPvFY2tx0zXoAw1tz2/WuI8XocEn1oA44jPUYqN8Gpn5NRMOOKAImGM44qFhxU7daiYZz/AEoAryVTlHPrxWjImRxVCVSH6UARelHenYPekOT6UAIafbrmQAdM0zBq3Zx/vMnnHpQBfRflFPRfl96UAbQOakQDIoAkiyB0rrvC9v8AKDiuUjUlhnpXofhi2IiTHXvQB0UY8q3A7nv6VAzYUhTxUt4dpUAcjvVZgS2TnHXpQA7dtyCM0M5JznnvUTkFDuIFNEmWAORj1oAtsMAA45HpSKpfjv7VNHMroIyfnxxxSRrtYhzhh2oA04U22OTk+vFcD44cLHjPfivQ9uLLcCcdxXmXjogTIoz680AcdIAe9N6A9MinN+tMP3eRQA1jxUPf5hUrdPU1HjigCNunt1pjEgY9Ke/HGaik5TnpQBTuMEHBquOnSp7g8kVBigBKD0paD0AoAaeMVHcDEEmf7p/lUhFR3H+ok/3TQB+nVFFFAHk/7RZxoXhg/wDUaH/pJc15ldoDaqf9nrXpn7Rf/IB8M/8AYaH/AKSXNedJHvsVJ5A4xQB5X4oiC3mR0rCI9a6rxjFtuAw6HpXMEZ460AQMODnNREdasOOKZtGQB1oAhxjtxTSM1Kw9AaaaAKE8QDcVFs7ir0yA84zUGzPbrQBDs9RTkjyen61Jt9hxUkafMO9AFuBcJjHapVXHNEfHapQMnnpQAqKPSuj8I24kuSTWCi9B1Nd34OstturbTluhoA6uBTHanA6jiq0YRZhuO0evpV29ZYYFUA9O3rWRNKcZ4JHU96AHTyAs0ZwwHQiq0nIG386h3lpFUHt/kVI+QzKuMetAE8BCwFyuQe9RCbD4XoaaJiqPGw4bioFwCcNhaANewkKyqR1zWrrp3W7dxjFYNk2Xy3PYHPNbfiA7rAckALz78UAeL6h813Kc/wARNUzyeevtVu7wZpMnnJqo3+7z60AMYH14phPIqRufrTCe35GgCPg96jf8hUjg9qjfH40AVpj8vHaqJq1OeDVXH+TQAnSkxSgenWjHFACUhpTSe+aAE9TX2V4k/wCTW/Dv/Xjof/o61r426dK+yPEv/JrXh7/rw0T/ANHWtAHB2AElq/fFcn4vhHkMR1rrtGUsrIOhHSsLxdB/orkDPc0Aeatx/Ko2BzjNTuOTTGXAxigCs1NK/nUxXrmmlQKAIiB271WuIgRkVbI4pjqGU0AZ2znFGw+mKsFOcAU3bjtxQBCI+RgVes0CjPPWoFU1etlwooAlC/UVIi+tKOR0zUiLgdsGgCewh33Ua+pr1TRIPKjTgEYz9K4Dwza+dehiMgV6hZRiG2Zj17UAVLoBpSSOAabcMI1Q5DKRj3FMmmyWAOVHSs+eU856jjFAErgAHqe+KS3G6X5hk4zTCTsViM5PaiOUxursO/PFAE00qhyUzgGnxSlpA2TmqMxDyll6E5IqWFiSFzkdTg9KAOst5C+mjpzXlnjg/wDEwUZ4xmvTtPYf2bJ0Jzxn6eteW+Ms/wBqEMc4HWgDmWHZvzprA9QafJgE5H5Uz2oAjbjOfrTGPQVIfeo2AxxzQAxhx6n3qCTHPrUxyRzxVeY8UAUpvv8AWo8c058ls5puBmgAPPNJ29TSgflSGgBKiuP9RJx/Cf5VLzjHemXH+olP+yf5UAfpxRRRQB5L+0acaB4ZP/UaH/pJc15xpknmWrRHgj5s16L+0kdvh3w0f+o0P/SS5ryfSp2R1weaAOe8bQYGQO/pXFsOTXpXjG3Mto7Ads15wygHFAELDjtURHPap2GfwpjDJoAibjOBzUbc49amI/8ArU1l4oAgZSRzURHNTuuTmmlfUUAQ7eKmgQ5zShc1PEmBzQBKq8c1Ki5JwKRRgdDUyDA70ASW8QZ1Udc4r1jw3aLDAm7jaoNeeeG7T7TqMYxkDk16fLi0sABjeePwoApajcB5WI/Ks65cFc96WWQgZOSfeqvmbwQP4elAEqRbVDtnpnOKheUgtgEDPWh7lwBGW+TvUSEHcFc4PPPpQBI7h8FT9aaehOMnpilVUC5xwT2609gNu1GyByaAJbDCybmJODiul1wbtNIAz8v9K56yRZGABxk1ssfM0+UE5x+ooA8cuRiaT1BNVeBWjqqBL2Yf7RrPPfFADDzniomz74qRuajIBOKAI2/AZqFuAT0qduBx1qCQ8UAUpzg/jVc+tTTnmosY60AJQaX86KAGGl/nS0h46UAJX2P4l5/ZZ8PD/pw0T/0da18c/wAq+xvExx+yz4eP/Thon/o61oA8/wBGmCTAEEA8fnUPiiDNs5z2qnaTbZAQcVsagTc2Gcc4wTQB5BMuHP1qMg1d1GIxXcit1BqoR6d6AK7D8KTGOtSkcUwjHT8qAIWOc57dKjIPTHFWCOvtUbKaAK7DFN2+tTY9qNv+TQBFGpJ4FXol4ANRRR81ajXA4oAcq9KlSP14pEGTmrEUe91A5J6UAdh4JtCVMhH3jiu01F1hhWIdQOvrWf4XsltrFS44C5NRXs5lmYkjAoAiZ1K+4/WqYj8xic5A74pzyjdjjkYpq3DQA7cYPtQAsrhCo64phkDIefmB/Oo2k3OH3jPcUqx5fJA3D0oAAMgA8GiLLScHAzT0CgFgwyexp0KjeAfvA5oA6rSMNpz4+bmvLfGi41Zh2Ir0bTS0ZSItw3OPSuE8dRgagG9qAORfG49MUw444zT3/wA5pjccCgCJuDxUbdPXFSNxnk0wjH0oAhbrVac/SrTn1FU5zwfWgCo1JS80lAAfekPpmnCkoAaMd6juP9RJ/un+VTVFcf8AHvL/ALh/lQB+m9FFFAHkP7Spx4a8N/8AYaX/ANJLmvHbSTaAx6jtXsX7Spx4a8Nn01pf/SS5rw9Zdzjbx7UAdJqEaXmnEjldteV3sPl3EiH+E4r07S5/3Xls3y5xXHeLrLyrzzEHD9TQBzJHy9KjKk1YIyMCmEe+KAID1JppHGKl28mkCYzQBAy9aNuTUgXk5GKeq89KAIlQgjNSovNPVM8flUirg9OaABRgdKlVeaEXgEn3q/pto11dJGvGTQB2HgOxCI08i/e6GtvVJjJKQDhRwKSErYacEXAIA6VQmuWYtnoTxxQBXupW34UDB4zUKKOdo57mnKY8nJIHoagEpXeFNACTHkDvTI8AtkdKjDsx+p/KpomwzK4yccGgCeIBkBUgHnANMzgnBxmmqwUoozgcn3pGwWz2Y5+lAFyzYLjnn1rdsmElpKvc5P1Fc/Eqrz0BFadjOVnRR06YNAHnniKHy9SlGMZ5rFYZI/pXW+MoQt15i/xccCuVkXHagCFx1qA5qd+lRMuT0oAiZgBVeQ8deKsOOuarScjHOKAKc3LfrUZFPl6/1po9KAEP60lLjI60hoARhxzzRjrml/pSEdKADpX2J4o4/ZX8P/8AXhon/o61r47PWvsPxQM/sr6AP+ofon/o62oA8mtWy2P1robF1mtmTPzDrXMeYFG0HDCtLSp2jlByBkYoA5PxZa+RqDEdGrB284r0HxjZrPaCZMEjnI71wWCDz+VAFcjk4BppHbqamx19aY455oAiNMKmpSh3U1wQw4+lAEW3IpQntmpdoFSbaAI1XgVOgFCpUqrk8cCgAUccCtrw3ZfadQjyPlU5NZcaZIA613/g+wFrB50qjc3NAHRXjrb2qxR9+vtWFcSFEz1OatXd7vcdCASCazpWDtw2M9vagCD/AFjBmBz2FEvCnPFLKRHKpUjHrVeeYtIc/jQA3+IDuasxgMxAPPcmqysRtLD5c/lU7lQzMCfQZoAfINrDPBHanRHMpLH6monbcq4JyBzmnRKCMjOR70AbunSjz0BI4HWuZ8fwYkV8dDzWzBIEDbTz0qv4wjFzYLJjnAPNAHmkg5PFRsOATViVc84qBvyHrQBA+c0xj61I3NRuMdRQBA5qnOfpmrbYHfmqc+PwNAEGPf60duaB05pcc4oAbjmjtR9aO1ACAVFcj/R5f90/yqY981Fc5FtL/uH+VAH6bUUUUAeQftMceGPDmRn/AInS/wDpJc14bFg5B4OM5r3L9pgZ8MeHAP8AoNL/AOktzXhAPz5HJzQBp6fIwlK/p6VL4htTd2WcDeBVSxOLhSCMd625kYAIwJVgDigDy902uRjpxUTDJ6Gt7X7HyLgugO1/0rHZeM96AK5XHvSEEjgVLjjpQq5PHf0oAi2cHinBfQVLtNPRD7mgCJVPTHIqQJnFO2jPTmpUTjmgBsSZbbiux8P2QtYRM4+dumaytFshIQ7KOOma3bl2VVXPAPegCe4maSYrng9aruXaRQOlJGdyvKeM8fWnEf8ALQHkdBQBBINrEMAc+nakAI42jjpTicMpxyf0odXwT0J9KAK5jJY7SOaIIn8zbnntzUvAcAdTQGP2nB6L+tACSjMwx97+VBVfM2k9vyqUqBOWGQfSkEZ6sOOcZoAm2ARphsEVNE+zawJ3iq6/6pj7jFTL88gPTjr70AZvieHfZCQj3ripVxXomox+dYlQM9SK4OdAjsD2NAGc4pjg46VZccHaagYcYoAruODVWXuatycGq0vNAGfL96mYqSYc5qMetACfTpRwaOtHvQAc5pDnFBooATFfYXio4/ZV0E/9Q/RP/RttXx7+NfYPizj9lPQiBk/2dovH/bW2oA8dG1sHHFWY2aOUYqlzhM8d6ljJIU9+vNAHQsv2izkQrwRla871S2Ntdsh9eK9Fty/2ZW49DXPeJbESxiZMhhyaAOOYCmFeParJQ8g1HjnkUAQ9sYpAueoqXbkjApwUnpQBCq4J9akVfUcU8Lk1IU9QeKAGKv509UwfWnIuTVyyt/PnCDmgC3oVgZ7gFh+7Xk12E1wYoFSMYCniqNpH9kt9qDH9aYjGUoh5I5zQBLK7KpIHJ5NQyBtqFh25qYgvkKehqKQ5BzkbRQBEACS23OfXtUcq5IxgY/Wpzl1GB8vXPrTHyeXOcUAQMsgYZ+6TU8i7YQHGPf1FJKxWJfc8VJKu6NOTkcZNAERU+WCTjtViCPhvm4Iz1qN13EKBkAen61JCuHVAcetAE0XQqzcY4Jp93m5tHUjhVxUSnMZAH8XFWVXAYE5yv6UAecXUeyZxjoSKpyDrzW5rUHlXjZGAeRWRIo7YoAq468VE3JqwwOeagkGPpQBWlH5iqM/rV+QjB7VSuFyD0oArfhSHjp1pe/Wg0AJ6Zoxj60YpPzoAD19Kiuv+PeX/AHT/ACqUdTUVz/x7y/7h/lQB+m1FFFAHj/7TWf8AhFvDuOv9sr/6S3NeExgsG457V7z+0qM+GvDY/wCo0P8A0kua8NJAYYAoAltVKgnBLCuks8s6pyQUyM1z8CuqHc3J6EdK3LGQB0R2wdvB96AM7xFZCSLdjAx2rhriLYxDV6rdWolspGOSV5IFeea1AI7r5fukZoAxStKi4HHUU9hyKXHpQBHjkYp6DnFKqknpT9pFACAcnHFWII8sOuM0yJQSAauwJhl+ooA6bS7MJZq7YAJp06b5ioII9u1aFigNusZA+Zfypstr5TqIuR1OfWgDO2l8YDHac57U6SIqpIJ2jtU6rIi42kc1JEjyRSrtJweMUAUzHkI+QMnHNSpbFwdhzg8D1q7HaSPCuEbCnnirkNowxuVuOcYoAx0tN0oIIyO5piW4+dgBnP61tR2eM/IT8xJxVVl+dwsZwxoAzxakjkEc9jT2i2KVx90fnV2NDGzbwWPQc0rqXjyw2tnGe9AFGKEHYFyG6kVAQRIzqMAdvatdbfLDjPGc1Quo2K/JkHnPFADbeQO2w/dPIrjNYtjBeSKRwTkV2SKwdMrz/WsfxDbmSMPjay/rQByMij61Vbg/Sr8qnBqrIv4mgCm44/lVaZSM561bccHNVpRgEUAZ1x35qDvVu4Hyn1qqT0oAQn2o/Sj9KCeaAE6DNJjnkUuaOKAE719g+LBn9lTQgOv9n6J/6Ntq+PulfYXij/k1fQP+wfon/o62oA8WBLMAwzViBcy8/dzxQyhV5Az1+lTQBywIxsHf0oA1tPcrbtjO3cARj9at6paiWFwF5x+lU7JyFcueCcZ7VtpH5rbQwIIxmgDy7UbUwzMBytZ7KM/Wut8TWYj3kfeU4NcvIuD6UAQBPmpxBxz2p6jigj1HNADVGDUu0cetAXAGaeBk80AEa54rodAs/NkyASByayIUAwe1dT4bG2AsQODg0AWLhPLiHI681XCeWMHjI7da1Li0GGlXGey1VdWWUEqfu0AV0iOwYI3dCDSKm8kZyV6mrcbMZk460+GA+bIoUkngcUAU4oSQvIBIxSvasVwRyePrWnbWxA6dOMkdKme1zKpwxwuPqaAMaS0JdFYDIHGO9Ibcl8YIX+Vas8axtHw+4dah2NuVgCEJoApJAVXJywfgZ4oEYLyHOCvArS+VztCHaORmmCHKkkBlzigDPuIyhRR940JLtYZ+8PlNXbmLYcMDuC5GaoKrYbeuTnsKAMfxVb/NHKvQjmuXdB6YrvdRi860KMDjb8pririIxuynBIoAzpBjsagfkg47VckXk5qq4welAFR149qpTjr0BrQkHftVOUDnPHvQBn9zR0FObgkU30oAQY/P1oxk9qXtR+XNADTzUdz/AMe0uP7h/lUvvUV1/wAe8uP7p/lQB+mtFFFAHkn7SALeHvDQAyf7ZHH/AG6XNeFOjY5UgjgD0r6A+PcRn03wtGDgtrP/ALZXVeQXenEo2AVlB6HvQBjW+AjI2QzdK09LXlQQXA6VTEDu2ACWAPXvWlpULORuY5B5wMUAdMluzWRcY2shzXluuyebeSY5A4r1O4uPslg6k/NtPTsK8lvPnlkbuWoAzpEx0HtSBcjpUrDr60IuT6igBoT605Rk+1S45GelCrlsAZoAWJfQdauRDGM/pRGo2DGKnRAMfSgDr/DsiXVvliQyDB961AQSzCINzgDPT3rj9Gu3s7pSv3SfmFejaQdPmHnSypk88npQBk21nPJLv2IV7A8jNa9lpDlznAY/e2rWh9u0y3zsYSemOlZ914hZHzaoirnvyTQBuWWkhINqdAckEdR6U+TTVfaRGdo6kHrXKS+ILghyrMpPT0pia/dRn5n7YFAHSSabDFI2IHXd6jvVWfRbJnkC5VgKzbbxPcxN+9IdfStCDX7a5kH2mMI5PUDpQBlXGlpDMEQ7tuSSfWsx7XymwVLOTnbXfxQWk0JkhHndiCar3GnQl1G0K6DljQBxlmjq0yyLhSuFz2qlNb7C7FySeAvaujktnAleOZHUcAdMVh3dsDMU83DkZx1zQBRkMIQAx5nB4xWHqJdkPmEbScitmW3aNBwWcGsfUIykZMuQ3Ye9AHJ3Cje+OmaqSJzkfrWpKM54qlIuAcUAZko5OKqyDAPPWtCZSSf5VTlXB5/OgDMuB1qpir1yBjvVA9SOKAD60nWlPFIfzoAT60HrR2pPSgA+lfYfiYE/ss+HwBkmw0T/ANHWtfHh9q+ytYQSfszeFkPRrTQh/wCR7WgDxqdT5hBUjjnIpLc7ZAWJCg9a6W/07MxV+CRlWxxWNLbtGzRvgfQUAPtwRM2DlGPT+tdXpMO+PEa528jPWuXtUkWfYcL6etdhpGYIi7txjr3oA5DxwfLmaMgbmOa4iRc54+ldd43n+0asSDwAPauVcYP0/WgCso5wKkCUuD37VMFwOBQBFjH9akRBn1pSB171Zt4xySKAFhH5Gui8NyKX8hj97kGsVEyD61Zt3aGVZE4I5FAHePGmVjxuPfHp6VFLE0rAQQ4HTmrOiSRalHGZGCMPvDua6ZbawtyC0yrgYIByaAOeh0tnKH7OibRxnqa3bDRsTbnCliMY20l1qtpbgC3Tew5HOBVB/E0h24Gwj0oA3X0lAjK0WX9FXvVWfSYRteQOXX24rHPiS63sS2Rnrn0qUeKbgN0DJ05oAuXGjW021y5BztB6cVmX2iC3ywk3A8ItaaeIbS5AWeIKB3HatK3itL5VKS7hj7lAHD3FkUdcnYoX86gUFZI9qNsJw2a7q5023eN8oVDcAH+9WVe6fIkyJC0QOBlScmgDndQt2efKEIpOfWqQSLcwmyE5+YVrajDJ8xbCYOB6VkTWrh23uCpHGPpQBnXjsoCwqdgGMn0rktSRRKMEZ711lyHcdCFAwCa5q+C+aQOQOlAGLKgP1qrMoBrSlQZ4NU5lyenNAGdIOenFU5x1xWhMnFUrheDQBmSfePNNNPl4b60w8igBD9KDR6mk6c0AB6VFc/8AHtLz/Af5VL+lRXP/AB7S/wC4f5UAfprRRRQB5Z+0DdGy0nwtcDGU1ruOObO6H9a4W01TSr6PE0i282MDniut/aYjaXwv4dRASx1kHA9rS5rwEhlbGTQB6fPpttJMskVxGQOysMGm3NxZ6VEX3oW9O1ecRXEyfckYfjSSTSzH967Mfc5oA19d12S83JHwh4J7mueIPY81KVxkfpTSoyQTQBWcc5700LzketTSLhjxzTRjI9KAEAIHrVi3UEZIpoGatwKAox1oARFJPFWAM4yD+FCqNwx25NShcmgBVTHPap42fscUic49alCggDp9aAHJJIP4z9M1csUuJpVWPccnrUEEXmH1PtXe+GdPW3093YKHbBUkcigCjZaUqkeexkbHToK27aytArKLOJhjp3FWYYI/MRSuCeQcVO2IJwWUYxg+tAGX9g0+RWMkKjJwAeKryaHbm4XyX2DPAJzWpLa71jYYBDEmopIWd5GJKjoox+tAGHcNPp0+PNKqrcMp4rYsPE2nyIsV6+05/wBZj+dUZ7XEfluN0Z+8DXN6rpv2cGWEM0LHGfSgDtdVlsLmJmtpoWJ/unGa5C9JgkaViFA6E/0rEy24HJ/wqKVmcAO7NjjrmgC1NeszN5s7FTzWLqMglICn5R61NIMZPr1qvIoAyRz6UAZksXPUCqVxHnqOB0rVkTd9P5VRnTtigDJlUVSnXGa1Jk9elULlR3oAx7nkH1NZzcE81rXS81lyDDGgBnfnoaQmlPakPXigA4yaafrS9s5pDQAnpX2Trspg/Zi8MyqQDHZ6EwJ9prU18b19heKVL/sraAi/ebT9EA/7/W1AHO2GrWOoLsvdsTH+MdPyqa90mGdCYJon9GU9q8vkSWJtrEqQakhu7iI/JK6/jQB6PDpsUCh5pFBUDJ9aytZ8QwwoYrZVJHQLXJy6peSLseZ9n1qngkg//qoAS6me4maSRssTmqrjI5AFWCOOSKZIuMUAViORjrT0BwPSnYxnt609AMe9ACRKGfGPxq2FHGBTLdBnJq0F+megoAVFIBDDmpUTOMc0BcAcdKmjGOO9ADoJHjP7tip9QatC5uMj94351EgHPHP0qSNMnBIoAlW4mYj5ia3tOsbi4iWSVgikenJpPC+mie9VpFzGv3s9hXYtbxqzBgAq8Db2FAGda6VZjBkiLnPOWxU0mkae82xYjHnk7jWo9uqQAgAjgjHaknQXDsV67MDnvQBh3GgW5izbOy88AnIqGa0uNMSOSM/If4hWuYnEUcS8MepPpVW5ik8xm3FgBtAPIxQA/S/EEahY9RkDjHXuK1Jf7PuoFeCaGRsHa27BHtXD6npQYebBnf1ZBWEXdMhGKn64oA6XVom8xkUbgW7/AKVjXN9IpCI6BRwcCqb3M/llPNfYR0zVKUEj7x9RQBLqE/7tgJNzHjA6Vz08ZOcV3HgX4fXPizw/PPpeuJ/alnM0Nza38Xytn5kZZEwVUoR1VvmDDPFZ3iHwT4n0FWOpaHctAvW4sx9piPv8nzKPdlWgDjJ48DFUJUAOK098U6F4JFkXoSrA4PpxVOZDzxQBlzLgVnXAHI5rXnTis24Tj2oAxpx82ajJ5qe5XDCoCcZoAQnAo+p5o49aTr6UABqK5/49pf8AcP8AKpDUVx/x7zf7h/lQB+m1FFFAHk/7RbbNC8MsCQRrI/8ASS6rw6+tlkHnRrhu4x1r2/8AaNGdA8NYz/yGR0/69LmvGEZt2WXAoAxWXnBGKMcYxV++tinzqOO49KqbcjmgBqrjk/hTSuCfepcYPvSEdaAK8iZxgURx7myB1qUqScEUq8Mcc96AGooDAZq5EgxnpUEcf7wHrV1UBPqKACNByeualVAOT+lCqNuRzU0aH1GaABExjtU6oSQSKFUY61dsrczyKB2oA0tB07z3LMCYxyeO3pXeaYqmRN6AKR071n6TZiGGOLByeTjjJ962FjERChf3hzjJ5zQBA86PdLJgoEbAx0NTfu5J/nf58dD0NZt0/wA7xh1IA+bA/UVN5i74PulthAPTNAFi4xti2bcA4J9arSny88HYuSD71FuK26ySjaVYgBecn3p8ZZ51k5IHJX1oAzLhZGTYgyRySajuIgLSSPgq3GK0rtVjWZ9vL8s5/kKwJZXOfmATsD3FAHL3cLRTtE3VT1qochug57VtatCGAlQ54wxFZW0k9s9jQBVZOTkEH3qu6856n1q9L171WkU/Me+KAKMqce1UZ146c1pyADrVGUAE+tAGXOpx0rPmXk+talx68Vm3H60AZN4MZrFm+/3rcu+h9axZxhzQBF2pDR60fzNAB27ikPGKDnjFIevWgAzmvsbxFz+y54cH/Tjof/o61r44zzX2R4iOP2XfDh/6cdD/APR1rQB5VexJdArwZF6MO9Yrx7DtYEEd62WY7sYJ7kgYpI9J1nVNNj1Gx0DULizkLiOeExuHCsVPyh9/UHqtY1sTRw6TrTUU9NWlr8xpN7GKABnNOC569O9LdiaxyNRsr6xA6m7tJIR+bKB+NRW91bXC/wCj3MM2e6OG/lVwqQqLmg015CasSSLkj2pjKCDg1Oe1RFJ3kjitbeS5mkdUWOPG4knHGcZ+lVKSinKTskBB5fTj86lCbeTgZ4oRlLOPmV0YpJG6lXRu6sp5U+x5qVkLDv6UJpq6AkhQEA96seXlsccc4pIl+QYzU6IOxwR2pgAiyxxwKlRAeeTQi/N7VYROOcA0AIqEgD+VXLC282VQo5zUcSEttXvXW+G7AxjzmHIHymgDV0e1W2i8sLl87mPvWzemGONYlGGcZJHOKbDAAodizDHfjNR3zFNr/KM8JnqRQBMSrW0aFwABgNjvT2iRFcADJXjbWdEf9GmD4POQB1FOLM07IqnHl8PmgB7HEYYjLEYIFUbpv3hIOVA2gDuan80vFthb7vQ+tPmjQrCWU/J1UDG8+poAyraNw/mMu05OQT0Fctrtv5Vy0gXEbnge9dJfTOsxEfJ756CsnUI/PgYMRvHI5oA5pwwwOpqJxk9xVl1OSGFNcEJjn2oA1vh14h/4RXxtZ3krhNOvcWV5zwqs37uQ/wC6569ldzXovxF8U3Otare+E/DGryaXrtuw2LIRHFqWUDNDHMOY5FzntnBHI3FfGLqFJ4XilQNG42sD0IIwQaqXEBniZLyWW5kY7nmkbLu+c7y3Zs85HSgClMrLcXEVxFNBdRuVnhnUrJG/Uhwec8598571QlXr14ruDf2nitILDxVeJZ67Goh0/wAQOMJMO0F5jqOgWT1PY538rrVhfaRqU+maxaPZ6hB9+F+dw7Oh/iQ4OGHuOCCAAYM65rOulwpwK1bjGDnpWbc8g56UAYV5wetVc1cvBzVM9fpQAmfyo+vWj8eKTnmgAqK5P+jy8fwH+VSHJFRXP/HvJ/un+VAH6b0UUUAeV/tBxmXRvDCL1Oscf+Ad1XiswIlI6HOORXu/xqAMPhEMNwOskY/7cruvJPENh9mvMjBU+negDHjQOhBOB0we9Z11b+S59O2KvRjDbiSTnhT0FOvEEkJI5I5NAGQVJAI5pNpZOP0qYruBIOPpTAOeRgUAQhck5BpAOQcdalxg4GetPVeuaAHQpkjkZ/pU6ptPXHtTYV6Ec+lTqAGHSgBUTpnOKsxpjjFMVQcd/SrManCnvQARpkj5TnPQV1fh+xDGPAG4cnNZOm2gZ0d+h9a6/SIwkmAMcfnQBuQweZJsJAYcrgdKmuMwM8jrum27R3Aq1Y2wMqSbSFA4BqnrExkkKAYGcA9waAOeLwhpftIYK3AwO9SOMSRvbj5VXGT2qzcqZSEKqAPvNjsO/tVe5UR28ZhdSHPLUARwbkikVSxX7zFqsW4KJA8YY+Y3TuKSyjd2McmBGxzk9xV2eMRSJJJlEU4GD1FAEHiiHARU3FCNxBrlXYMQQAQvAz0FehX6x3FpwQEK9cdq4TVbX7M2EwVzwP60AZ0xU7kkUAMOgrFnjMUhB5HUNWrOwUg7VGep74qtdrkE9QBxj0oAyW+9257VDKMdasOvfvVSY8kqT0oArzKADtPNZ8/CnHJ71dc85B571VlweKAM24BAHr/Ks2fgH1rUuT1FZlx68UAZV1WLdA7q27o5rGueSee9AFU8e1ITzSmg9aAG5pO1KaToaAA+9fZurIJP2aPCqN91rXQQfoZ7WvjLp1r7Q1Agfs3eEiTgC30HP/f+1oA8s1KIwTMhJxkgVmW2l2aTeZBAlvO3JktyYmPvuXBrufEdgstv9phXKn1rk3Uhwqtt454pOKkrNASf2jr+nbW0/wAR6vGo7Pcm4A/CXfUE/iHVbsn+1Lfw/rQ/iOpaTG7Hn1Qrg++Ksja8e0nAx371lPHtcr0YE1wTyrBTfM6Ub90kn961LVSS6kgutIkyLrwbbI3/AD00zVZ7XH0jwVP4mruhQaBda9p0VifFthem5jMKSrbXMO8MCDlfnwMdT0xn1rJbIPrUljfahpepLe6XeLbzLGUV/JWRkJ6ld4Kg446Hgn1rmxOVfuZLDSkpNaJzk180+bTvZDjPXU978ZeBdH8UKZrlGtdRVcJfW+FkAHQN2dfZs+2DzXges2v9ia7/AGVc39jeyNnZNZSiQNj++gJaNvZuPRjRqNzeavn+2L+91AHrHczM0Z/7Z52D8AKSCBIxsiVUUdFUYArh4fyXGZXHlrV+aP8ALbRejbuvS1iqtSM9kTqhABzgmpFUnnOKAvy57e9Ton/16+nMQjQcHk1YVATjGPekiU4I7CrltA0zADPTNAFvR7USyZIyO2e9d/p1t5NrGjouO9c9plqkYTA59a7G1h86EgZyMZ9BQBI1uwgCSn91nINYuqypLeJ8oVBgAY6Cun1B1gtlTbuYCuefHlMXQPnkZ6j60AU2SEwzfZpGkLHp3pBI63CPlhtAUIO9TQ2wRGYFdyru2A9KrwvIJI3KBhnkUASwpulk5wyDcVHStIfNopuA2HHQFetR/ZWWHCq25+WYdq0tOMcliULCQg/MDQBwVwApdDwx6+pqtJhQDsxjqc1u67p/lzPNHjd/IVzkuNpyrED3xQBm6hCFk8xOUPWqEnI47da2ZPni4A54bnpWTOvzFcfpQBWkHFVpFB5z+FWZsgdeQapSnJI9OlAFO5jV1ZZArKRgqRkH2rV0/W7K+0uLQPGhmk0uHjT9WQbrnSieMHvJD6qc4A7gDbmynOSefeqM+FGKAE8V6Bf+G9QjtdT8qWKdPNs723O6C8i6h426HjBK5yM9wQTzNzyDXbeHvEkWnafLoXiCzbVPCdw++S0BxLZv/wA9rZuqsOu0YB5xjJzzHie0sNP1me00jV4Na08IksN5EMEqwyEkHaRf4gP0OVABy973qga0bzis5hzQA0n6UZpe1IeaAEqK4/495f8AdP8AKpDUdzn7PL/uH+VAH6b0UUUAed/GQbl8ID11k/8ApDd1534ptnHlAKSSc9a9F+MLIp8HmT7o1o5/8Abuud8R2ouNMLR4U4zgGgDzNoCAwJVcc9aZHtcFeXwMHFXrmDbIQUL+wNQR/K4Uoq54IHagDFlXZIQR09KjK5Y46kdK0NTi2XJIHDciqWDkds96AIwOcYpQPUfrTlU5OPWnsoyBnjODQBJGoC4APFTAHjA49KbEufXBqfaCfegBUGGHA3Vbt4/MYKeOaiVRg9KuWhAlRiKAN6xjO6IAcdDXT6NCDPt67ep9KwbYKEXOQK6PRQzDI4Y4OfWgDo1kEELvg7GGMGsC5/elSRjbnk9c+9bF5kBEjxtX5jz3rCdmeSTcck8/WgCrKskbsWIYyIQQtVnt2aJIVwCvOM84rSZ1BjMqgbeMCq96I452kVflIxkdRQBV3SyIeDgcLxgYrSLedAkeCzIMknt7VUjuUkA3yEgD7o71ZghjU71J565PQ0AbgCXVjGCyDA+YD+Vctr1qzRsIkHcZNb1tIpt5oQrZxncfWuf1cOIyGeRs859qAOXMbAMGwW9hTJkHkMCwzjt1q0UKKTnI9fSqszDyHKqMY79aAMCQ1VfnI6Z71bk6tnAFU5M5YDGD3oAqyduhqnN064q3IcbvQ9KpXBx9RQBSuCRms24wQc1oTtwRWbc0AZtznBrHul9Ola9xzmsm5xuoArHmmkc+lSEU0igCI+9HQ9KeQMUxqAGn35r7Sv8A/k2/wj/176B/6UWtfF2D17V9oX7Bf2bvCTE4At9AOfT/AEi1oAzdVhY2ErbTtCnArhJIG3DK57ZNerRRRT2jqmH9W7V57qtq8czhy3DECgDG2+W5ViPYDrVS/jCyblzyOtaBRFYt5bfVqbqUYe2SQde/0oAxmAIyPXrSFcHkHmpCOOnSkYEsueaAGAcjrU0CgHvkik28ZP5VJCDgHv16UASquQcZOKlRBjkYoVRtx3zU0SAgA8/WgB8fXGK29MiKREgZY8j3rJiHJBrotLw0QIz0/OgDYsY8bCc4PYetdnYRiNE28FeSK5LTceagzuA6exrrrctHal8kyH5RQBU1adZpJFUMRjgehrGuUlWPK8omDknrV2+dlaNCMfXrmoONsqlOD/F2oAosGaeeUZBcYPOBUEDSQAxHgty3HOO1aF1FFLaxlCSQemagS4GSocLnoWHSgCfT5mSKRZSdrHAXrWroqhIpo2UB+uSeSayVhWVtySMSvbpmr9pJHDcI7ktnjFAEGr2gRGH3mPPHrXD3MUiTkOgRM5wa7fVHkR32yERjoAOa5C5DtMzE7vUd6AKSR/MeB1rHvvlnYE5zW25UucgMfQ8AVi35BuCQMc4oAzpDzyM1VlHXPPfNW5wQcjn2qnP97pzQBVl9vSqM5Pfmrsx4PPHSs+VqAKE/PtWXOAM4Hqa0p+M+9ZlwcfWgDKuxkn1rPx61oXXQnNUSKAIyMdqaakI9qbjmgBmABxUVz/x7yemw/wAqmqG5z9ml/wB0/wAqAP03ooooA8x+OzMlj4UZfvDWuP8AwDuqytLuGu9OKSlfMK8j0rR+PzBdL8LE9ta/9s7quW0K6MZ54OMnigDKubZ4rp4wp4zkjvWHcDypWUY612OsRGWUXAIXcvQd64+6KiU7V6HuM0AVdUUtHG7EZbg1n7eo71p3m422Wwec4FZpBJ460ANRcEdeevvUhAY8dKaiknI/KpNpJoAnj9MdB+dSY5zxn2qKIEDluv61PGMg+tAE0fSpovvZ61FGeBgYIqxEw980AdVp6edZoQvzYrqNCjdJAI8EKPmJrmvDWGiCvnb711Wnt9nKh+GcigC1rKhZlJDE9Nq8YrAvZCrsy/exyf6V0esowlDKBjGc54FcfKQsrEZ5OMZ6CgCO5nZyoBxx17GoJJ3AXaQ2RjBPQVUuGGc/wngVHuYsFXg+lAGjHIOTtVcdvep7Riu5BIRuGTz2rJjkKFgyk88getXLWcBFIUbm4Pc0AdVpDRpES7+YR0B6isrX45LidSJQqAdM9avaRInz+Qm4hOSexqHU7cyhBH97OTQByk4iVpEBZnA7ng1m3soS3YABTjBrZ1OzlhjaTgtu6r2Fc9qL4t8Z3e2KAMaVtwbPWq8jZB5PpxUrkdjwO3rVWaQ49qAIJjtX19aozN681Ync1nzMSeOtAFe4bOf51mztnOatTuaoynqc0AU5+lZU+N5rSuGAHHes2Q/NQBHjn1ppHPSn0mOfWgCMimH2FSn0xTT1oAjIr7K1g7f2ZvC7elpoR/8AI9rXxs3J7V9j68239mHw0w6iz0I/+RrWgCv4bv3Z2ikGFx9496o+KLbZeGXbxJ0x61Q0e4CyIR0BBH1roNWIvLTCBd64ORQBxWoxkOrsDVRi8lpIvVV5xWhq4CuPMOWxgelUIiSpCqu3BzQBjAdz09RQQc56fSnsOSB0puGJx3oAf/COhPXmpIhtGD3pmD6c1JGCD1BFAFgjKj07VLF6fhUS5J65+lTxjBxj6YoAkHt0roNBw25G/P0rBRhnnFbehORdcE46cCgDp9MhZXJAJOQFWusuFLWGTiNu5FYVmgWVJByi/Nn3relJm0reMlcnvQBz126tGCNx5yCRyTWbNdN5bhuo7+lWdV3ecMkrjrz2rGvXycjOSMntQBOJ5VRvm6c4zgfhUSyCQ5aMBzxVHzOCQSc80CRlZCc47YoA1VkZZgyuVVeMdea19P3Pc/vJBtPUHt9K5y3kRpDlSQBnrjJrY0+SN2Dty24YQUAauuEtautrgMRyT1FcdcRGEg3EuGJ6gV2OoKJkkO3aAMAYrmbuxldQWT5QDn/CgDFk2I7nBzng1z17KGmbsO1bczEBt+0Y4ww6Vzs5HmMRnJPFAEDnkgkc1VkOcnJPpU0rAZ4+tU5ZOKAK8zZHH5GqEzDHFWJ3zuFZ87nH60AVZ27ZrOn7+lXJiSapTEAH1FAGbd9P6VUI9OlWblsmq5HPtQA0j6imEVIeR60h69KAIjUNz/x7y/7p/lVg+tQ3f/HtL/uH+VAH6Z0UUUAeXfH0Z0zwqMZ/4nXT/tzuq5vTbXOCFwHGOntXVfHBS9r4SUDOda6f9uV1UWj2oezLSrhVPHr0oA5TXZYowkS53AY47VytzEcbCCRnOa6rVrbE80rthc/KDXIahfoHeOHntntQBWuxshwSCWNUdvGexoZ2Zst+FPGMdxQA0df8KcpwSfWlQc54qQDLYPAoAIsjrwKnjJ/DtioF796nBBHoaAJhgDHrU0ZGcjPHeq6gHPGKnjb1H4UAdl4ZU+VGFIOSTXQyZa4TeGyh7Vi+FYQ0cRxkDkit2635byxtPXNAFiS7WWD5z83TGe1crfEpK6jG1uTW2yfKFxkkbiSaxNRjJmODgZ6YoAy2JJyF+VfxqOXd5mVU5PP4VamzGCOGA9qjkLyICudyn5qAIHyYt24B+mM1Y05HRtvBx685qNI/MdTjI6mr0SlQAuN7Ajd6UAbOkOVBMZ/fNkEAfzqSdPL3CR2GGwgHJz71P4bgKqWZgAv3iwqS+eEqzuB94sCOMntQBi38aRwNjgsMlTya4DV5w0pVCQOmK67VtSjMTIq5bHXPQVwt9Jvdmzxn1oApzHHI78ZzVSd85wMY4qaR+PQVSmcDIH50AVp2xkc+5qhO3J5qeeTHGaoSv1oAgkbk+9VJTwanlPWqUzZz6UAVJ2yeKpSY3dKuTdOlUn+9QAlIR1pc0daAGkcH2ppFScf0pCMdqAISK+xdd/5Nh8Nd/wDQ9C/9HWtfHhHrX2JrYJ/Zj8MAdTZ6F/6PtaAOd0a3EkaEKcg7iDW9crHBaSPI23cM0/wxb7yqbPvDJzUniazO+OKI5GOc9qAOIvTvkMg5XGMelZwQr0+71rT1SWK14Lc9Metc/c3LyOdvANAELDc5wPekA4pycmlxyOmPX0oAQ9R3xUgOWyKXHA4pQNpGD70ASr2GKnXGc+nFQR46EdT1qRe2TQBOmPXqa29AGbrcD0HSsOM7f8a6Dw2u+4bH60AdoCVtApGA3f0q9Y3OyAQk8YzUBUJbxjDEgd6rfM25pf4eMD9KAKmtHEglQZI659a5+4bLNgHLVt6mhCDsxJzntWOUKKGIU/zoAqybfLAx07Y6GhGZ+G+UgdzUyvuDLjBIOOOpqE7iPmBDjigBkIkEwY8g8YPTit+wGZ03YTYMhves23hUJyvygZx3JrV0yOSa7BYDttBoA1p2lmdX6K3B7AAd6oOgk+cSFtvRjwMVu3yIpRHC/KvOOxNc7f3EFuDHligH50Acn4gkSJnAwrGuVmO4E9TnPFbWu3AmmJXIz69qwJGwT3PegCGV+D1yf1qjO3GW456CrErAc5z7CqFw5GeaAK87HFUJ255PSpppM85qnKcigCGU5PFZt5KEU5DcnHAzVyZ8dKozAMGDDOR3oANV0vUdOUnUtNv7MDkm5tni4/4EBWYrI4yjAj2NfTn7Pvj46tYDw1q0xOo2aZtZHPM8I/hz3ZOnuuDyQTT/AI4o82k3kXh3w5o+rTw/LqE4gjnubLcoYHyyMglSDu5IHOO4+PXE1eljvqGIoJO/xc1lbo9Vs/XfTc6PYpx50z5iPtmkIpI9uwbCNuOMU7FfYHOMI5qvdj/Rpv8AcP8AKrRGRmoLz/j1m9Nh/lQB+l9FFFAHAfFqMST+DEJwDrZ/9IburcsS2unuznoM034kR+bqnghPXW2/9ILuqHjy8Flok7ZwAu0UAeTeMNbM908EJ+QHkj+Vc2Muaa5LOzN1Y809V2gDp9aAFK4Xn8KfjKjikwOpBxThjd6UAPQfnSt1ye3WnIvydacQMdRmgCNV2gZHfrUqHIGTTD6inoOegzQBKM8DJqRcg5JOD60wDpg9KeMg4AzxQB6L4KUGBGIOcZro3tyyFmzgN1FYPgMD7EgP3vautvQIocDvzxQBzt4BGhBwQDkH0rJb5izSKcdua1roec+08DP1qlcRHy2G05oAw5Y90jHOMnP1psikAYHHpjrWoIssGZRx3pkkBdlBAB9KAKSIqqFGVLdquQ2z+cuRkdBilktdzA5zz271v6XAZWQuu0LycigCyIxDZfMNq4yR0ri/FWqeVCY4jjf+ldfrN2IoWxwAOSe9eRa7dm5unKtlVPHNAFSW4Yqct/8AXrOll4O77xNOkkwCcjHSqMz9fWgAlkxnk4qhPJk8ninSy9QMYqpNIaAIZm5OOtVJTUsjZz6etVJX9DigCKVs9KrSDFSnnNRvznigCnMMqcDiqDZyRWjMBjP6VnMcNQAZpen8+tN6jg4pQfagB1Jj3oBpfoaAI6+x9QXf+zb4SU/xW2gj/wAj2tfHR68ivsi6G79nPweo6mDQB/5MWtAG/wCH7Hy7dGGMAckVyfj7Vo7Auq8yHgAdTXfwR/ZdLXpkrzXgvjO7N7r1w2SVQ4FAGPLcNcuXc5JpAhA5/Gmxr1IyBUoHAA/IUAEY6jqKci856dxSAADAzUsS5b144oACCFOB9MUgX5s4Jxx9Kl2jnJFNx270AKhyMflUy8Dg/pUPUc9KnUfL6e1ADhuPf3ro/CXzXRH41zoyozXSeCwDqLZGFoA9HMO/YoGflxVGaLy8ZO4cg9q3oowIg5wSB+dYl/JycZ9M0AYd0xaTYNxAOM+lZ16nzKqGtlodmO+eeKoyRZyNpPNAGYI9q+r+tLAili2SCO/Y1ovDhNqrgYx9aYtqfKA49ee9AEKxO6blG5W/lXR6HAFj8wL8y9Ce1Z+lxEJ5e0k+uK6QhbS2C5+bHagDD1q7S1SR93zAfNmvNL/UZZ7h33HB5Az0roPGV/l/KQgFuDiuIkc5I70AFxOWfLcj1zVGWT0P4Us8gJPuOaoyyY6flQAk8npWfO4PfippJO9UpXz15oAikbIzVSVhz6+1SytjjqaqSEk560ARPzzVaXp71aaq8o69qAK9nf3ek6pbX+nzNBeWsglhkX+Fh7dx2I7gkVp6h4v1W68Y3Xieymk0zU55N+63f7owBt54ZeBwQQe4rDuPv/SohzjHWsJ4WjUn7ScU3a3yetvQfM1oeitrHhnxyx/4SeOPw74ifprFqn+i3Des8X8J/wBofUkDiua8V+FNX8Kzxrq1uv2ebH2e8gbzLe4BGQUccdOxwfasAehrpvCfjTVPDkEligh1DRJsifSr1fMgkB64B+4fcd+oNcH1Svg9cG7w/kb/APSZdPR3XblL5lL4jmj146VBeDFrN/uH+VekN4V0TxgrXHw/uDbant3yeHr+UCTpk+RKThx7E59SOBXnmqwTWq3lvdwyQXEIaOWKVSrIwHIIPQ11YXHUsS3FXUlvF6NfLt5q6fRkyi0fpTRRRXYScZ8QzjVvBB/6jL/+m+8rh/izeBbWK3zned2K7b4jnGp+Cj/1GZP/AE33leT/ABNuTNraxkjCL0oA45Fx269KXjJyfajnkUhHYdaAHDHUmnKoDDk00Dueo/WlXr2oAmAwARwfUUAZx0/Gjr0ppLBsEflQBKpGfw/CpEA/iPaoh7n/AOvU0Zx2/CgBy8jjj0qRRzgDnvTOcc8+lPTOcLz60AemfD9d1hGR/eIrrtUUGBAT68+lcx8O1zpSEd2Nddqqj7MCwGBQBy0wAII6mqjLk/KTg9at3AbzRgAj09KiZAqD+9nigDOZWXdgHjtRDA7npn0zVtxuIHf19alUH5UxjPYCgB9naic5I27fStY4gt22gbz0pLKNVTAyFHaqWr3eyNwhAwMYoA5PxhqOyN1VsEjFecTNuPOOK2/FV6ZJyqnkc/hXMzP1Izk9M9qAIrh/Q4FU5AWyOo9amlIZice9QsevrQBTkjOMZFV5Vbuc1afvuqJyOcc0AZ0oIHvVRw2elabDcScVCY+uKAM5gRk4qFvStMp2xUE0Qx0oAy5j8p/Ks+Qd61LiIjpzWfKp5oAg+mKBR3pOc5oAeD2peKaOmaUdeaAFIxX2WBu/Z98Ej1j8PD/yZtK+NAM8V9mxf8kB8Df7nh7/ANKbSgDofEl19l0qeTdgKh5r57uCJLmST1Yk17H8TLsxaJInA3kCvG+lABjAAGADSjGcZpMdzQoJGD3oAdtz0Yc+lSoo7VFz09KlXpj1oAU5zk0oGAOgNNJKjkcd6cpyAeKAJAM5xwKlG0NxUSdT3P8AOpgecgcd6AHADqema6XwOu7UyuMErXMqcDPT0zXV+AQW1jJHIQ8UAerRKPsRPGNveueu0AJ3Hp3rqIk/0UjH8NczqAwX2D6+9AGfL0BB5A4FVJVYPkHkj8KvKm4/N8vGKjf7vzDI7fWgDPw7uQoO0djVy3g3fuypDE9c0+JdmSRntk+laGnxgsHOSzevpQBYsrRYQN4yF5JxWZr96I4XJ+X2raupFijxkFj1rzzxdqGEfPWgDjdYujcXcrsQSeBWPO2znuakllLk7jg55qnK+VzQBBIxI9fYVTlQ7s1bYgHpiq8vLc80AVHD/wBaqSAjNX2x65FV5PmOMUAZcueeKhYexrSeMFulRNHg8igDOY89Khk6HPetKSEEHiqM8PHFAGXcDcx4qD+dW5lOeRVVhgmgBOh6Uo4603pj1pRQA8Eq6urFHQhlZSQVI6EEdDUd+0ksF1LNI8srh3eSRizOxySSTySTzk07OajvP+PSb/rm38qVle/UD9LKKKKYHE/En/kJeCv+wy//AKQXleKeM3MviO7JJwGwOa9p+Jpxf+DD/wBRiT/033leG+I236xdlu7k0AZoABpDkj1yaaST1/SnoPU44oAF/P604dfm+7SN7c/SlXAUcZFAEoIH+ApTnrnI9aauBjPSnKCQMYHNADl68dalAGQe1Rp1x0qTBPQAewoAfuyOB09aegJwOhNRjkj+VSxr8wGcE+tAHrvgCLbo8P8AtZJro9XIECdOazfCEHkaXbJ32DP1q/rYGQPagDnZUJcEfeHJqu4J6kEg96tSjcw3de2KrlecZ5FACInzbscgc1btEUOWYDjpmq23IyckHirMZY5bbhcc+1AE004SNgvBPH0rj/EF8Y0lZjwO1b+py+TDsByx6n0rzzxVe5UqGy3Qf40AcpezebcvIc5qlIc53YyamcgD1JqvK3HA9qAIWHynA6VA5yOKmcgZ5NRN6kZoAgkHHJ5qnIcnHT2q3KeQO1V2QZJoAi74zQRxmpSgx6UxuOmKAIiP1qGQA1P9etRyDPOelAFGWPOazbuHGSK2nGarXEY2mgDnHGDSd/Wp7mPZIfQ1Djn3oAT1pQaKAOaAJIl3N3wK+y4/+SA+Bsf3PD3/AKU2lfHVuvA/KvsWP/kgHgf/AHPD3/pTaUAZHxblYQ20QyMsTXmZUDnPFegfFeQm7tkPG0HNeek4465oAdzxTQM4z+VA5Oc/nUhHf+VAAenAqRcAcYNRL1Jp6Yxx/wDqoAkJz05FKuCOtIOvHpTsYI4oAkA+Udvp2p6kAY7mmgcdOvelGQD6+tAD1OT06cV2fw6j3ajI57L371xg+vFehfDKBt08xPcAUAelAFbZj0+XtXMXg3s3p2NdPcjFkT0zXMXIxkEYHc+lAFNtw+VsdOaiEeRgj6VNID3JI6ZNNAJGM+9AEiRhmAYcZq+CkQGOoH51SiOBgAkk9fWpJW2q0j8ADp74oAz9ZvD69T1PpXlvim9+0TlAxwOtdlrt4BC+SFB6ewrze8k86d2PTPSgCrK2eO3c1Vb7x61OxGKrsQRnOOaAInOCQc596hbJBz0qVueeo9ailbCnHBoAqS8H39ahGR3qeRQ1MEY6UAMIz71GRmpiMZx2qNvfpQBE4HQdaqyp7VcfJx2qBl4xQBlXMORnvWVKpDGukkj3Csa/iwcj9KAKH0opSPyo70AGe9R3f/HpP6+W38qkptyM2dx/1zb+VAH6VUUUUAcN8Tzi98GH/qMv/wCkF5Xivi2MJrlzgZBOa9q+J/8Ax++DP+wy/wD6QXleP+OYyusvnqV7UAc2AOvUe1PAwoGR9KbjjAoI9OQKAFHfjp3pcnGBS4wRg9qTGTyKAFHIOetTLgLx2qEE9vzqQDg59aAHsefQVIpAAJqPhhg8GnLwMelADx1yD+VaGlxeff26dQWGaoY5AwM10fgq287WEOOI+aAPY9GjCwp2AFQa4371jnoMVp6dGFiXFZWukfaGHbvQBiE7Q2f/ANdVtrFvTuOallPzD0FEUZzk4weaAJFBK4xg+varUW2OLLdP51FGDtOAT1p067LcsRmgDntdn8tSx6Y4ry7WrszXTc8A4Fdn4rvditg9QQK87l+Zsk8nvQBE7YJ75qEk9CSKlJAxzUTe3NAET49PrUTnGeeaczZPXio2AOM9aAI2Abr+VRlDn2qcqM9xSBR0zQBXPvUbDJPYVOy8kAVA+QTQAxkwAajI9+tTDJGetNK8+lAFV15wRTJEyKtOoz0IqFx14FAGHfxYOazWUg9OK3r2PIzWZJH19aAKXQ8VLEmecc1IIST7VYjTHUUAESYOOtfXicfADwP/ALnh7/0ptK+S1TAH519aL/yb94I/3PD3/pTaUAYPxTjDGCTuDg150R6V6d8S4y1puCgAMDXmWBnOcntQAqDkkdPegnnnqfSkI496VR8ue9ACg4JI60qnnnvSHqPajOMdfpQBLEBk88089BxUS5JBqReBg/nQA9Oc89qecHp1x61GgwTzxUg+7nFAEqcqRmvWPh5beXpcZA+ZyWJryi3jLyIuPvEAV7p4UtVisIVHYAUAauo8WarnkmuWnJMnPTpxXU6xhbVelcpcnAYjqfSgCCclnO3OM/hT4cgfN17Ed6YFJxjoOtWEXDc+nbmgCS2TDZz9Kq6vIAjBeRjk/wBavRru3Hp2rnfENwI4ZNvGKAOI8VXwOUU9TiuQkbPJPetDWpzPduc8DgVmEYHWgCN2OTjgVFJjv+FSvzg/pUEjY6dfSgBhwB1wKhf5icmpG5HNR7Qe5+tAELJjgUhXAxipwuO9MdMY70AV3HT9ajKZzippARUakk0AQkfpUbr39assvWmOowM0AVSvHtWfew5U1qsMe9VLlcg0Ac3ImM4FMx+daEsYzVZoyTQBEi7iKddpiwuD/wBM2/lViKIg8ilv0/4l10fSJ/5GgD9GqKKKAOF+KH/H74M/7DL/APpBeV5L4851kjpha9b+KH/H74Mxj/kMv1/68LyvJPHgH9sEf7NAHMNnApQeOQOtIMg8gGgnrn1/OgBdxU8d6TPU/nTS3GRTGOSAB9KAJYgMe1THOMVEoIx04qXBPb8aAHD0H51IvA9DTARtIP505Tkeo9KAJFILdq734b2uZJJSOpCiuBVfm4zmvWfAFt5NlFwcnkmgD0G0XbGvNc7rLZuHH4V0gOyI5HauX1D552J5NAGY4OTgcVYQYjAGcnmm+Wd2Cc1KqsWwB0HWgBYfvAHP0qprE+1CAfl9K0gAiE8bumTXKeILoBHOeRkdaAOC8XXReXy+hzk1yxyeSeK0dUlMt27k5Gaz36E9vSgCOQDJxUL9QRU7cqSKiYY4xz1oAgIHUdPemEc471M3AI60xuMZ/OgCIjqaaR6GpWzjoMUzGelAEeecCo2APJ4NTEGoiDxigCMIRnmo8Hpip144xzSMMn2oArlTio3HFWSM0x04oAzLpeM9Kz/L3HpWvcLkY7VTVME4oAgWLAFL5XPvVnZ7U7ZQBXVCOlfVq/8AJv8A4I/3PD3/AKU2lfLsURdsKCSa+oR/yb94I/3PD3/pTaUAUPiMf+Jcf94V5eQcnjmvUPiN/wAg4k8fMK8uOQfagAQ88ilJxg9qM9McelNz6UAKW3f4Umcv159Kazg5NLGDjP8Ak0AWEGPcGlHAy3WmKeOhyKkj4PzUAOXkjNSZ46c0xTg4FKADzn86ANfw9b+fqtug6bgfyr3bRotkK4GABXkHgK233/mNn5RtFe0acMQqcUAV9ebEaDNctL1yBk5ziui11txxngVguhzntQA22XBJPb9akXgk+3WkVdoHBOTVmOPP3hgUAJPJ5cBK9e9ef+K7zZFIT3H512WsT7EK5xxkV5Z4tujJJ5YY4HODQBy0rMzH1zzUTD5c1K3J4xnvUfHpQBA33T61EwyQe9TkY+92qMjGDigCEgDr/wDrppGcfnxUhHBpOwxzQBCRnJyKQ8detPP5elNYeo4FAEb/ADDmoimG4xipm79aYRzkigCFsg80zBPSrLDrxTCO1AFZl65qtMuRir5XNV5RgHFAGLKmWPSkSHue9Wnj+enBMigCt5XHtVfUkI027/64v/6Ca0tnHFVtVUf2Xef9cH/9BNAH6FUUUUAcN8Txm98Gf9hl/wD0gvK8l8enbq4PqvSvWvid/wAf3gv/ALDL/wDpBeV5T4/jK6mjdAVoA5Nfvc0j5yaeFzyetNYZH86AIzkUiKWOQKVuenAFOhUZJOcUASxj1p4JYEck0ijI9hQAQMigBQMAZPapR65qMcE5qRQMeg/nQBb02IzXkaAHrkivbfCtv5dqmO1eV+ELbzroSEc9BXsuiR7IFAFAGlcnZDgnqK568wXJ6Vuag21BzXPykyPz3PNAEaruPA61LAvBOO9SKgC46UpARQM8n+VAFW/kWKE8c4ya868W3oSFwO/Ars9YnKowzXlviq5Mk4TOSOaAOdb5iSTUZP6d6cW59KT17ZoAj7dOD2qKT26DrUxJAwM89qZ/EM9KAICDSFcDipSBk4HWk28fjQBAwyMCmYweevvVh16etQshyOBQBGwxkUxsD0qZh9c0xgO1AFfOTkmg5zT2Az71GRQAvXjFMIwak4pMce1AFOdeuBVZU69K0XjO05quE5oAg2VcsbFrh+hxSQx7pFHr1rqbS38u3Hlrz60ARW2mJAgJwK9uH/Jv3gj/AK5+Hv8A0ptK8VuXkjJDZr2tf+Tf/BH+54e/9KbSgCh8RRjTW56MDXlrNknHA9K9W+IaZ02QjPBzXlRXJwePegAf7o71GwPPHTipCCMio24470AMbk4qaMEdRUQBLDrnrVkDBIByfWgBwO3A7UAHLZpMZOB+NOyTjPHagBydOKkB5HWo0Azx1FXLCLzrlIvVgTQB6H8P7QrGhI+Y16fbDbD1GAK4/wAJ23lRrkc4rsWyID6Y6UAY2pEOTzznqazGAJx1OavX0hLYx0qvDH3PegBiJiRQR71M+FUluAKcq4JY4wBmql/KUQ89eTQBzuv3SqrnP59q8o1Wcz3jtnjPFdx4ruysMvOM8V55I2W5HJoAjbAPqaZ0PvUnXFMPBODzQBG3QkdTUByec81OxJ5701gvBzQBEFyOajPWpwMnPrSMvHNAFbbg88UEd+1PdetNC4XnigCIjrmonPbtU5A7dajdRQBHnApM+opWHWgY/KgBrA4qGVcrVnHPHTpTGTPtQBmMuXzShevHNWJEw5z1pQnagCGOEu4UDrVzVNJ2eHNTmYZK2srf+OGtbRbRMb2GW7U7xQZF8M6rwdn2WUf+OGgD7SooooA4f4m/8f8A4L/7DL/+kF5XmPxDXN7GegAIr074m/8AH/4L/wCwy/8A6QXledfESPLRNjnJ4oA4Ns9PSmsPl9akxk+gpj8HNAEOOmT1qZAcjj2FRjLEE1KOOD+PagB/1waUAE5oAGPlHHSjjHGM0AKpIqRTn+VR9CMjNSwDfIox3oA73wTb42ccH2r1awACLgHIFcL4LtsQIxHau8tRtGSeMUAV9WYcDPSsdIh5hOTkkmruoyh5foaqx+5oAmHHbgVBMSNzt96pG5RRjJ61U1Kb923qBQBzGvXQVWOc9c5ryvUZ2mu5HJ5zXb+KLvbC4U5PNcC5JbPrQBEwyTTccZqTHPPSmnB5I5oAiZjkdKXbuHFKefShcgYoAYEB4x9aRl46Din5IJ5/GggfiaAIStRkYFWCufvVG6jPFAFdu+RUbcj3qwyjpmoyvPNAEDL69KYRz1qwwyD6Uzy+aAItoJpxUdO1SiJiMgZFOMD9gcUAVJDweagxmrssRAPFVtuO9AEtkoFynpmuwjVRAMdSOlcfEwSRSecHNdLDMskS4cCgBWiWUlHYoc8Zr2Ff+TfvBH+54e/9KbSvKIoPM2hnTd1zmvWF/wCTf/BH+54e/wDSm0oAb47GdKmC9cV5I3BJ9a9j8YJv0+cY/hPWvHW4JHegCPnrmojkk+lTMMD+dROc8AUAKgOOO/eplzgEDio0+UdeKlQDrk59KAAfl60vcDqO9KPU0nuaAJFP61t+GYQ94GwOtYSkcYHSuy8E25aQZHJPNAHqWgRBYFzwSM1s3TYtzz2xVDT4yiKBxiptTlxGFzzigDFnXc4O48Z6d6lRcLjqelRjlqmU4z7DigBs3ICYwvesXWJ8IeeQOnrWvI4SIgj8a5PX7jbvLY6HrQBwXiy73zCJeB1Nc0/OM8Vf1aYzXcjds1ROT9aAI8dccU1jgHFSkDp6UwjHTp60AMA3DpzSFMHnNOUENQxORQA0pjj8ajKkipjz1PSmkZPTigCFl5qJx2I4qwyDb3qMrjigCA8kjtURBI4qwVppGKAKxXpzRjipWTqaBGewzigCMJjnvSMMcVOI2wcA01oiByKAKTcse9CrUjIQ59aVegoA6fRUU26t0Iql4u48OasDkA2k30+4al0iZfs23d045pniZXbwxrG7BUWcxBz/ALBoA+yaKKKAOI+Jf/IR8Ff9hl//AEgvK4fx9D5luccFeSa9f1vRdK161W11zTLHUrZHEixXlukyK4BAYBgRnBIz7msX/hXHgf8A6E3w3/4K4P8A4mgD50IAGfX1qFztODz3r6R/4Vx4H/6E3w3/AOCuD/4mj/hXHgf/AKE3w3/4K4P/AImgD5sX1P41ICT9a+j/APhXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4mgD51A4wBkUMOMfrX0V/wAK48D/APQm+G//AAVwf/E0f8K48D/9Cb4b/wDBXB/8TQB869OT0q1pvzXUe7oTzX0B/wAK48D/APQm+G//AAVwf/E0f8K48D/9Cb4b/wDBXB/8TQBj+FkQW0eGVtwyMGurUAQsR1wazP8AhXHgf/oTfDf/AIK4P/iaP+FceB/+hN8N/wDgrg/+JoAq3HLk9aWBRg8DHerP/CuPA/8A0Jvhv/wVwf8AxNH/AArjwP8A9Cb4b/8ABXB/8TQBAxwCT24Fc/rswSMkHk8V0/8AwrjwP/0Jvhv/AMFcH/xNH/CuPA//AEJvhv8A8FcH/wATQB4V4nuN0mxfWuebJ7c19Lf8K48D/wDQm+G//BXB/wDE0f8ACuPA/wD0Jvhv/wAFcH/xNAHzScYAA+YHrTDgCvpn/hXHgf8A6E3w3/4K4P8A4mj/AIVx4H/6E3w3/wCCuD/4mgD5ideeDxTe1fT/APwrjwP/ANCb4b/8FcH/AMTR/wAK48D/APQm+G//AAVwf/E0AfLxz2NAY+ntX1D/AMK48D/9Cb4b/wDBXB/8TR/wrjwP/wBCb4b/APBXB/8AE0AfL27nAxzTD94V9Sf8K48D/wDQm+G//BXB/wDE0f8ACuPA/wD0Jvhv/wAFcH/xNAHy044HFRle/evqn/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4mgD5TKdxU0MOV3MPavqb/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4mgD5jiRQM4zSsFGfavpv/hXHgf/AKE3w3/4K4P/AImj/hXHgf8A6E3w3/4K4P8A4mgD5ZugRGcYPtWe6YwcV9bf8K48D/8AQm+G/wDwVwf/ABNH/CuPA/8A0Jvhv/wVwf8AxNAHyNg59qmidkxg19Z/8K48D/8AQm+G/wDwVwf/ABNH/CuPA/8A0Jvhv/wVwf8AxNAHytHO5OAea95T/k3/AMD/AO54e/8ASm0rsP8AhXHgf/oTfDf/AIK4P/ia2rnRNKutGGkXWmWM2kqiRiykt0aAImNi+WRtwNowMcYHpQBwviVN1rIDzkcV4zdRlLh1J5Umvob/AIVx4H/6E3w3/wCCuD/4mj/hXHgf/oTfDf8A4K4P/iaAPnCQ4ye1RZy3FfSn/CuPA/8A0Jvhv/wVwf8AxNH/AArjwP8A9Cb4b/8ABXB/8TQB83hsDFSJxz3r6M/4Vx4H/wChN8N/+CuD/wCJo/4Vx4H/AOhN8N/+CuD/AOJoA+dR60ig49a+i/8AhXHgf/oTfDf/AIK4P/iaP+FceB/+hN8N/wDgrg/+JoA+dlPP0r0rwHCpiD5XA6nNd/8A8K48D/8AQm+G/wDwVwf/ABNH/CuPA/8A0Jvhv/wVwf8AxNAF60TgZyOO9UtUz5pHpSf8K48D/wDQm+G//BXB/wDE0f8ACuPA/wD0Jvhv/wAFcH/xNAFKMAuOOlTlcHaBgHqam/4Vx4H/AOhN8N/+CuD/AOJo/wCFceB/+hN8N/8Agrg/+JoAy9RcBDzwOlee+JLoCORmPOT1r1b/AIVx4H/6E3w3/wCCuD/4mj/hXHgf/oTfDf8A4K4P/iaAPmt2LEkg8nrTABzvBHWvpf8A4Vx4H/6E3w3/AOCuD/4mj/hXHgf/AKE3w3/4K4P/AImgD5nwOKjdQRkda+nP+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDiaAPmDBH1pG619Qf8K48D/wDQm+G//BXB/wDE0f8ACuPA/wD0Jvhv/wAFcH/xNAHy8D60pbjOK+oP+FceB/8AoTfDf/grg/8AiaP+FceB/wDoTfDf/grg/wDiaAPl1zxnGM00gYOfrX1J/wAK48D/APQm+G//AAVwf/E0f8K48D/9Cb4b/wDBXB/8TQB8rFcjFMKn0r6s/wCFceB/+hN8N/8Agrg/+Jo/4Vx4H/6E3w3/AOCuD/4mgD5UijLuFzVuOFQeMZ619Qf8K48D/wDQm+G//BXB/wDE0f8ACuPA/wD0Jvhv/wAFcH/xNAHzKUUcgY+tQyL1wAfrX1B/wrjwP/0Jvhv/AMFcH/xNH/CuPA//AEJvhv8A8FcH/wATQB8lyruZjiosYHFfXP8AwrjwP/0Jvhv/AMFcH/xNH/CuPA//AEJvhv8A8FcH/wATQB8lRsycqcVFr9y58PampJwbWUdf9g19df8ACuPA/wD0Jvhv/wAFcH/xNH/CuPA//Qm+G/8AwVwf/E0AdVRRRQB//9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The plain x-ray of the left hand is from a patient with radiologically mild rheumatoid arthritis. The magnified view of the second metacarpophalangeal joint&nbsp;in (A) is shown with arrows in (B). Subtle erosive changes are noted at the second metacarpophalangeal joint (white arrow), while soft tissue changes are more obvious (yellow arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Richard Waite, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 506px\">",
"   <div class=\"ttl\">",
"    Plain radiograph of normal left hand (AP, lateral, and oblique)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 486px; height: 598px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The radiographs of the left hand in the AP (A), lateral (B), and oblique (C) projections are normal.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_33_9753=[""].join("\n");
var outline_f9_33_9753=null;
var title_f9_33_9754="Carbapenemases";
var content_f9_33_9754=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"6\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Carbapenemases",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/33/9754/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/33/9754/contributors\">",
"     John Quale, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/33/9754/contributors\">",
"     Denis Spelman, MBBS, FRACP, FRCPA, MPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/33/9754/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/33/9754/contributors\">",
"     David C Hooper, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?9/33/9754/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?9/33/9754/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?9/33/9754/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 14, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbapenem antibiotics have an important antibiotic niche in that they retain activity against the chromosomal cephalosporinases and extended-spectrum beta-lactamases found in many gram-negative pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. The emergence of carbapenem-hydrolyzing beta-lactamases has threatened the clinical utility of this antibiotic class and brings us a step closer to the challenge of \"extreme drug resistance\" in gram-negative bacilli [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Issues related to carbapenemases will be reviewed here. Penicillinases and cephalosporinases are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30553?source=see_link\">",
"     \"Extended-spectrum beta-lactamases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbapenemases are carbapenem-hydrolyzing beta-lactamases that confer resistance to a broad spectrum of beta-lactam substrates, including carbapenems. This mechanism is distinct from other mechanisms of carbapenem resistance such as impaired permeability due to porin mutations, although the susceptibility patterns for isolates with a carbapenemase and those with porin mutations can be identical.",
"   </p>",
"   <p>",
"    The carbapenemases have been organized based on amino acid homology in the Ambler molecular classification system. Class A, C, and D beta-lactamases all share a serine residue in the active site, while Class B enzymes require the presence of zinc for activity (and hence are referred to as metallo-beta-lactamases). Classes A, B, and D are of greatest clinical importance among nosocomial pathogens.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Class A beta-lactamases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Class A beta-lactamases are characterized by their hydrolytic mechanisms that require an active-site serine at position 70 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/4\">",
"     4",
"    </a>",
"    ]. These include penicillinases and cephalosporinases in the TEM, SHV, and CTX-M-type groups (which do not hydrolyze carbapenems), as well as additional groups that possess beta-lactamase (including carbapenemase) activity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/1,5\">",
"     1,5",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30553?source=see_link\">",
"     \"Extended-spectrum beta-lactamases\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Class A beta-lactamases with carbapenemase activity may be encoded on chromosomes or plasmids. Chromosomally-encoded enzymes include SME (Serratia marcescens enzyme), NMC (non-metalloenzyme carbapenemase) and IMI (imipenem-hydrolyzing) beta-lactamases. SME have been recovered in a small number of S. marcescens isolates, while IMI and NMC have been identified among Enterobacter isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. Plasmid-encoded enzymes include KPC (Klebsiella pneumoniae carbapenemase) and GES (Guiana extended spectrum). GES has been described in P. aeruginosa and K. pneumoniae [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/5,9-11\">",
"     5,9-11",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H19876835\">",
"     'Klebsiella pneumoniae carbapenemase (KPC)'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19876835\">",
"    <span class=\"h3\">",
"     Klebsiella pneumoniae carbapenemase (KPC)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most clinically important of the Class A carbapenemases is the Klebsiella pneumoniae carbapenemase (KPC) group (",
"    <a class=\"graphic graphic_table graphicRef60389 \" href=\"UTD.htm?5/29/5596\">",
"     table 1",
"    </a>",
"    ). These enzymes reside on transmissible plasmids and confer resistance to all beta-lactams [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/9\">",
"     9",
"    </a>",
"    ]. Several different variants of KPC enzymes have been identified. Some of the variants hydrolyze beta-lactams at varying rates, which may contribute to different susceptibility profiles in KPC-producing bacteria when tested in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. KPC can be transmitted from Klebsiella to other genera, including E. coli, Pseudomonas aeruginosa, Citrobacter, Salmonella, Serratia, and Enterobacter spp. [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/14-19\">",
"     14-19",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Class B beta-lactamases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Class B beta-lactamases are also known as the metallo-beta-lactamases (MBLs), which are named for their dependence upon zinc for efficient hydrolysis of beta-lactams. As a result, MBLs can be inhibited by EDTA (an ion chelator), although they cannot be inhibited by beta-lactamase inhibitors such as tazobactam, clavulanate, and sulbactam. The first MBL, IMP-1, was described in Japan in 1991 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/20\">",
"     20",
"    </a>",
"    ]. Subsequently, additional groups of acquired MBLs have been identified: IMP, VIM, GIM, SPM, and SIM. There are a number of variants within each MBL group (for example, there are 19 IMP variants within the IMP group) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/21,22\">",
"     21,22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There are both naturally occurring and acquired MBLs. Naturally occurring MBLs are chromosomally encoded and have been described in Aeromonas hydrophilia, Chryseobacterium spp., and Stenotrophomonas maltophilia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/21\">",
"     21",
"    </a>",
"    ]. Acquired MBLs consist of genes encoded on integrons residing on large plasmids that are transferable between both species and genera [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/4,23-28\">",
"     4,23-28",
"    </a>",
"    ]. In a hospital outbreak involving 62 patients (including 40 intensive care unit patients), for example, an MBL gene (bla IMP-4) spread among seven different gram-negative genera (Serratia, Klebsiella, Pseudomonas, Escherichia, Acinetobacter, Citrobacter, and Enterobacter) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/23,29\">",
"     23,29",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19877222\">",
"    <span class=\"h3\">",
"     New Delhi metallo-beta-lactamase (NDM-1)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Enterobacteriaceae isolates carrying a novel MBL gene, the New Delhi metallo-beta-lactamase (NDM-1), were first described in December 2009 in a Swedish patient hospitalized in India with an infection due to Klebsiella pneumoniae (",
"    <a class=\"graphic graphic_table graphicRef60389 \" href=\"UTD.htm?5/29/5596\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The gene encoding this MBL is located in a very mobile genetic element, and the pattern of spread appears to be more complex and more unpredictable than that of the gene encoding KPC [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/30,31\">",
"     30,31",
"    </a>",
"    ]. Furthermore, the large number of resistance determinants in the isolates studied raise concern that this gene is an important emerging resistance trait [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/32\">",
"     32",
"    </a>",
"    ]. In general, bacteria containing NDM-1 have tested susceptible to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    , though such susceptibility may be short-lived.",
"   </p>",
"   <p>",
"    In addition to K. pneumoniae, NDM-1 has also been identified in other Enterobacteriaceae (including E. coli and Enterobacter cloacae) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/33\">",
"     33",
"    </a>",
"    ] as well as non-Enterobacteriaceae (including Acinetobacter) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Class D beta-lactamases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Class D beta-lactamases are also referred to as OXA-type enzymes because of their preferential ability to hydrolyze",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"     oxacillin",
"    </a>",
"    (rather than penicillin) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/35\">",
"     35",
"    </a>",
"    ]. Enzymes in this group are variably affected by the beta-lactamase inhibitors clavulanate, sulbactam, or tazobactam. OXA carbapenemases have been identified in Acinetobacter baumannii [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/35-44\">",
"     35-44",
"    </a>",
"    ] and Enterobacteriaceae (especially K. pneumoniae, E. coli, and E. cloacae) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among the heterogeneous OXA group (which includes more than 100 enzymes), five subfamilies have been identified with varying degrees of carbapenem-hydrolyzing activity: OXA-23,",
"    <span class=\"nowrap\">",
"     OXA-24/OXA40,",
"    </span>",
"    OXA-48, OXA-58, and OXA-51 (",
"    <a class=\"graphic graphic_table graphicRef56259 \" href=\"UTD.htm?43/13/44251\">",
"     table 2",
"    </a>",
"    ). The first four groups are carried on transmissible plasmids, while the last group, OXA-51, is chromosomally encoded and intrinsic to A. baumannii species. While most isolates of A. baumannii possessing an OXA-23,",
"    <span class=\"nowrap\">",
"     -24/40,",
"    </span>",
"    or -58 type carbapenemase are resistant to carbapenems, Enterobacteriaceae with OXA-48-type enzymes have variable susceptibility to these agents. Expression of a promoter insertion element (ISAba1) in OXA-23 and OXA-51 likely contributes to carbapenem resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21045519\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92008072\">",
"    <span class=\"h2\">",
"     Distribution",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92008083\">",
"    <span class=\"h3\">",
"     Klebsiella pneumoniae carbapenemases",
"    </span>",
"    &nbsp;&mdash;&nbsp;The Klebsiella pneumoniae carbapenemase (KPC) is the most common carbapenemase in the United States (",
"    <a class=\"graphic graphic_table graphicRef60389 \" href=\"UTD.htm?5/29/5596\">",
"     table 1",
"    </a>",
"    ); as of 2010, KPC-production has been identified in isolates from 36 states [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. It was first described in a clinical isolate of K. pneumoniae in the late 1990s in North Carolina [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/9,48\">",
"     9,48",
"    </a>",
"    ]. Shortly thereafter, several reports described hospital outbreaks in the northeastern United States involving K. pneumoniae carrying KPC-2, an enzyme later found to be identical to the initially described KPC [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/49-52\">",
"     49-52",
"    </a>",
"    ]. Subsequently, an outbreak involving K. pneumoniae with KPC-3 (which differs from",
"    <span class=\"nowrap\">",
"     KPC-1/KPC-2",
"    </span>",
"    by a single amino acid) was described in New York City [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2011, an outbreak of carbapenem-resistant K. pneumoniae occurred at the US National Institutes of Health Clinical Center that affected 18 patients, 11 of whom died [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/54\">",
"     54",
"    </a>",
"    ]. The CDC reported that the proportion of Enterobacteriaceae that were carbapenem resistant increased from 1 to 4 percent between 2001 and 2011; the proportion of carbapenem-resistant Klebsiella increased from 2 to 10 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/55\">",
"     55",
"    </a>",
"    ]. Los Angeles County noted 675 cases of carbapenem-resistant K. pneumoniae between June 2010 and May 2011; the incidence was higher in long-term acute care facilities than in acute care hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/56\">",
"     56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    KPC-possessing isolates have also been increasingly recovered from other regions of the world, including Europe [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/57,58\">",
"     57,58",
"    </a>",
"    ], Asia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/14,59,60\">",
"     14,59,60",
"    </a>",
"    ], and South America [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/15,61\">",
"     15,61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92008117\">",
"    <span class=\"h3\">",
"     Metallo-beta-lactamases",
"    </span>",
"    &nbsp;&mdash;&nbsp;Metallo-beta-lactamases (MBLs) were initially described in Japan in 1991 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/20\">",
"     20",
"    </a>",
"    ]. MBLs have since been described in Korea, Singapore, Taiwan, Hong Kong, China, Malaysia, Brazil, England, Italy, Canada, United States, Australia, and Colombia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/21,62-65\">",
"     21,62-65",
"    </a>",
"    ]. The transfer of patients between hospitals and the increase in international travel may be important factors in the geographical dissemination of MBL genes [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/21,27,62,66,67\">",
"     21,27,62,66,67",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The MBL gene, the New Delhi metallo-beta-lactamase (NDM-1) (",
"    <a class=\"graphic graphic_table graphicRef60389 \" href=\"UTD.htm?5/29/5596\">",
"     table 1",
"    </a>",
"    ), was first described in December 2009 in a K. pneumoniae isolate from a Swedish patient who had been hospitalized in India [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/30\">",
"     30",
"    </a>",
"    ]. Subsequent reports have included patients who have traveled and undergone procedures (so called &ldquo;medical tourism&rdquo;) in India and Pakistan [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/33\">",
"     33",
"    </a>",
"    ], as well as cases reported in Asia, Europe, North America, and Australia [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/31,33,47,68,69\">",
"     31,33,47,68,69",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the United States, between January 2009 and February 2011, seven Enterobacteriaceae isolates with NDM-1 production were reported to the Centers for Disease Control and Prevention (CDC) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/47\">",
"     47",
"    </a>",
"    ]. These were all identified in patients who had traveled to India or Pakistan, the majority of whom received medical care there.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H561110\">",
"    <span class=\"h3\">",
"     Class D carbapenemases",
"    </span>",
"    &nbsp;&mdash;&nbsp;While A. baumannii carrying OXA-23-,",
"    <span class=\"nowrap\">",
"     OXA-24/40-,",
"    </span>",
"    and OXA-58-type carbapenemases are especially problematic in Europe, they have also been recovered from medical centers in Eastern Asia, the Middle East, Australia, South America, and the United States [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/35\">",
"     35",
"    </a>",
"    ]. The first isolate of K. pneumoniae with OXA-48 was identified in Turkey; since then, hospital outbreaks from that country have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/70\">",
"     70",
"    </a>",
"    ]. Enterobacteriaceae with OXA-48-type enzymes have subsequently been recovered in Europe, the Middle East, and Northern Africa.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21045526\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbapenemase-producing organisms can arise from previously carbapenemase-negative strains by acquisition of genes from other bacteria. Use of broad spectrum cephalosporins",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    carbapenems is an important risk factor for the development of colonization or infection with such pathogens [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/29,66,71\">",
"     29,66,71",
"    </a>",
"    ]. As an example, in one case-control study, 86 percent of patients with a KPC-producing Enterobacteriaceae isolate (n = 91) had a history of cephalosporin use in the past three months, compared with 69 percent of those with extended-spectrum beta-lactamase-producing isolates and 27 percent of those with fully susceptible isolates [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/72\">",
"     72",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although a risk factor, prior receipt of carbapenems is not essential for acquisition of these strains. Reported carbapenem use among patients prior to the isolation of MBL, for example, varies from 15 to 75 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/59,60\">",
"     59,60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Additional risk factors that have been associated with infection or colonization with a carbapenemase-producing organism include the following [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/16,18,23,49,60,61,73-75\">",
"     16,18,23,49,60,61,73-75",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      trauma",
"     </li>",
"     <li>",
"      diabetes",
"     </li>",
"     <li>",
"      malignancy",
"     </li>",
"     <li>",
"      organ transplantation",
"     </li>",
"     <li>",
"      mechanical ventilation",
"     </li>",
"     <li>",
"      indwelling urinary or venous catheters",
"     </li>",
"     <li>",
"      overall poor functional status or severe illness",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Clinicians should be also aware of the possibility of NDM-1-producing Enterobacteriaceae in patients who have received medical care in India and Pakistan [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H92008117\">",
"     'Metallo-beta-lactamases'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21045553\">",
"    <span class=\"h2\">",
"     Transmission",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many carbapenemases reside on mobile genetic elements, such as transposons or plasmids, and have the potential for widespread transmission to other isolates and genera of bacteria. Furthermore, Enterobacteriaceae, which may harbor carbapenemase-encoding genes, can spread from person to person.",
"   </p>",
"   <p>",
"    One particular clone of K. pneumoniae that carries the KPC gene has been reported as the predominant isolate across several geographic areas, suggesting cross-infection within and outside of healthcare systems [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/70\">",
"     70",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Limited data using DNA fingerprinting and pulse-field gel electrophoresis also suggest cross-transmission of bacteria with MBLs within hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/28\">",
"     28",
"    </a>",
"    ]. This was illustrated in a study of 66 MBL-positive isolates from 54 hospitalized patients in a hospital outbreak [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/63\">",
"     63",
"    </a>",
"    ]. Environmental screening isolated MBL-producing organisms from sinks and stethoscopes, suggesting these as possible environmental reservoirs; interestingly, there were no positive cultures from the hands of the 10 healthcare workers screened. The outbreak was curtailed following intensive environmental cleaning with hypochlorite, replacement of poorly designed sinks, and disassembling and cleaning of stethoscopes. In another outbreak, environmental screening demonstrated a single positive swab from a ventilator; all other environmental swabs of hands, gowns, medical fluids, air and water samples, and endoscopes were negative [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/75\">",
"     75",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    NDM-1-positive bacteria have been identified in public water supplies in India, highlighting the potential for environmental dissemination, and the importance of environmental surveillance [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/76\">",
"     76",
"    </a>",
"    ]. In addition, two isolates of Pseudomonas aeruginosa containing an MBL gene (bla VIM) have been also detected from aquatic sources (one isolate from a river and the second from sewage), raising the possibility of aquatic reservoirs for these organisms [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/77\">",
"     77",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients themselves may also serve as an important reservoir for resistant Enterobacteriaceae, as intestinal colonization with carbapenemase-producing organisms has been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/21,28,78,79\">",
"     21,28,78,79",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92009070\">",
"    <span class=\"h1\">",
"     DETECTION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92009113\">",
"    <span class=\"h2\">",
"     Clinical laboratory testing",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most K. pneumoniae and E. coli without carbapenemases have minimum inhibitory concentrations (MICs) to imipenem and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    that are &le;0.5",
"    <span class=\"nowrap\">",
"     mcg/mL.",
"    </span>",
"    Thus, the identification of E. coli or K. pneumoniae with overt resistance to any of the carbapenems should raise suspicion that it may be harboring a carbapenemase enzyme. Certain susceptibility patterns in other Enterobacteriaceae may be suggestive of the presence of a carbapenemase. As an example, recovery of an isolate that is susceptible to third generation cephalosporins but resistant to imipenem should raise the possibility of an underlying Serratia marcescens enzyme (SMC) in Serratia species and a non-metalloenzyme carbapenemase (NMC) or imipenem-hydrolyzing beta-lactamase (IMI) in Enterobacter species [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/6-8\">",
"     6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Detection of carbapenemase-producing Enterobacteriaceae can be problematic. Some isolates have MICs that fall just below the traditional breakpoints for susceptibility and therefore may not be recognized as carbapenemase producers by the clinical laboratory [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/23,63,80-83\">",
"     23,63,80-83",
"    </a>",
"    ]. In one report, up to 87 percent of K. pneumoniae carbapenemase (KPC)-producing K. pneumoniae were reported to be susceptible to carbapenems according to breakpoints typically in use prior to 2011 [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/84\">",
"     84",
"    </a>",
"    ]. Detection of Enterobacteriaceae harboring OXA-48-type enzymes can be similarly challenging [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In 2010, the Clinical and Laboratory Standards Institute (CLSI) updated",
"    <a class=\"external\" href=\"file://www.cdc.gov/hai/organisms/cre/cre-toolkit/rCREprevention-AppendixA.html\">",
"     new MIC and disk diffusion breakpoints",
"    </a>",
"    for the Enterobacteriaceae based on pharmacokinetic-pharmacodynamic data of recommended dosage regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/85-88\">",
"     85-88",
"    </a>",
"    ]. The new MIC breakpoints are one to three doubling dilutions lower than the original breakpoints, and the new disk diffusion criteria include larger zone diameters than those in previous guidelines. Thus, many organisms that previously would have been categorized as susceptible using the former breakpoints may now be considered intermediate or resistant. In clinical laboratories that have implemented these new breakpoints, additional tests to detect extended-spectrum beta-lactamases and carbapenemases need not be routinely performed for clinical management. However, phenotypic or genotypic testing for carbapenemases may be useful for isolates that test in the susceptible range to carbapenems but have reduced susceptibility. Additionally, carbapenemase testing may be performed for infection control purposes, and isolates may be forwarded through state public health laboratories to the United States Centers for Disease Control and Prevention (CDC) for further characterization [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/31\">",
"     31",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H92009120\">",
"     'Other phenotypic tests'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    P. aeruginosa and A. baumannii can become resistant to carbapenems without harboring a carbapenemase; determining which isolates have a carbapenemase based on susceptibility profiles can be difficult. In regions where metallo-beta-lactamases (MBL) and OXA enzymes are endemic, isolates of P. aeruginosa and A. baumannii that are highly resistant to carbapenems, cephalosporins, and penicillins should be suspected of carrying one of these enzymes. In addition, presence of an underlying MBL should be considered if an isolate retains susceptibility to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92009120\">",
"    <span class=\"h2\">",
"     Other phenotypic tests",
"    </span>",
"    &nbsp;&mdash;&nbsp;For laboratories that have implemented the updated 2010 CLSI breakpoints for carbapenem susceptibility, additional tests are no longer routinely recommended for detection of carbapenemase-producing organisms. For clinical laboratories that have not yet implemented the updated CLSI breakpoints, additional tests are often employed to improve the detection of carbapenemases.",
"   </p>",
"   <p>",
"    For example, the modified Hodge test can be used to detect carbapenemase activity [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/90,91\">",
"     90,91",
"    </a>",
"    ]. This test involves streaking a clinical isolate near an imipenem disk that has been placed on an agar plate containing a susceptible control organism. Growth of the control organism around the imipenem disk in the region of the streak suggests carbapenemase activity in the clinical isolate. However, the modified Hodge test has several drawbacks. Assessment of the test result may be difficult and subject to individual interpretation. Additionally, it has poor sensitivity for metallo-beta-lactamase (MBL) detection, although this can be improved with the addition of zinc [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/92\">",
"     92",
"    </a>",
"    ]. False positive Hodge tests have also been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/93\">",
"     93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other methods of carbapenemase detection include rapid biochemical tests [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/94\">",
"     94",
"    </a>",
"    ], mass spectrometric detection, and microbiological methods that take advantage of particular characteristics of carbapenemases, such as their zinc dependence [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/80\">",
"     80",
"    </a>",
"    ]. The particular test employed varies widely across different laboratories.",
"   </p>",
"   <p>",
"    Other tests are not always reliable for detecting MBLs in organisms with apparent carbapenem susceptibility [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/21,27,95\">",
"     21,27,95",
"    </a>",
"    ]. These include a combination disc tests using imipenem and EDTA discs or using two carbapenem discs (including one with EDTA incorporated) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/96-99\">",
"     96-99",
"    </a>",
"    ] and the commercially available MBL E-test.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H92009127\">",
"    <span class=\"h2\">",
"     Direct genotypic identification",
"    </span>",
"    &nbsp;&mdash;&nbsp;Identification of specific carbapenemases can be accomplished utilizing molecular techniques [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/23,38,82,100-102\">",
"     23,38,82,100-102",
"    </a>",
"    ]. These include multiplex polymerase chain reaction (PCR) assays and DNA microarrays that can screen at once for several different types of enzymes, including Klebsiella pneumoniae carbapenemases, specific MBLs, and OXA-type carbapenemases. Detection of organisms harboring these enzymes will be greatly improved as these technologies become incorporated into clinical practice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     CLINICAL DISEASE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbapenemase-producing organisms can cause clinical infections or asymptomatic colonization [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/18,59\">",
"     18,59",
"    </a>",
"    ]. Blood stream infections, ventilator-associated pneumonia, urinary tract infection, and central venous catheter infections have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/23,28,63,98\">",
"     23,28,63,98",
"    </a>",
"    ]. These organisms have been isolated from respiratory tract specimens, abdominal swabs, catheters, abscesses, urine, and surgical wounds [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/28,29,59,63,98,103,104\">",
"     28,29,59,63,98,103,104",
"    </a>",
"    ]. Sporadic hospital-acquired infections and outbreaks due to hospital-based clonal spread have been described in both tertiary and community hospitals [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/23,29,63,105\">",
"     23,29,63,105",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The above clinical syndromes are discussed in more detail in the corresponding topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The optimal treatment of infection due to carbapenemase-producing organisms is uncertain, and antibiotic options are limited. Because the presence of a KPC or metalloenzyme carbapenemase confers resistance to all penicillins, cephalosporins, and carbapenems, selection of antibiotic therapy should be tailored to antimicrobial susceptibility results for agents outside the beta-lactam and carbapenem classes. Additional antibiotic susceptibility testing should be requested for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"     aztreonam",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/36/6724?source=see_link\">",
"     fosfomycin",
"    </a>",
"    (particularly for urinary tract isolates), and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/106,107\">",
"     106,107",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H6760690\">",
"     'Possible antimicrobial options'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Furthermore, despite limited clinical data, for patients with severe infections (including bacteremia) due to a carbapenemase-producing gram-negative organism, we suggest using combination antimicrobial therapy with two or more agents because of the high associated mortality, the concern for emergence of resistance during monotherapy, and the lack of clearly effective single drug alternatives. (See",
"    <a class=\"local\" href=\"#H21045149\">",
"     'Combination therapy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Management of patients with infections due to carbapenemase-producing organisms should be done in consultation with an expert in the treatment of multi-drug resistant bacteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8852028\">",
"    <span class=\"h2\">",
"     In vitro susceptibility",
"    </span>",
"    &nbsp;&mdash;&nbsp;The reliability of carbapenem susceptibility testing to determine clinical management depends on the breakpoints utilized by the clinical laboratory. If the 2010 Clinical and Laboratory Standards Institute (CLSI) breakpoints are being implemented to determine carbapenem susceptibility, carbapenemase-producing organisms generally will test intermediate or resistant, and therefore carbapenems and beta-lactamase inhibitors should not be used alone to treat such organisms. In contrast, organisms that test susceptible to carbapenems according to the 2010 CLSI breakpoints likely do not produce a carbapenemase, and thus carbapenems will likely retain efficacy. However, if older breakpoints are still being utilized, carbapenems and beta-lactamase inhibitors should not be used alone against organisms that have phenotypic evidence of a carbapenemase (eg, positive Hodge test) or are otherwise suspected of harboring a carbapenemase, regardless of susceptibility results [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/23,27\">",
"     23,27",
"    </a>",
"    ]. Although some carbapenemase-producing Enterobacteriaceae (especially K. pneumoniae) may have carbapenem minimum inhibitory concentrations (MICs) within the susceptible range using older breakpoints, the MICs vary with the susceptibility testing method and can rise as the inoculum increases [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/103\">",
"     103",
"    </a>",
"    ]; thus, carbapenems cannot be relied upon as single agents in such cases. (See",
"    <a class=\"local\" href=\"#H92009070\">",
"     'Detection'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Beta-lactamase inhibitors are ineffective against K. pneumoniae carbapenemase (KPC)-, metallo-beta-lactamase (MBL)-, and most OXA-possessing strains; most multidrug-resistant isolates of A. baumannii have reduced susceptibility to sulbactam [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/39,53,108,109\">",
"     39,53,108,109",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition, resistance genes for other antibiotics outside the beta-lactam class, including aminoglycosides and fluoroquinolones, are frequently present in carbapenemase-producing strains [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/21,28\">",
"     21,28",
"    </a>",
"    ]. For KPC-carrying K. pneumoniae, resistance rates of 98 percent have been reported for the fluoroquinolones, and approximately 50 percent are resistant to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/16/34056?source=see_link\">",
"     amikacin",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/108\">",
"     108",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6760690\">",
"    <span class=\"h2\">",
"     Possible antimicrobial options",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Polymyxins retain activity against most multidrug-resistant gram-negative pathogens, although clinical experience with this drug class for treatment of these organisms is limited [",
"      <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/21,110\">",
"       21,110",
"      </a>",
"      ]. Polymyxin-resistant, MBL-producing K. pneumoniae has been reported [",
"      <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/111\">",
"       111",
"      </a>",
"      ]. Combining",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/20/17733?source=see_link\">",
"       polymyxin B",
"      </a>",
"      with other antimicrobial agents (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"       tigecycline",
"      </a>",
"      , carbapenems or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      ) can result in enhanced in vitro activity, although the clinical utility of combination therapy has only been preliminarily evaluated [",
"      <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/112-116\">",
"       112-116",
"      </a>",
"      ]. (See",
"      <a class=\"local\" href=\"#H21045149\">",
"       'Combination therapy'",
"      </a>",
"      below and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23031?source=see_link\">",
"       \"Colistin: An overview\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"       Aztreonam",
"      </a>",
"      may be a useful treatment for patients whose isolates (particularly MBLs) demonstrate in vitro susceptibility to this agent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/117\">",
"       117",
"      </a>",
"      ]. However, clinical experience with aztreonam for treatment of serious infections due to MBL-producing bacteria is very limited. Investigation is underway to develop specific MBL inhibitors for clinical use [",
"      <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/118\">",
"       118",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"       Tigecycline",
"      </a>",
"      may be an alternative agent to which carbapenemase-producing isolates demonstrate in vitro susceptibility, although clinical experience with this agent in the setting of multidrug-resistant gram-negative pathogens is limited [",
"      <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/49,53,59,108\">",
"       49,53,59,108",
"      </a>",
"      ]. Tigecycline treatment failures have been reported, even though pretherapy tigecycline MICs predicted clinical success [",
"      <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/119\">",
"       119",
"      </a>",
"      ]. In addition, the efficacy of tigecycline in the setting of bacteremia requires further evaluation. Moreover, tigecycline has been associated with an increased risk of all-cause mortality compared with other agents, most clearly among patients with hospital-acquired pneumonia [",
"      <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/120,121\">",
"       120,121",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=see_link&amp;anchor=H14#H14\">",
"       \"Antibiotic studies for the treatment of community-acquired pneumonia in adults\", section on 'Tigecycline versus other drugs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/36/6724?source=see_link\">",
"       Fosfomycin",
"      </a>",
"      is an oral antimicrobial agent primarily used to treat urinary tract infections. In one study of a panel of 81 carbapenem-resistant Enterobacteriaceae of various types and species, 60 percent tested susceptible to this agent [",
"      <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/107\">",
"       107",
"      </a>",
"      ]. In a small prospective study of 11 patients, an intravenous preparation of fosfomycin was used to successfully treat various carbapenem-resistant K. pneumoniae infections [",
"      <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/122\">",
"       122",
"      </a>",
"      ]. Of note, intravenous fosfomycin is not available in many countries, including the United States and Australia.",
"     </li>",
"     <li>",
"      The combination of polymyxins and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"       rifampin",
"      </a>",
"      appears to have synergistic activity in vitro against carbapenemase-producing organisms [",
"      <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/108,123\">",
"       108,123",
"      </a>",
"      ]. Although some experts have used this combination in clinical practice, there are no published clinical reports evaluating its efficacy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21045149\">",
"    <span class=\"h2\">",
"     Combination therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Outbreaks of polymyxin-resistant, carbapenemase-producing K. pneumoniae have been reported, and emergence of polymyxin-resistant K. pneumoniae in patients receiving polymyxin monotherapy has been documented [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/111,124,125\">",
"     111,124,125",
"    </a>",
"    ]. Additionally, in an in vitro infection model, emergence of resistant subpopulations of P. aeruginosa was observed during exposure to polymyxin at doses that exceeded those used clinically [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/126\">",
"     126",
"    </a>",
"    ]. Thus, there is considerable interest in using antibiotic regimens that include more than one drug.",
"   </p>",
"   <p>",
"    Clinical evidence suggests that treatment with combination therapy may be beneficial [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/127-132\">",
"     127-132",
"    </a>",
"    ]. In a retrospective study of 125 patients with bacteremia due to K. pneumoniae confirmed by polymerase chain reaction to harbor the KPC gene, the overall mortality rate at 30 days was 42 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/131\">",
"     131",
"    </a>",
"    ]. The mortality rate was lower among patients who received combination therapy with two or more drugs (27 of 79 [34 percent]) compared with monotherapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"     colistin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/10/36000?source=see_link\">",
"     gentamicin",
"    </a>",
"    (25 of 46 [54 percent]). Patients treated with a combination of a polymyxin plus tigecycline had a mortality rate of 30 percent (7 of 23), while the regimen of colistin, tigecycline, and extended-infusion",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/38/32359?source=see_link\">",
"     meropenem",
"    </a>",
"    (a dose of 2 grams infused over three or more hours every eight hours) was associated with the lowest mortality rate (2 of 16 [12.5 percent]). Similar findings were observed in a smaller retrospective study of 41 patients with KPC-producing K. pneumoniae bacteremia, in which the mortality rate was 13 percent (2 of 15) with definitive combination therapy (generally a polymyxin or tigecycline with a carbapenem) compared with 58 percent (11 of 19) with monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/127\">",
"     127",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Based on these limited clinical data in addition to in vitro studies demonstrating synergy with combination regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/133\">",
"     133",
"    </a>",
"    ], we suggest treatment with a combination of two or more agents instead of monotherapy for patients with serious infections (including bacteremia) due to carbapenem-resistant Enterobacteriaceae. In the few published reports, the&nbsp;combination of a polymyxin with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"     tigecycline",
"    </a>",
"    has been described the most and is thus a reasonable first choice,&nbsp;assuming the isolate is susceptible to both. For patients who are critically ill or have deep-seated infections (eg, meningitis), we often add a carbapenem as a third agent to this combination regimen. If the isolate is resistant to the polymyxins, we generally use tigecycline with a different second agent (most commonly a carbapenem, regardless of in vitro susceptibility testing). Conversely, if the isolate is resistant to tigecycline, we generally use a polymyxin with a different second agent (most commonly a carbapenem or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    For carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa, a polymyxin is usually the backbone of therapy. Convincing clinical data to support combination therapy for these organisms is lacking. However, in vitro studies have demonstrated enhanced antimicrobial activity against such strains when a polymyxin is combined with other agents (most commonly a carbapenem or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/31/10746?source=see_link\">",
"     rifampin",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/114,115,123\">",
"     114,115,123",
"    </a>",
"    ]. Based on these and personal experience, we frequently use a polymyxin in addition to rifampin or a carbapenem for patients with serious infections (including bacteremia) due to these drug-resistant organisms.",
"   </p>",
"   <p>",
"    Management of patients with infections due to carbapenemase-producing organisms should be done in consultation with an expert in the treatment of multi-drug resistant bacteria.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     INFECTION CONTROL",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hospitalized patients infected or colonized with carbapenemase-producing bacteria should be placed on contact precautions [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/28,61,63,78,134\">",
"     28,61,63,78,134",
"    </a>",
"    ]. Other standard measures, such as hand hygiene, minimizing the use of invasive devices, and antimicrobial stewardship, are important to infection control in general and likely to limit spread of resistant organisms.",
"   </p>",
"   <p>",
"    Screening high-risk patients to detect rectal colonization has been suggested as an important infection control modality [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/21,28,78,79\">",
"     21,28,78,79",
"    </a>",
"    ]. Several studies have documented reduced transmission of KPC-producing Klebsiella pneumoniae when comprehensive infection control protocols, including active surveillance, have been enacted [",
"    <a class=\"abstract\" href=\"UTD.htm?9/33/9754/abstract/135-137\">",
"     135-137",
"    </a>",
"    ]. Although the impact of surveillance itself is difficult to assess, it may be useful in the setting of outbreaks due to carbapenemase-resistant organisms, as recommended by the United States",
"    <a class=\"external\" href=\"file://www.cdc.gov/mmwr/preview/mmwrhtml/mm5810a4.htm\">",
"     Centers for Disease Control and Prevention",
"    </a>",
"    (CDC), or among patients with recent travel to areas where carbapenemases are more prevalent. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=see_link\">",
"     \"General principles of infection control\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The carbapenem-hydrolyzing beta-lactamase is an important emerging mechanism of antimicrobial resistance among nosocomial gram-negative pathogens. These enzymes are classified on the basis of their amino acid homology; Classes A, B, and D are of greatest clinical importance. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Classification'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The clinically most important of the Class A carbapenemases is the Klebsiella pneumoniae carbapenemase (KPC) group, which has been implicated in several outbreaks (",
"      <a class=\"graphic graphic_table graphicRef60389 \" href=\"UTD.htm?5/29/5596\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Class A beta-lactamases'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19876835\">",
"       'Klebsiella pneumoniae carbapenemase (KPC)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Class B beta-lactamases are known as the metallo-beta-lactamases (MBLs), which are named for their dependence upon zinc for efficient hydrolysis of beta-lactams. The New Delhi metallo-beta-lactamase (NDM-1) is an important emerging carbapenemase in this group (",
"      <a class=\"graphic graphic_table graphicRef60389 \" href=\"UTD.htm?5/29/5596\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Class B beta-lactamases'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H19877222\">",
"       'New Delhi metallo-beta-lactamase (NDM-1)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Class D beta-lactamases are referred to as OXA-type enzymes because of their preferential ability to hydrolyze",
"      <a class=\"drug drug_general\" href=\"UTD.htm?8/15/8437?source=see_link\">",
"       oxacillin",
"      </a>",
"      (rather than penicillin). (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Class D beta-lactamases'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Implementation of the",
"      <a class=\"external\" href=\"file://www.cdc.gov/hai/organisms/cre/cre-toolkit/rCREprevention-AppendixA.html\">",
"       lower 2010 Clinical and Laboratory Standards Institute (CLSI) breakpoints",
"      </a>",
"      for carbapenem susceptibility improves the detection of carbapenemase-producing Enterobacteriaceae. Identifying strains of P. aeruginosa or A. baumannii with carbapenemases can be difficult. Isolates resistant to penicillins, cephalosporins, and carbapenems with retained susceptibility to",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      should be suspected of carrying an MBL. (See",
"      <a class=\"local\" href=\"#H92009070\">",
"       'Detection'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Use of broad spectrum cephalosporins",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      carbapenems is an important risk factor for the development of colonization or infection with carbapenemase-producing organisms, although prior receipt of carbapenems is not essential for acquisition of these strains. (See",
"      <a class=\"local\" href=\"#H21045526\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Carbapenemase-producing organisms can cause clinical infections or asymptomatic colonization. Carbapenemase-producing bacteria have been implicated in a variety of infections, including bacteremia, ventilator-associated pneumonia, urinary tract infection, and central venous catheter infection. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Clinical disease'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Selection of antibiotic therapy should be tailored according to the antimicrobial susceptibility test result. In particular, antibiotic susceptibility testing should be requested for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/14/43238?source=see_link\">",
"       colistin",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/25/43414?source=see_link\">",
"       aztreonam",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"       tigecycline",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/36/6724?source=see_link\">",
"       fosfomycin",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients with serious infections, including bacteremia, due to a carbapenemase-producing gram-negative organism, we suggest using combination therapy with two or more antimicrobial agents instead of monotherapy (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Preliminary clinical evidence suggests that treatment with a regimen that combines a polymyxin,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?39/7/40053?source=see_link\">",
"       tigecycline",
"      </a>",
"      , or a carbapenem (or all three) is associated with lower mortality than single-agent regimens for infections with carbapenemase-producing Enterobacteriaceae. (See",
"      <a class=\"local\" href=\"#H21045149\">",
"       'Combination therapy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients infected or colonized with carbapenemase-producing bacteria should be placed on contact precautions. Screening high-risk patients to detect rectal colonization may also be helpful in controlling transmission. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Infection control'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/1\">",
"      Jacoby GA, Munoz-Price LS. The new beta-lactamases. N Engl J Med 2005; 352:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/2\">",
"      Queenan AM, Bush K. Carbapenemases: the versatile beta-lactamases. Clin Microbiol Rev 2007; 20:440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/3\">",
"      Paterson DL, Doi Y. A step closer to extreme drug resistance (XDR) in gram-negative bacilli. Clin Infect Dis 2007; 45:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/4\">",
"      Shibata N, Doi Y, Yamane K, et al. PCR typing of genetic determinants for metallo-beta-lactamases and integrases carried by gram-negative bacteria isolated in Japan, with focus on the class 3 integron. J Clin Microbiol 2003; 41:5407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/5\">",
"      Walther-Rasmussen J, H&oslash;iby N. Class A carbapenemases. J Antimicrob Chemother 2007; 60:470.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/6\">",
"      Queenan AM, Shang W, Schreckenberger P, et al. SME-3, a novel member of the Serratia marcescens SME family of carbapenem-hydrolyzing beta-lactamases. Antimicrob Agents Chemother 2006; 50:3485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/7\">",
"      Rasmussen BA, Bush K, Keeney D, et al. Characterization of IMI-1 beta-lactamase, a class A carbapenem-hydrolyzing enzyme from Enterobacter cloacae. Antimicrob Agents Chemother 1996; 40:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/8\">",
"      Pottumarthy S, Moland ES, Juretschko S, et al. NmcA carbapenem-hydrolyzing enzyme in Enterobacter cloacae in North America. Emerg Infect Dis 2003; 9:999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/9\">",
"      Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/10\">",
"      Poirel L, Weldhagen GF, De Champs C, Nordmann P. A nosocomial outbreak of Pseudomonas aeruginosa isolates expressing the extended-spectrum beta-lactamase GES-2 in South Africa. J Antimicrob Chemother 2002; 49:561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/11\">",
"      Jeong SH, Bae IK, Kim D, et al. First outbreak of Klebsiella pneumoniae clinical isolates producing GES-5 and SHV-12 extended-spectrum beta-lactamases in Korea. Antimicrob Agents Chemother 2005; 49:4809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/12\">",
"      Wolter DJ, Kurpiel PM, Woodford N, et al. Phenotypic and enzymatic comparative analysis of the novel KPC variant KPC-5 and its evolutionary variants, KPC-2 and KPC-4. Antimicrob Agents Chemother 2009; 53:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/13\">",
"      Hidalgo-Grass C, Warburg G, Temper V, et al. KPC-9, a novel carbapenemase from clinical specimens in Israel. Antimicrob Agents Chemother 2012; 56:6057.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/14\">",
"      Navon-Venezia S, Chmelnitsky I, Leavitt A, et al. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escherichia coli clones in Israel. Antimicrob Agents Chemother 2006; 50:3098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/15\">",
"      Villegas MV, Lolans K, Correa A, et al. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing beta-lactamase. Antimicrob Agents Chemother 2007; 51:1553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/16\">",
"      Bratu S, Brooks S, Burney S, et al. Detection and spread of Escherichia coli possessing the plasmid-borne carbapenemase KPC-2 in Brooklyn, New York. Clin Infect Dis 2007; 44:972.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/17\">",
"      Miriagou V, Tzouvelekis LS, Rossiter S, et al. Imipenem resistance in a Salmonella clinical strain due to plasmid-mediated class A carbapenemase KPC-2. Antimicrob Agents Chemother 2003; 47:1297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/18\">",
"      Hossain A, Ferraro MJ, Pino RM, et al. Plasmid-mediated carbapenem-hydrolyzing enzyme KPC-2 in an Enterobacter sp. Antimicrob Agents Chemother 2004; 48:4438.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/19\">",
"      Marchaim D, Navon-Venezia S, Schwaber MJ, Carmeli Y. Isolation of imipenem-resistant Enterobacter species: emergence of KPC-2 carbapenemase, molecular characterization, epidemiology, and outcomes. Antimicrob Agents Chemother 2008; 52:1413.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/20\">",
"      Watanabe M, Iyobe S, Inoue M, Mitsuhashi S. Transferable imipenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 1991; 35:147.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/21\">",
"      Walsh TR, Toleman MA, Poirel L, Nordmann P. Metallo-beta-lactamases: the quiet before the storm? Clin Microbiol Rev 2005; 18:306.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/22\">",
"      Poirel L, Nordmann P. Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 2006; 12:826.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/23\">",
"      Peleg AY, Franklin C, Bell JM, Spelman DW. Dissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia. Clin Infect Dis 2005; 41:1549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/24\">",
"      Houang ET, Chu YW, Lo WS, et al. Epidemiology of rifampin ADP-ribosyltransferase (arr-2) and metallo-beta-lactamase (blaIMP-4) gene cassettes in class 1 integrons in Acinetobacter strains isolated from blood cultures in 1997 to 2000. Antimicrob Agents Chemother 2003; 47:1382.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/25\">",
"      Hawkey PM, Xiong J, Ye H, et al. Occurrence of a new metallo-beta-lactamase IMP-4 carried on a conjugative plasmid in Citrobacter youngae from the People's Republic of China. FEMS Microbiol Lett 2001; 194:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/26\">",
"      Shiroto K, Ishii Y, Kimura S, et al. Metallo-beta-lactamase IMP-1 in Providencia rettgeri from two different hospitals in Japan. J Med Microbiol 2005; 54:1065.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/27\">",
"      Rossolini GM. Acquired metallo-beta-lactamases: an increasing clinical threat. Clin Infect Dis 2005; 41:1557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/28\">",
"      Hirakata Y, Izumikawa K, Yamaguchi T, et al. Rapid detection and evaluation of clinical characteristics of emerging multiple-drug-resistant gram-negative rods carrying the metallo-beta-lactamase gene blaIMP. Antimicrob Agents Chemother 1998; 42:2006.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/29\">",
"      Herbert S, Halvorsen DS, Leong T, et al. Large outbreak of infection and colonization with gram-negative pathogens carrying the metallo- beta -lactamase gene blaIMP-4 at a 320-bed tertiary hospital in Australia. Infect Control Hosp Epidemiol 2007; 28:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/30\">",
"      Yong D, Toleman MA, Giske CG, et al. Characterization of a new metallo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob Agents Chemother 2009; 53:5046.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/31\">",
"      Centers for Disease Control and Prevention (CDC). Detection of Enterobacteriaceae isolates carrying metallo-beta-lactamase - United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:750.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/32\">",
"      Nordmann P, Poirel L, Toleman MA, Walsh TR. Does broad-spectrum beta-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J Antimicrob Chemother 2011; 66:689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/33\">",
"      Kumarasamy KK, Toleman MA, Walsh TR, et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect Dis 2010; 10:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/34\">",
"      Livermore DM, Andrews JM, Hawkey PM, et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J Antimicrob Chemother 2012; 67:1569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/35\">",
"      Walther-Rasmussen J, H&oslash;iby N. OXA-type carbapenemases. J Antimicrob Chemother 2006; 57:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/36\">",
"      Dalla-Costa LM, Coelho JM, Souza HA, et al. Outbreak of carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme in Curitiba, Brazil. J Clin Microbiol 2003; 41:3403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/37\">",
"      Jeon BC, Jeong SH, Bae IK, et al. Investigation of a nosocomial outbreak of imipenem-resistant Acinetobacter baumannii producing the OXA-23 beta-lactamase in korea. J Clin Microbiol 2005; 43:2241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/38\">",
"      Turton JF, Ward ME, Woodford N, et al. The role of ISAba1 in expression of OXA carbapenemase genes in Acinetobacter baumannii. FEMS Microbiol Lett 2006; 258:72.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/39\">",
"      Hujer KM, Hujer AM, Hulten EA, et al. Analysis of antibiotic resistance genes in multidrug-resistant Acinetobacter sp. isolates from military and civilian patients treated at the Walter Reed Army Medical Center. Antimicrob Agents Chemother 2006; 50:4114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/40\">",
"      Afzal-Shah M, Woodford N, Livermore DM. Characterization of OXA-25, OXA-26, and OXA-27, molecular class D beta-lactamases associated with carbapenem resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother 2001; 45:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/41\">",
"      Bou G, Oliver A, Mart&iacute;nez-Beltr&aacute;n J. OXA-24, a novel class D beta-lactamase with carbapenemase activity in an Acinetobacter baumannii clinical strain. Antimicrob Agents Chemother 2000; 44:1556.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/42\">",
"      Lopez-Otsoa F, Gallego L, Towner KJ, et al. Endemic carbapenem resistance associated with OXA-40 carbapenemase among Acinetobacter baumannii isolates from a hospital in northern Spain. J Clin Microbiol 2002; 40:4741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/43\">",
"      H&eacute;ritier C, Dubouix A, Poirel L, et al. A nosocomial outbreak of Acinetobacter baumannii isolates expressing the carbapenem-hydrolysing oxacillinase OXA-58. J Antimicrob Chemother 2005; 55:115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/44\">",
"      Vahaboglu H, Budak F, Kasap M, et al. High prevalence of OXA-51-type class D beta-lactamases among ceftazidime-resistant clinical isolates of Acinetobacter spp.: co-existence with OXA-58 in multiple centres. J Antimicrob Chemother 2006; 58:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/45\">",
"      Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J Antimicrob Chemother 2012; 67:1597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/46\">",
"      Won SY, Munoz-Price LS, Lolans K, et al. Emergence and rapid regional spread of Klebsiella pneumoniae carbapenemase-producing Enterobacteriaceae. Clin Infect Dis 2011; 53:532.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/47\">",
"      Gupta N, Limbago BM, Patel JB, Kallen AJ. Carbapenem-resistant Enterobacteriaceae: epidemiology and prevention. Clin Infect Dis 2011; 53:60.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/48\">",
"      Nordmann P, Cuzon G, Naas T. The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. Lancet Infect Dis 2009; 9:228.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/49\">",
"      Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumoniae in New York City: a new threat to our antibiotic armamentarium. Arch Intern Med 2005; 165:1430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/50\">",
"      Smith Moland E, Hanson ND, Herrera VL, et al. Plasmid-mediated, carbapenem-hydrolysing beta-lactamase, KPC-2, in Klebsiella pneumoniae isolates. J Antimicrob Chemother 2003; 51:711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/51\">",
"      Bradford PA, Bratu S, Urban C, et al. Emergence of carbapenem-resistant Klebsiella species possessing the class A carbapenem-hydrolyzing KPC-2 and inhibitor-resistant TEM-30 beta-lactamases in New York City. Clin Infect Dis 2004; 39:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/52\">",
"      Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing beta-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 2001; 45:1151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/53\">",
"      Woodford N, Tierno PM Jr, Young K, et al. Outbreak of Klebsiella pneumoniae producing a new carbapenem-hydrolyzing class A beta-lactamase, KPC-3, in a New York Medical Center. Antimicrob Agents Chemother 2004; 48:4793.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/54\">",
"      Snitkin ES, Zelazny AM, Thomas PJ, et al. Tracking a hospital outbreak of carbapenem-resistant Klebsiella pneumoniae with whole-genome sequencing. Sci Transl Med 2012; 4:148ra116.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/55\">",
"      Centers for Disease Control and Prevention (CDC). Vital signs: carbapenem-resistant enterobacteriaceae. MMWR Morb Mortal Wkly Rep 2013; 62:165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/56\">",
"      Marquez P, Terashita D, Dassey D, Mascola L. Population-based incidence of carbapenem-resistant Klebsiella pneumoniae along the continuum of care, Los Angeles County. Infect Control Hosp Epidemiol 2013; 34:144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/57\">",
"      Naas T, Nordmann P, Vedel G, Poyart C. Plasmid-mediated carbapenem-hydrolyzing beta-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother 2005; 49:4423.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/58\">",
"      Hoenigl M, Valentin T, Zarfel G, et al. Nosocomial outbreak of Klebsiella pneumoniae carbapenemase-producing Klebsiella oxytoca in Austria. Antimicrob Agents Chemother 2012; 56:2158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/59\">",
"      Leavitt A, Navon-Venezia S, Chmelnitsky I, et al. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumoniae strains in an Israeli hospital. Antimicrob Agents Chemother 2007; 51:3026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/60\">",
"      Wei ZQ, Du XX, Yu YS, et al. Plasmid-mediated KPC-2 in a Klebsiella pneumoniae isolate from China. Antimicrob Agents Chemother 2007; 51:763.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/61\">",
"      Villegas MV, Lolans K, Correa A, et al. First detection of the plasmid-mediated class A carbapenemase KPC-2 in clinical isolates of Klebsiella pneumoniae from South America. Antimicrob Agents Chemother 2006; 50:2880.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/62\">",
"      Centers for Disease Control and Prevention (CDC). Update: detection of a verona integron-encoded metallo-beta-lactamase in Klebsiella pneumoniae --- United States, 2010. MMWR Morb Mortal Wkly Rep 2010; 59:1212.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/63\">",
"      Crespo MP, Woodford N, Sinclair A, et al. Outbreak of carbapenem-resistant Pseudomonas aeruginosa producing VIM-8, a novel metallo-beta-lactamase, in a tertiary care center in Cali, Colombia. J Clin Microbiol 2004; 42:5094.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/64\">",
"      Peleg AY, Franklin C, Bell J, Spelman DW. Emergence of IMP-4 metallo-beta-lactamase in a clinical isolate from Australia. J Antimicrob Chemother 2004; 54:699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/65\">",
"      Centers for Disease Control and Prevention (CDC). Carbapenem-resistant Klebsiella pneumoniae associated with a long-term--care facility --- West Virginia, 2009-2011. MMWR Morb Mortal Wkly Rep 2011; 60:1418.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/66\">",
"      Nou&eacute;r SA, Nucci M, de-Oliveira MP, et al. Risk factors for acquisition of multidrug-resistant Pseudomonas aeruginosa producing SPM metallo-beta-lactamase. Antimicrob Agents Chemother 2005; 49:3663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/67\">",
"      Peleg AY, Bell JM, Hofmeyr A, Wiese P. Inter-country transfer of Gram-negative organisms carrying the VIM-4 and OXA-58 carbapenem-hydrolysing enzymes. J Antimicrob Chemother 2006; 57:794.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/68\">",
"      Sidjabat H, Nimmo GR, Walsh TR, et al. Carbapenem resistance in Klebsiella pneumoniae due to the New Delhi Metallo-&beta;-lactamase. Clin Infect Dis 2011; 52:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/69\">",
"      Centers for Disease Control and Prevention (CDC). Carbapenem-resistant Enterobacteriaceae containing New Delhi metallo-beta-lactamase in two patients - Rhode Island, March 2012. MMWR Morb Mortal Wkly Rep 2012; 61:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/70\">",
"      Nordmann P, Naas T, Poirel L. Global spread of Carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2011; 17:1791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/71\">",
"      Schwaber MJ, Klarfeld-Lidji S, Navon-Venezia S, et al. Predictors of carbapenem-resistant Klebsiella pneumoniae acquisition among hospitalized adults and effect of acquisition on mortality. Antimicrob Agents Chemother 2008; 52:1028.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/72\">",
"      Marchaim D, Chopra T, Bhargava A, et al. Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship. Infect Control Hosp Epidemiol 2012; 33:817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/73\">",
"      Deshpande P, Shetty A, Kapadia F, et al. New Delhi metallo 1: have carbapenems met their doom? Clin Infect Dis 2010; 51:1222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/74\">",
"      Toleman MA, Biedenbach D, Bennett DM, et al. Italian metallo-beta-lactamases: a national problem? Report from the SENTRY Antimicrobial Surveillance Programme. J Antimicrob Chemother 2005; 55:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/75\">",
"      Borgmann S, Wolz C, Gr&ouml;bner S, et al. Metallo-beta-lactamase expressing multi-resistant Acinetobacter baumannii transmitted in the operation area. J Hosp Infect 2004; 57:308.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/76\">",
"      Walsh TR, Weeks J, Livermore DM, Toleman MA. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect Dis 2011; 11:355.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/77\">",
"      Quinteira S, Peixe L. Multiniche screening reveals the clinically relevant metallo-beta-lactamase VIM-2 in Pseudomonas aeruginosa far from the hospital setting: an ongoing dispersion process? Appl Environ Microbiol 2006; 72:3743.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/78\">",
"      Aubron C, Poirel L, Fortineau N, et al. Nosocomial spread of Pseudomonas aeruginosa isolates expressing the metallo-beta-lactamase VIM-2 in a hematology unit of a French hospital. Microb Drug Resist 2005; 11:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/79\">",
"      Gij&oacute;n D, Curiao T, Baquero F, et al. Fecal carriage of carbapenemase-producing Enterobacteriaceae: a hidden reservoir in hospitalized and nonhospitalized patients. J Clin Microbiol 2012; 50:1558.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/80\">",
"      Franklin C, Liolios L, Peleg AY. Phenotypic detection of carbapenem-susceptible metallo-beta-lactamase-producing gram-negative bacilli in the clinical laboratory. J Clin Microbiol 2006; 44:3139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/81\">",
"      Yan JJ, Ko WC, Tsai SH, et al. Outbreak of infection with multidrug-resistant Klebsiella pneumoniae carrying bla(IMP-8) in a university medical center in Taiwan. J Clin Microbiol 2001; 39:4433.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/82\">",
"      Yan JJ, Hsueh PR, Ko WC, et al. Metallo-beta-lactamases in clinical Pseudomonas isolates in Taiwan and identification of VIM-3, a novel variant of the VIM-2 enzyme. Antimicrob Agents Chemother 2001; 45:2224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/83\">",
"      Scoulica EV, Neonakis IK, Gikas AI, Tselentis YJ. Spread of bla(VIM-1)-producing E. coli in a university hospital in Greece. Genetic analysis of the integron carrying the bla(VIM-1) metallo-beta-lactamase gene. Diagn Microbiol Infect Dis 2004; 48:167.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/84\">",
"      Tenover FC, Kalsi RK, Williams PP, et al. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg Infect Dis 2006; 12:1209.",
"     </a>",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute. 2011. Performance standards for antimicrobial susceptibility testing; Twenty-first informational supplement; M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA.",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement; M100-S20. June 2010 Update. Clinical and Laboratory Standards Institute, Wayne, PA",
"    </li>",
"    <li>",
"     Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; Twentieth informational supplement; M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.",
"    </li>",
"    <li>",
"     CLSI M100-S20 (2010) Cephalosporin and Aztreonam Breakpoint Revisions Fact Sheet file://www.clsi.org/Content/NavigationMenu/Committees/Microbiology/AST/CephalosporinandAztreonamBreakpointRevisionFactSheet/CephalosporinAztreonamBreakpointFactSheet.pdf (Accessed on January 26, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/89\">",
"      Cornaglia G, Akova M, Amicosante G, et al. Metallo-beta-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues. Int J Antimicrob Agents 2007; 29:380.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/90\">",
"      Anderson KF, Lonsway DR, Rasheed JK, et al. Evaluation of methods to identify the Klebsiella pneumoniae carbapenemase in Enterobacteriaceae. J Clin Microbiol 2007; 45:2723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/91\">",
"      Carvalhaes CG, Pic&atilde;o RC, Nicoletti AG, et al. Cloverleaf test (modified Hodge test) for detecting carbapenemase production in Klebsiella pneumoniae: be aware of false positive results. J Antimicrob Chemother 2010; 65:249.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/92\">",
"      Girlich D, Poirel L, Nordmann P. Value of the modified Hodge test for detection of emerging carbapenemases in Enterobacteriaceae. J Clin Microbiol 2012; 50:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/93\">",
"      Wang P, Chen S, Guo Y, et al. Occurrence of false positive results for the detection of carbapenemases in carbapenemase-negative Escherichia coli and Klebsiella pneumoniae isolates. PLoS One 2011; 6:e26356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/94\">",
"      Nordmann P, Poirel L, Dortet L. Rapid detection of carbapenemase-producing Enterobacteriaceae. Emerg Infect Dis 2012; 18:1503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/95\">",
"      Yan JJ, Wu JJ, Tsai SH, Chuang CL. Comparison of the double-disk, combined disk, and Etest methods for detecting metallo-beta-lactamases in gram-negative bacilli. Diagn Microbiol Infect Dis 2004; 49:5.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/96\">",
"      Lee SH, Jeong SH, Lee KJ. Evolution of TEM beta--lactamase genes identified by PCR with newly designed primers in Korean clinical isolates. Clin Microbiol Infect 2001; 7:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/97\">",
"      Lee K, Lim YS, Yong D, et al. Evaluation of the Hodge test and the imipenem-EDTA double-disk synergy test for differentiating metallo-beta-lactamase-producing isolates of Pseudomonas spp. and Acinetobacter spp. J Clin Microbiol 2003; 41:4623.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/98\">",
"      Pitout JD, Gregson DB, Poirel L, et al. Detection of Pseudomonas aeruginosa producing metallo-beta-lactamases in a large centralized laboratory. J Clin Microbiol 2005; 43:3129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/99\">",
"      Galani I, Rekatsina PD, Hatzaki D, et al. Evaluation of different laboratory tests for the detection of metallo-beta-lactamase production in Enterobacteriaceae. J Antimicrob Chemother 2008; 61:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/100\">",
"      Monteiro J, Widen RH, Pignatari AC, et al. Rapid detection of carbapenemase genes by multiplex real-time PCR. J Antimicrob Chemother 2012; 67:906.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/101\">",
"      Cuzon G, Naas T, Bogaerts P, et al. Evaluation of a DNA microarray for the rapid detection of extended-spectrum &beta;-lactamases (TEM, SHV and CTX-M), plasmid-mediated cephalosporinases (CMY-2-like, DHA, FOX, ACC-1, ACT/MIR and CMY-1-like/MOX) and carbapenemases (KPC, OXA-48, VIM, IMP and NDM). J Antimicrob Chemother 2012; 67:1865.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/102\">",
"      Stuart JC, Voets G, Scharringa J, et al. Detection of carbapenemase-producing Enterobacteriaceae with a commercial DNA microarray. J Med Microbiol 2012; 61:809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/103\">",
"      Marra AR, Pereira CA, Gales AC, et al. Bloodstream infections with metallo-beta-lactamase-producing Pseudomonas aeruginosa: epidemiology, microbiology, and clinical outcomes. Antimicrob Agents Chemother 2006; 50:388.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/104\">",
"      Souli M, Kontopidou FV, Papadomichelakis E, et al. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 metallo-beta-lactamase in a Greek University Hospital. Clin Infect Dis 2008; 46:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/105\">",
"      Koh TH, Wang GC, Sng LH. Clonal spread of IMP-1-producing Pseudomonas aeruginosa in two hospitals in Singapore. J Clin Microbiol 2004; 42:5378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/106\">",
"      Zavascki AP, Barth AL, Gaspareto PB, et al. Risk factors for nosocomial infections due to Pseudomonas aeruginosa producing metallo-beta-lactamase in two tertiary-care teaching hospitals. J Antimicrob Chemother 2006; 58:882.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/107\">",
"      Livermore DM, Warner M, Mushtaq S, et al. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int J Antimicrob Agents 2011; 37:415.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/108\">",
"      Bratu S, Tolaney P, Karumudi U, et al. Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agents. J Antimicrob Chemother 2005; 56:128.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/109\">",
"      Lolans K, Rice TW, Munoz-Price LS, Quinn JP. Multicity outbreak of carbapenem-resistant Acinetobacter baumannii isolates producing the carbapenemase OXA-40. Antimicrob Agents Chemother 2006; 50:2941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/110\">",
"      Tognim MC, Gales AC, Penteado AP, et al. Dissemination of IMP-1 metallo- beta -lactamase-producing Acinetobacter species in a Brazilian teaching hospital. Infect Control Hosp Epidemiol 2006; 27:742.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/111\">",
"      Antoniadou A, Kontopidou F, Poulakou G, et al. Colistin-resistant isolates of Klebsiella pneumoniae emerging in intensive care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother 2007; 59:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/112\">",
"      Falagas ME, Kasiakou SK. Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections. Clin Infect Dis 2005; 40:1333.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/113\">",
"      Li J, Nation RL, Turnidge JD, et al. Colistin: the re-emerging antibiotic for multidrug-resistant Gram-negative bacterial infections. Lancet Infect Dis 2006; 6:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/114\">",
"      Yoon J, Urban C, Terzian C, et al. In vitro double and triple synergistic activities of Polymyxin B, imipenem, and rifampin against multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2004; 48:753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/115\">",
"      Landman D, Bratu S, Alam M, Quale J. Citywide emergence of Pseudomonas aeruginosa strains with reduced susceptibility to polymyxin B. J Antimicrob Chemother 2005; 55:954.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/116\">",
"      Garnacho-Montero J, Ortiz-Leyba C, Jim&eacute;nez-Jim&eacute;nez FJ, et al. Treatment of multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia (VAP) with intravenous colistin: a comparison with imipenem-susceptible VAP. Clin Infect Dis 2003; 36:1111.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/117\">",
"      Bellais S, Mimoz O, L&eacute;otard S, et al. Efficacy of beta-lactams for treating experimentally induced pneumonia due to a carbapenem-hydrolyzing metallo-beta-lactamase-producing strain of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2002; 46:2032.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/118\">",
"      Olsen L, Jost S, Adolph HW, et al. New leads of metallo-beta-lactamase inhibitors from structure-based pharmacophore design. Bioorg Med Chem 2006; 14:2627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/119\">",
"      Anthony KB, Fishman NO, Linkin DR, et al. Clinical and microbiological outcomes of serious infections with multidrug-resistant gram-negative organisms treated with tigecycline. Clin Infect Dis 2008; 46:567.",
"     </a>",
"    </li>",
"    <li>",
"     FDA Drug Safety Communication: Increased risk of death with Tygacil (tigecycline) compared to other antibiotics used to treat similar infections. file://www.fda.gov/Drugs/DrugSafety/ucm224370.htm (Accessed on July 11, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/121\">",
"      Prasad P, Sun J, Danner RL, Natanson C. Excess deaths associated with tigecycline after approval based on noninferiority trials. Clin Infect Dis 2012; 54:1699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/122\">",
"      Michalopoulos A, Virtzili S, Rafailidis P, et al. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect 2010; 16:184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/123\">",
"      Tripodi MF, Durante-Mangoni E, Fortunato R, et al. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolates producing OXA-58 carbapenemases. Int J Antimicrob Agents 2007; 30:537.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/124\">",
"      Marchaim D, Chopra T, Pogue JM, et al. Outbreak of colistin-resistant, carbapenem-resistant Klebsiella pneumoniae in metropolitan Detroit, Michigan. Antimicrob Agents Chemother 2011; 55:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/125\">",
"      Lee J, Patel G, Huprikar S, et al. Decreased susceptibility to polymyxin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J Clin Microbiol 2009; 47:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/126\">",
"      Tam VH, Schilling AN, Vo G, et al. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrob Agents Chemother 2005; 49:3624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/127\">",
"      Qureshi ZA, Paterson DL, Potoski BA, et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob Agents Chemother 2012; 56:2108.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/128\">",
"      Zarkotou O, Pournaras S, Tselioti P, et al. Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment. Clin Microbiol Infect 2011; 17:1798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/129\">",
"      Jernigan MG, Press EG, Nguyen MH, et al. The combination of doripenem and colistin is bactericidal and synergistic against colistin-resistant, carbapenemase-producing Klebsiella pneumoniae. Antimicrob Agents Chemother 2012; 56:3395.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/130\">",
"      Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J Antimicrob Chemother 2010; 65:1119.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/131\">",
"      Tumbarello M, Viale P, Viscoli C, et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy. Clin Infect Dis 2012; 55:943.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/132\">",
"      Sbrana F, Malacarne P, Viaggi B, et al. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit. Clin Infect Dis 2013; 56:697.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/133\">",
"      Pournaras S, Vrioni G, Neou E, et al. Activity of tigecycline alone and in combination with colistin and meropenem against Klebsiella pneumoniae carbapenemase (KPC)-producing Enterobacteriaceae strains by time-kill assay. Int J Antimicrob Agents 2011; 37:244.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/134\">",
"      Centers for Disease Control and Prevention (CDC). Guidance for control of infections with carbapenem-resistant or carbapenemase-producing Enterobacteriaceae in acute care facilities. MMWR Morb Mortal Wkly Rep 2009; 58:256.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/135\">",
"      Kochar S, Sheard T, Sharma R, et al. Success of an infection control program to reduce the spread of carbapenem-resistant Klebsiella pneumoniae. Infect Control Hosp Epidemiol 2009; 30:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/136\">",
"      Munoz-Price LS, Hayden MK, Lolans K, et al. Successful control of an outbreak of Klebsiella pneumoniae carbapenemase-producing K. pneumoniae at a long-term acute care hospital. Infect Control Hosp Epidemiol 2010; 31:341.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?9/33/9754/abstract/137\">",
"      Ben-David D, Maor Y, Keller N, et al. Potential role of active surveillance in the control of a hospital-wide outbreak of carbapenem-resistant Klebsiella pneumoniae infection. Infect Control Hosp Epidemiol 2010; 31:620.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 471 Version 21.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0602-201.77.166.39-6F9A708CB0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_33_9754=[""].join("\n");
var outline_f9_33_9754=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H13\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Class A beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19876835\">",
"      - Klebsiella pneumoniae carbapenemase (KPC)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Class B beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H19877222\">",
"      - New Delhi metallo-beta-lactamase (NDM-1)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Class D beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H21045519\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92008072\">",
"      Distribution",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H92008083\">",
"      - Klebsiella pneumoniae carbapenemases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H92008117\">",
"      - Metallo-beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H561110\">",
"      - Class D carbapenemases",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21045526\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21045553\">",
"      Transmission",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H92009070\">",
"      DETECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92009113\">",
"      Clinical laboratory testing",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92009120\">",
"      Other phenotypic tests",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H92009127\">",
"      Direct genotypic identification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      CLINICAL DISEASE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8852028\">",
"      In vitro susceptibility",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6760690\">",
"      Possible antimicrobial options",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21045149\">",
"      Combination therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      INFECTION CONTROL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/471\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/471|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/29/5596\" title=\"table 1\">",
"      Comparison of KPC and NDM",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?43/13/44251\" title=\"table 2\">",
"      Carbapenemase subgroups",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/33/29210?source=related_link\">",
"      Antibiotic studies for the treatment of community-acquired pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/31/23031?source=related_link\">",
"      Colistin: An overview",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/53/30553?source=related_link\">",
"      Extended-spectrum beta-lactamases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/12/19658?source=related_link\">",
"      General principles of infection control",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f9_33_9755="Toxic blood lead levels children";
var content_f9_33_9755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64183&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Blood lead levels considered toxic",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        Prior to 1971",
"       </td>",
"       <td>",
"        &ge; 60 mcg/dL (2.88 micromol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        1972-1975",
"       </td>",
"       <td>",
"        &ge; 40 mcg/dL (1.93 micromol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        1975-1985",
"       </td>",
"       <td>",
"        &ge; 30&nbsp;mcg/dL (1.45 micromol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        1985-1991",
"       </td>",
"       <td>",
"        &ge; 25&nbsp;mcg/dL (1.20 micromol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        1991-present",
"       </td>",
"       <td>",
"        &ge; 10&nbsp;mcg/dL (0.48 micromol/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_left\">",
"        2010-present",
"       </td>",
"       <td>",
"        &ge; 5 mcg/dL (0.24 micromol/L)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     mcg: micrograms; dL: deciliter; micromol: micromoles; L: liter.",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_33_9755=[""].join("\n");
var outline_f9_33_9755=null;
var title_f9_33_9756="Misgav-Ladach Joel Cohen";
var content_f9_33_9756=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F70112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F70112&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Misgav Ladach technique (modified Joel-Cohen technique)",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        A straight transverse incision is cut only through the skin 3 cm below the level of the anterior superior iliac spines. By comparison, a traditional Pfannenstiel is curved and placed more inferiorly, about 3 cm above the pubic symphysis.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The subcutaneous tissues in the middle 3 cm of the incision are incised down to the fascia.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The fascia is opened transversely in the midline and the fascial incision is extended laterally in both directions using scissors placed underneath the subcutaneous adipose tissue, which is not cut with the scissors.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The rectus sheath is separated from the rectus muscles by pulling the sheath caudally and cranially using the two index fingers.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The peritoneum is opened by using one or two fingers to perforate the peritoneum and then the opening is stretched by pulling caudally and cranially with the fingers to create a transverse opening.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        All layers of the abdominal wall are manually stretched laterally to both sides to provide an opening as large as the skin incision.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A transverse superficial incision is made through the visceral peritoneum 1 cm above the superior aspect of the bladder. The peritoneum with the bladder is reflected inferiorly using fingers or a swab.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        A small transverse hysterotomy incision is made and extended laterally to both sides by pulling with the fingers.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The hysterotomy incision is closed with a one layer continuous locked stitch. A second layer is placed only if needed.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The visceral and parietal peritoneum are not reapproximated.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The fascia is reapproximated with a continuous running stitch.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        The skin is reapproximated with two or three mattress stitches.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    A key aspect of the Joel-Cohen approach is minimization of sharp dissection.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Holmgren, G, Sj&ouml;holm, L, Stark, M. The Misgav Ladach method for cesarean section: method description. Acta Obstet Gynecol Scand 1999; 78:615.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_33_9756=[""].join("\n");
var outline_f9_33_9756=null;
var title_f9_33_9757="Guidelines use dexrazoxane";
var content_f9_33_9757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F70814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F70814&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Guidelines for the use of dexrazoxane as a cardioprotectant",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Breast cancer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Initial use in patients with metastatic breast cancer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       It is recommended that dexrazoxane not routinely be used for patients with metastatic breast cancer who receive initial doxorubicin-based chemotherapy.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Delayed use in patients with metastatic breast cancer who have received &ge;300 mg/m2 of doxorubicin",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       It is suggested that the use of dexrazoxane be considered for patients with metastatic breast cancer who have received &ge;300 mg/m2 of doxorubicin in the metastatic setting and who may benefit from continued doxorubicin-containing therapy. Management of patients who have received &ge;300 mg/m2 in the adjuvant setting and are now initiating doxorubicin-based chemotherapy in the metastatic setting should be individualized, with consideration given to the potential for dexrazoxane to decrease response rates, as well as the decreased risk of cardiac toxicity, and the fact that these patients were not included in the clinical trials of dexrazoxane.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Use in patients receiving adjuvant chemotherapy for breast cancer",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       The use of dexrazoxane in the adjuvant setting is not suggested outside of a clinical trial.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Other malignancies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Use in adult patients with other malignancies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       The use of dexrazoxane can be considered in adult patients who have received &ge;300 mg/m2 of doxorubicin-based therapy. Caution should be exercised in the use of dexrazoxane in settings in which doxorubicin-based therapy has been shown to improve survival.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle2_single\">",
"       Use in pediatric malignancies",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"indent1\">",
"       There is insufficient evidence to make a recommendation for use of dexrazoxane in the treatment of pediatric malignancies.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Use in patients receiving other anthracyclines",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       On the basis of the available data and extrapolations from the experience with doxorubicin plus dexrazoxane, the use of dexrazoxane may be considered for patients responding to anthracycline-based chemotherapy for advanced breast cancer, and for whom continued epirubicin therapy is clinically indicated. Data for using dexrazoxane with epirubicin for treatment of other cancers are limited. Data are insufficient to make a recommendation regarding the use of dexrazoxane with other potentially cardiotoxic agents.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Use in patients with cardiac risk factors",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       There is insufficient evidence on which to base a recommendation for the use of dexrazoxane in patients with cardiac risk factors or underlying cardiac disease.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Dose of dexrazoxane",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       It is suggested that patients who are being treated with dexrazoxane receive dexrazoxane at a ratio of 10:1 with the doxorubicin dose, administered via slow IV push or short IV infusion 15 to 30 minutes before doxorubicin or epirubicin administration. A ratio of 10:1 with the epirubicin dose may be reasonable. However, it should be noted that the optimal dose ratio has not been determined.",
"      </td>",
"     </tr>",
"     <tr>",
"      <td class=\"subtitle1_single\">",
"       Monitoring during therapy",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Patients who receive dexrazoxane should continue to undergo cardiac monitoring. After cumulative doxorubicin doses of 400 mg/m2, cardiac monitoring should be frequent. The Panel suggests repeating the monitoring study after a cumulative dose of 500 mg/m2 is reached and subsequently after every 50 mg/m2 of doxorubicin. The Panel recommends that the termination of dexrazoxane/doxorubicin therapy be strongly considered in patients who develop a decline in left ventricular ejection fraction to below institutional normal limits or who develop clinical heart failure.",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Data from Schucter, LM, Hensley, LM, Mreopol, NJ, et al. J Clin Oncol 2002; 20:2895.",
"     <br>",
"      Updated in Hensley, LM, Hagerty, KL, Kewalramani, T, et al. J Clin Oncol 2008; 27:127.",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_33_9757=[""].join("\n");
var outline_f9_33_9757=null;
var title_f9_33_9758="PCI related delay and death, MI, and stroke";
var content_f9_33_9758=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F80787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F80787&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 584px\">",
"   <div class=\"ttl\">",
"    Absolute risk reduction in the 4- to 6-week combined end point of death, reinfarction, or stroke with primary PCI as a function of PCI-related time delay",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 564px; height: 350px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Circle sizes reflect the sample size of the individual study. Values &gt;0 represent benefit and values &lt;0 represent harm.",
"    <div class=\"footnotes\">",
"     MI: myocardial infarction.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Nallamothu BK, Bates ER. Percutaneous coronary intervention versus fibrinolytic therapy in acute myocardial infarction: is timing (almost) everything? Am J Cardiol 2003; 92:824. Copyright &copy; 2003 Excerpta Media.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_33_9758=[""].join("\n");
var outline_f9_33_9758=null;
var title_f9_33_9759="Chronic pancreatitis ERCP child";
var content_f9_33_9759=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F64898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F64898&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Endoscopic retrograde cholangiopancreatography (ERCP) showing chronic pancreatitis in a child",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 248px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAD4AWgDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD1vYScAmp7e0YnMmQPfvWhFbrEST8znvUjdeeaAFt3AQQtzHjg96hnt2RyM5B6U/OMZOKsowaIluSlAFGeMIgXd9arthV3P8voPWlu7nk4+961k3EjNuyxOe9AEl3qDcrEce/eseTez5ZmJ9c1aZepNRsvPWgCsQSfvHP1pp69TmpmXB/lUbDFADPu88nNRSsRkA1KxJ4Az2qWOzJC7+KAMryzIcKWz9aljsHkyFLZrpbawiSIM+AD+tTZSMbYwPrQBwWu6ZdFcpnCjjB5qz4Rhngi8uUtljnLV0GoLIHPy/L1pbOJfLJJw46UAdTpqRLbL82WHXmnT3AwQvBHTNU9HhMy7ycY4AzWhLasy9ASKAKj3TA/fxUT3R6iQk/SrBt2OVI/SqMtu6seuKALVpcyeaMkkGi9upAdoz061XiVg2ec59aLmPccuQfXmgBn2l8ry2T71bhmckA59ahtrdD/ABA47VrqkcSDPLelAGLqc5KkDj3rnblTJuLE4rq9ZSJ4QwwDXOiLzYSqgdaAOB1q3xKwViBnoDXPXsEqN+7J/A16FqWmncXlAA+tZsGkJcSKMHAPPvQBS8OwSBA0m4n3rrbCFt3AIJ96jtbFYCuB14rvNF0iFII5SuXxnJoAk8N6aY1MkgwSOAetdNDAoHNRWyhFpXnIO0UAPuEJQgdKyp41VTkVpCUFfmPNZmo3axoc9KAOY1WcLJsESsD3Nchqeli6LNG21xzgd66nVpLd4XZQ6v0B7Zrz7U7nVIpysOXQd1H86AOV8S2n2JJJZnY84GD3rg5ruVpCS7fnXYeKJZmhZZcgMcnPY1xMhIJ70AP+0SA/fb86abpweWbH1quz8dKjPztwTQBpRXbHqzfnU6yswBEjfnWVt2Ec5qxE/QjNAGks0gPDN+dXYbiQIWLnAODzzWZG6sRuGD6iptjAE9R6igDQt7tjcLktyw5BoqhZy7btNx43CigD69OQSe1MPqRUp4znpVeaQMcbgPQUARSyhTx1pyz5s5T0+tUpmZWIYGpJyV00cHLGgDLmcsTzxUT9DgVI2c8HigjI6UAQ7eeelQOPmyatEdSPSiO2Z+owKAKeC2B+VL9lZ+W4FaiW6oPU09k9T2oAz4rZExtGW681cgtjI3XkDNKQvRQSasQJ5YzIcUARXPyhQPSqyqMls9KddXUZc7mAUVWF1CzhS+B6CgC2yq6AyD6VEIo0YkDBNNmu4gmS+BSC4ikBw3WgDV0yTybcgHPcfSrIvSejc+lZulkkygDgDilGGfgEUAajXAeMNk56HFUJ3Jb1BqzDGBByTyagu48A4PvQBCjHf6CluCcg44pltywGRUt2jKFbPWgBbVwJAwOaddyyGUgk9aS3XCgkfpUs67gHxmgCleOTEcnmqikLGduBmrbwlo5DjtzWDcSuMgMQPrQBLfeW0fzMPfJqtZSwISV+as+TqQe/XNWrZAkRIxjGelAFyxma7vwkKgYPfpXplgCIFUkHjtXlGkq32wbTg5xxXqen4gtlLNnigC9KwSM1zl/r0VpLtfJOecdq2pZVkQ4YYxXj/i/U/Iv2OCV3HNAHeN4ssQ2GLfWsnXvFFuiEwgyKfeuWtZbC9gDxA7m65PQ1wOs6j9n1CSJJGDq2AQeKAO/h8XRtKyXkA8gDJOeabd65p7xedb4H+yetef8A2jzkw5BJ64qpLLsUhDkCgDe8WXVnqliPKCmReWPevNLu2K7gp/A1sm+ZWZdvB75qhMRIxOcH3oAxWVlbDCmkDqOtajwBgc1Tltyu4rmgCKKTD4YZqwhB5AqmqkHJBzU0RxjOaALiMelWUkZB14PaobZAW3N0FTvh24xQBLaoJZ0HQlh9KKdYIfOT/eFFAH1bcXO5sEkDP5CqErksdrHGePWlYgk/WmbNzYoA0NNcTsEkGR3NaV5bwyRBDjHtWSskcNuURsuepHaqn7wthS3tzQBcl0vnMbZ9jVVrGbfjYfrV60WRE8ySRiueFq/DcBhg4BoAxVtViGX5NSrEWbPRR1rWeCOdxlfqRS3CxRW5DYCigDDYbnwnaopCkK5lbn0plzfohKwD/gVZE7tKdzMSSaALwugckdB6VS1DUW4RDjPFSRRNsIAxmqUlsqSl5X4zQBRuJC0uWboaWPO4OWwo702eSNZGKJuPqarTzlhzx7CgC/POrITvBqSN+FYEj3Nc1NcOH/dtgg1tafdefGqy4EnqOhoA7XQMvZyH16E1bjtsMc45qppp8u0RQMA1Pvc8g4FAFqXCqEBziqb43YpA7F/WiUMwBx+dADbaJftiZ6E1oXkS/ZgepDelUbcMJwT0rQucm2bPegCiGAO0DiniYR8H5gahCkE4NRSRuQOKALLyo6OANoIxxXI3ilJWA6A10YjcA8Vz9/8A69sHp1oAxby6S3fG3dJQuoSOoUgD6Vk6gzfb33cimpNh8cigDsfD8bPMJDwAciuzlmdLdQW69RXCeHrsoEJPHoa6x7yOXaWIAX3oAjvdSks4GkR/qDXifjTXJbnUHTpEDnpXreslbmJghA4xXnfiPRI2hMjIFfs1AHL6Z4h+wRvGCQGHWudurzzrpnOWZjnNTX1iySsBmqcFpIJM7SaANGxnYscZyelLqUzkhVyuOpzUEStHKASRSak7F9xxg+lAFQylCQ4yDQGVuQc+1QOdwqudyk4P60AXWbHSiQgj1qilx/eJqYSAj5TQAuFdSCMmmCHbyMmlQ5Y4qzGRQAyPOcZ4q2iFcGkWEMeMg+orUit45LVSWAlHGD3oAZpqBpk/3hRVmzh2TL9RRQB9GfLk8HrTXb04HoKcBubAySTVuG2CckZagCrFAW5bgH9atrEFGAOlWNmKaRnkUAQnI4J4pYkZnAUmpRCznngVNDPaWr4kkG6gB8s62cO6Q1lTX4u8gjA9Kh1e4W5uWKMTGOFzWcwwOCaAJ7qBdpZOtZfIfBFWzclAAxzmnYR1zQBCzMkWScVjTEybtze/WtS8fEeF6dKx55VUYoArE7W5qvcMADtBz7Uk7sxyDx9aYrE/cGTQBWddyZHBq5piO00fOMU9YsxsSM/hT9KcfaB7etAHd2N5EsCLIo3KOvrVk3ikcAY+lUNKs2niDMVVT3J61pjT8DqDQBUa4YNkHioZrsnqx/OrsliNpBIH41QntkDduKAI1uzuzubP1qzLfkx4xnPqar+QgPQDNStHGFA7UAV1vCwoEkr/ADKcCpVEHoea1IBAIwAgwB3oAxpZ5QuN5GaxNRk8sk966m4uYBwsaknviuQ1qFpZWYcR5oA5jUZA0pIbk+1Vl3HB/SrJhE11sUrge9TTWZibPQdjQBc0y4YKOCDW9HcGSPDNjtWHZuFAHX3xWrGUfGQB70ATKz5CnJUdzVDX4pLi3AUA4HStJUwvyMMe9VZvMDjeD1444oA4iTTzKrI0Y49apy6YYImZVyPUV6MsULqwKjJ4ziqkulqQ3lc8dDQB5LIm2Yl/yqtdQeYuU6V2/iHQmaMyohBHXFcdMjQkqw49KAMSSMxk561XY57VqXQyNwH1rKuFIORQBXdcn0pqsUzzSs9MbJzQBbgk3N1FX4lBI5H41jRttcVq2r5AzQBp26EtnNaltFuYbhwfWqdnGSMg/hWxbDGCetADxaPFIh6rkGittdjQxHI3A4NFAHt0MYQHjn1qXGBxxSAHvUmAMFjz6UAIBkc0jOqDoCaSSUKPSqU0hycHrQAl9duy4U4+lZe4lvmOSanlPvzVZuGyKAFzTXOTimk0wnnHagCG4GZB7VH5ojXriiWTBJY1kXNw7ybQDj2oAmurvecA4qhsZyQvJq5bWTSuGkJA9K0GtlQcLigDHW0/56kdOQKXYFBCLgVoyQjBNQNDsUnHHtQA1Y18jPc1VsIWS5zjPPFWyfMAHTHWr1kkUXzEbmHrQB0GmuRbqG4I6VcF0Vzk5rOtrlWIG3AxwaWZtrHByPWgC7POrJuXr3rKuZgTmrEL/JIT07Vm3gkIyqnB70AK1x836VoIy+SQOQUzmubSTMg8yQIScYzk1rJfQQWjHIJVTyTQAxpWGc9BSXOpLDbOzMWPHArjLzxJJPcYT7hyAKj+2STLIshzuXGKANHU/FPkodiAe4Nc+2vTXgJlfEZ4OTwKw9SSRtwBPFc/eXMyRckgdBigDqIJ4TucTsGJ6irq6t5WFNxvX0YVxEE8iqFTntgU27unjwG4J7ZoA9U0+6ilAO5Vz6mtJcggH8K8gs9bWA5MjH2Brp9L8ZogVJvnj9CeRQB6AjkthiAB0qx5zYAPP4ZrC07WrG8wUuEB/usea3bZo5CMOp/GgB4EchB+6f0qGZ2hbIyw7kVeMaAcsvFV5VXqCPwNAEQkinUq2CD1BrhfF+jLDK0sCDY3Nds0I3crz6iqeqW5MW1/nU9PagDx6cbGwaz7qHcGKd66jxJp5t2LKmVNcw74J54oAxJAVYg5BoXkHmr1zEJRkdRVTZj696AHwplu1aEC7cVTgQ7hWjEBQBoWcxVgCa37WVXAGcGubhTkVq2mVIzQB0Vq+HVWx1oqvaSAum4dxiigD6JA+UkGmSNtGaVmCdevpVK4mLcA0AE0ucjPWq75K5zzQB70NgLQBDIO/wCdV3APGKnfrWhpulNcMHlyE649aAMdLeSU7UVmPtU7aReFCwjP0zzXaW9pHCoVEA+gqbZQB5dNY3Ycq1vJn3BojskiP7xCGx1Ir05kGOlZ+oWMU0Z+QbvWgDg2h24YHjNSMV2ZkOMVl+JdUGj3LQyDLE/KM1zkN/cXt8BLIRGegBoA6K4vYUk5OQO1UbjWbcZAJBHeszUpEtmKk9eetctqWpw4bb8zA+tAHYRa1bCQAygE+tbun3kc4XBUg9wa8WbUHcsqnGBxgVJp+p3ETDypGVyfXrQB9C6dCJEJVhgds1N5PzYdsd65/wAHaoi6SjXH+sxzj1rRbV493mAZUnrQBrfZ1WIhWHrg1k6nOfskkRYKoGR7Uy81FZAQjHOM4FcL4h1u43PGxIjH50AZevX9wkpFrleuWzzS6fqMh0qUbsuFYHJ7kVAszXEZZseoFNcYRlRcKRknFACWMPl7GlIPtmrkcwWUsrdD2rCnuZkAVW/+vU+h295fz7IIZJHz1Hb8aAOinsLa8XejLlhkgnvXH+LbCGzs1fzAzA52Lir2rreafcNDPlHH909K5vU0lkgeRyWGMZ70AcvLrsi/8e/ynoD6VTP2q5jMpkY4OSKZcQBCGJ5ycirVkgEagv8AKxzgUAMgLnr1rRsxKWHUmrBtfMj/AHcZJyMYrptF8PmWxE0gYPnAHegDDV57dhuVkz0rVttbuY+RNICOmDUmvKbcrA/OAME9awnZl6UAdnZeN5osCfLitez8RQXhHlzYY/wk4ryt5PmzToZWVsqSCOlAHuFhrSghJssPU1qmSK5j+U59K8a0vX54AqzfvE9+tdjpOrLMu6GQsp6qeooAu67pplDdvpXnuraW8DMVXpzxXpM8rOoO/wDGuc1RkWcCUjYepoA4IpgdKqumCTW9e2aiRjGRjPasy4gbn5TQBXj4OBV2FSRzTrXTbiVVeOJmU9MVvafo9zKyQpau0rHoBQBnWqktyK1IFI5xXcWHgKVbXdOyeeRnYO1c/qGnG0Zl7qcEUAUoGxIg96KfCpEi59RRQB9AXErMW5qDOBzW0dNQk4B601tKDHqRQBjHr70jMQDWnJpUgJKnNVhYTG4VWHB6n0oAfpdkbiTe4yorpoYgigAUyzt1iiVQOlWgtADcUhqTFNIoAhbpVS8lSGJ3kYKqjJJ7ValO0EmvJviJ4lF8ZtK0+bB5VyO59KAOB+Ieuw6n4jleBgYk+RWHfFN0C9ijgd5WGUHH/wBauL1OCW0ujHKTvHWltZpBImwkj0zQB0mvajJNbyFSck4UCuOVnWU7yff2ruxp3naZ5o6nk1xOqRGOQqB0oAhuZo0hbyzuJ7jrUmiSk3SZ5NZsyuSABToDJDtcMQw7CgD2bTNRs7fS4klnXzz/AAjtWlaSrcKoRm2A9cda8i0ktdzgQuwlz0r0zTYJYLdQ5YEjucUAaOrX8WnQEquXPYmvPdX1d53LyPHyemecVua/BcyLI6ncQOB14rzm6srlpSZGf8RQB6H4PkS7jkZpVyDgA1e1qSEwPHbsQ+DkiuL0fdY6ezrI/mk4x6133hnRm1HTo55c/N60AeVXlzIkhBeTIPc1678OYTbaJFPlj5nzE9+az/FfgVHtnmgiIlH61f8AB+m6pBpaWz8RpwPUCgDmPFYE15czRBid3Gec1xl3cM0JCqQ+a9xm8IL9mkZpCxfJ5xmub8OeAojez3NzMkwjJAjx3oA8PvbaaRiShGeenFU7KJ0ukDZABxX0dc6JbEbJIUGDgDZ2rLufhjp1/O9xYSSxY5KHpmgDkNK8i1tBNJGCy84Falhr6S2jJawAEOSGPatjXfC9za6DJCtokkg6Sq3IH0qj4A0KKXT5Be28gk38hgelAHM62l3dTRvJGXZjxtHGKqapYzmJJBZtEMYbA4r1e6sYkuI4RCAoPygCtQ6XGbQtLCMMOhoA+eJLds9OarjKOeM12njCyjsdTYQqoRhuAHauOlBMrYBFAD4n5x0rT0+6kgkDRsQfUVkKpHrVmF8f/qoA9O8NXi38LrcYTA4YdCa5rxIkyak8LkFR90r3FVdAvJ1lEUCltxGfau8sNJea4MskQkJGcEUAebglOD0Fa9hdWsto1vcRhWPQ+tdnqOj2RyfKAOPmVh0rEnsLQDcVCgDg0AWvDNtaRSbTPx2U16D4Rs7WO5MrEFmGPpXjPlBbo+SxCg8HNb9pf3sWwpK2E5GKAPa9StkWJpIXwo55NeTeKwv9oHYR05HvU83ii/NsITyT3rFnaSdzJJ1J7+tADIl3Fc+ooqeBQNvuaKAPp4Q08RjHSrAUU7aKAKxiHpTVhXOcCrRHtQBQBCFxSkVIR7UmKAIzTG4FSt1qKTgUAcv491b+yPD9zOp/eEbU+pr5rg1aW31Hz2+di2TmvW/ivrUctz9hPKJ/OvGr23w7CLJbrk0AQ+IbpbzUmlXHI5FP0myklIkC/L60ado9xc3SAoShOT9K6uG22gLjCDgKKANDRQiRhJG3KeorK8VeH4x/pMIZkPoK7Hw7oQcrNJyp5CitbXLZI0jj2Ao3DKaAPBWtsyFQpA9T2q02jEQl3OF/vetenz/Dy6vZBNZBY435O/tVj/hXWprbmJ2ikXtg4NAHBeDbNoLiMwKpPJdyM5rtI70SAhgmQO61vaF4PnsLRkZFVyc5qS68PyQlpl2k/TpQBztxdTxt/qkMbDAO2sTT9DvNZuXFuyBVbB+Wt97i7USW91AGhGelbvgqFNPLFFzG7Fh6igDAtfBr205juWBcc/WuvsLJdO02OJd3LEjHaptbkDT+YpwwpJr79xHGwH3Qc+9AFm6t/tNkPnJwMc9a5a5vX069igAOxz1rfe9/fpGvC7cnisbU/IllBcgEHINAF59SmIb5RtHT3pLeVlnGVCiTk49ap3Go2lrZl5Dnb39ay01qN5YyM4+8MnjNAHavYq6+cQCR61XjLQhljx15rlLnxvDbcA7uxHaqyeN9NnuBDLP5TEZORx+dAHQXbtcyujf6vvjvWro9tFb22zaADzWNZ3NtdCN4ZAUJ7HrXQvlINy9AOMUAJ9mguZSXCqy9DTNThjEG0yg8dPWuX8T65/Z0aTs2wKecd65W58XLLEcXJcP3zjFAG5P4ct725M96ikDgD2rivFOiWNqZXt4xGV5GK77Qtd06WyTz5g7Y+tcX8RL+1kLpYnDMOQOlAHnE6hjmMZpYyFUBh3qEpNGx4PPtSo7BhmgDrPCYCeY3Rga7W11trZvmdQoHNcb4fuYDGdufNxjFV9btrpVaVyRHnoKAN/WfEsc94q78noStbS2ttfWEIk2h2OQRXlcKMX3DNdXpNxLHEjB2PPegDd1HRI7XDpkA9q37O0gt9IR5IwSw5OOa5mXU5JiombOOlWZNWnktlh3fKO1AFa4+S4bBBTPFRGQhlZ2OD0olcsOcVEuG684oAtI2ZFweMiikXKsmB3ooA+r8UEUo+tLigBhFGPWnUmKAGkU0in01qAIzVS9lEUEjt0VSatOa4X4qa4dH0NREw82dwgz6d6APOfFek3OqXz3IbCMc8ViSaB5UmZHzgA9f0rtdI1q0OlyXE7qNq8hq4bXPEi3Mg8oDZnGRQBZt8QEhF5xir+kWAvA5DYKdfese21K3ZfmYZx3q9ZXUkTs1u2A4xxQB6N4d8owpGpBZeK3o9CS4uknuTuVPup2z71heDdOmdIJXwq53e5rv1UAUAQrEFUADAoKCp8UmKAKskQI6VQmhHIxkGtYjioHTJOcUAcfqulo+8qoyRVbTIPKj2j+HiuuubcMpBFZL2yxFiOAe1AGLfW4kk3Fgo71gavrdnZSIkh3EcKBWxrV0I+OQa861O1F3qbK55U8kHtQBZ1HxXOWYWkJHGMmsr+1bydd0zYJ96ZeW/wBnBVFLVQcMjLkkH+VAGwRJNA4dizFc/jXL3V7dwIFR2UAnj0retwRGrPIeOcZqpqU9iz7XSQseSV6UAcvd6i86qCuH9ayJr79++4/w9a1PE7Q2KLLbR7g/IB7Vw9zeu8hfaFzxxQB1mjeKL/TZQYZzsBztJyK9P0z4oLJAouk2nHOOhrwWC42oQUOTjB9K0YptyYRue4zQB6b408X2+sWPlJwVOR9a8+lnlYDJ49apncTzmrUZBAGOKANjRNYmsD8pyp6irN3qYvHY5AJ9axdq8AZzU0UY5HrQBsWkquvlyAMPU1Uv7cKQ8eApOKqbjGw2GpGuGdQp7UAX9NP2RzI/THGK0bnUGvIDETgDpWDudgACcVZtY2zmgCxbxNuIPFa9opVcc1DaQjqw/GryLgdKAAnJqaFuQpqEA54qVV5GaALDj5eKbGhDH0FSRnj5utWoogVz1oAghcbl+tFL5e2YcdxRQB9YClpAaTPNAAetIetKT6UwmgAJpDSE0hNAEchxXinx1vM3Gn268kZc17PM2FNfOnxN1NbnxdcAtuSLEYoA56aeSXTRHnaOhA71mSwbIdyv06rWzo9n/aBlRDggZHvTv7J+yxTSz5JUdMcUAcmrzmb5cgZ611nhe6MV4gkBZR1zXKSTM87nPetLSbtxcIV4P0oA+lfCjb7dfTGR7V0orhfAl+DYRiUgPgZNdypyAe1ACkZwfSkIp2aYzDFADH6Gqsx2k88Ul3cCDLNwnr2rCv8AWoireTIrHpxQBpNcgEoDkiqlzMhUgnBrDtNUO5nlIAzge9Q32oeZISo4x2NAEesRLMjYIya5m308C6JkPf0rXkuctgE0yK4WSUpwcck0AZeoafE0Jn7D5W9q5g6clxccHpXfzSw/ZrkMEK4yK4W7vUt5T5agHPUUAXToyhNzlceorA1q3hhZOMenFPuNblf5Vxn35rKvp7iSNtzbu44oAxPFcOYIzH8yHtXnlwuJGBGOa7/VFuJbU7jwORXF3cBDE+/NAFWNMgkE8DJqWEHsce9IVIU9qfCCFFAGjbyBkAY8j0q9Gi/KFOayI91aFvJtOST70AXSvpSKxBIB5pwkBHBoUfMaADbuI7VMkRJoRSTzV61Uhh6UAMggJPStS3gCckVZggBGQKsBPlJx9RQBHFkLjFTqeOaRVH5U8+mOKABTU8ZBGDUO3B4oDFTQBYHDZ5q9A+F9M1mhySKsCTGOuKALEgzIuD3FFEXOMnvxRQB9UCj8aYDSjrQAH60hNBpKAEzTGNOJqGVwiFmIAHJJoAwvGesxaLod1dyMAVUhBnq3YV8rSyTX+oyTTMS8jliT7mu9+K/ieTWtUe1t2/0G3bAwfvH1riNNhJl8yQkKDkn2oA7XwtCtpiSd1BHGazvHviAKhtLSRX/vMlWNYmhl0cy2Ey4iXlR1PvXnanfc4c8k/WgBiyMEZ3Bya1PD84e7RNpYk9hWLfArMU3HA/WvZPg/4TgubL7fMNxIwMjpQBt6KJlhjeIFVUCvRvDmofb7LcR86Ha1UU0nypBhV8pRVdHl0i7RYYwYZPmYD170AdWWqNiM1Ekolj3qeDTQSPmY8UAJdRJPC0ciB0bgg1zF94fS3UNAP3eeh6iuvXB6Uk0YeMqRkEUAcC+mYi61QkscMcniuucbHKOg44rG1CdbeQqQBj2oAwmswCc547022tkCyMqncKS+1N/mKHgdzWFF4gmiuWBwUoA6K5sQbBj/ABMfzritQ04faGKx559av6z4hk+yt5bMqg4A9a4241V3csGOTx1oA2rHRRcXYUxcdeDV268ONIuI22AetZHh25na7LRsxOMYNdpBPB5ex/mYj5vagDkJ/D7rbOrAPlcZXnFeY6zpslveSI4xg19FR29qLKSeMcba828XaUt2rzQLl1+8PWgDyWW3IJAGRSRpg8CuiOkTMCVRj+FUptPliPzIfyoApRx5HSrCLxUkcRBwasLF09aAGRrkirCLg0IhBFWEjIwcdaAFjXkcVftwPxqvFHkirEXDUAbFswCCriAckVmW79BWrHIAAMDpQAjR7ce49Kd5QABapfMSQbSfpQFAHtQBEU5BHNN8v5eRVkjkYpCMdaAK4BXtTlODihn6ginRjIzigCeB/nUe9FMRcyrz0IooA+p0kBqXcK8e034sWjcXETBgccGtRvirpSR52Sk+mKAPTC1NLV45d/Gm0jJEOnyvjoWcCsO++M2ozBlsrOCHPdiWNAHu93dRW0TSTyLHGvJZjgCvIfiD8QVukk07Rn/dH5ZJwevsP8a851rxXrOunF9ds0fXYvCj8KyZZtg4oAlvvLjjO45Y8/Ssk3mzIJ3JjG0U7UnbC5bORzg1lE/Pk9KAO++GG2+1iW2aINCYjuU8iqnjrwdc6Pf+fZozWrkn5RnZXR/CKaxsoLiWV1W5c5XPUrXdXV3BrltNEoYAqVDf1oA+c7aCS8vkijVnd2CgYr6f8C2X9i6Fb2iqSyrk/WvPfh34GuINblur2P5YmPl5H3vevZHiEMIIABAoAHeZ1B4ALc/SsvxNqUNlavK6bti8EdRT7LUVvDNHE/Eb7cnjmnppK3DM1zJu3dsdqAOC0vWtQ1jWo7e1leKzUZeQdMntXpGn29xEhVpzJnoW7VWs9FtNPnfyIlRGO7AFbKYCjaOKAHpuVQDjNBajO6sjxDqYsLZioy5HHtQBmXl6z3rxj7pJwfSuO8X3UlsgcZxnBrQF4ZJUbcSTzWN4hlFzEyzOAOw9aAOXmvn8vdvyD1Gaxry/VXNVNQkaCWRI33H+EVz11cXLuBKrflQBvyahHIxjkYgdsmqZmiaXEZzk4qt/Zt3JCJghRCM896q28TpMctigD0XwjboDu4DAZqvcXksd6y/NjJFV/DV+yzRo+SuOo71q21j9q1GUMcYJAxQBr2zu2iDbuw7YqvaW0LqRMc56it54ks/D6b8Daa5BrtVutqvjNAGlbx2sVyYdi88dKraxodjOrrCnzN3qO+YmRNud2OTW9osSSxKSCSKAPKdf8Ptpx34+Q1iRwkt0r1/xXaJOPLZRXGz6ZFE+wrj3FAHOR25zyOKtrCAnzCtuPSt6kqwyOxqK4s3jVdy4FAGd9nxGGxxioVGGrpLmxK2KkDkjNYfk89OaAHwfeUVpkfKMdaisLYySqAK13s2RunNAFCMYGSKtCQYBxz3qdoNu3K81EVJfgUAKPmyVoCE53A5qZE24BqUDJ2kcmgDPkQbge9PAIHTirjW37zBU0G3IyDx6UAVoI2eQYGeaK0rRVjIz1yOlFAHl6XJSViCc5NXTdO6gljmslv8AWtj1NSpuB7mgCwTkkkmpIySvy8e9Q84zipI+RQBYR2GPmpsk+6TocAVGuQ+AKnyEyWUDI70AQbzJuDdMcUxYgSGBBx1FSnZIDtIzVdlCZ+cCgDqr77NYaXZXFpODKMMwHY9xXcfD27+2X6Q7ziTBzmvGpZHkQLu3AdBXUeEL660vZcQMSVPHtQB9TwQpHEFUAYGKoatcJDGUkbbuGB7mvOvC/wAQri9vvsdxjPZjxXZ28i6kWFxg7W+X296AMSEOl15aAsCeMCu3sIm8ld+c4qpY6ZDFkyAM3Zq0llSJcZ6cUANuoiy5XqOa53VfE9jpTlLuULIP4eprpJ5gsDOvOBmvJviJo7apNDdWR2yMcOPWgDsLfxQLy1eW0X93nAY96pzs+oQ7nJPPINcjafaNJs0hlB2qO3eqmo+I7m3hHlnaSc/hQB0Ep+zCVgOg4zXAeItWZ5WDDGM9KytV8UX6Xe4ysyk8r2qreXBvYyzqBkdaAMt79ftDbsHPGTWlos0dxcRrIikbgCK56WBhLgrirujRzJfxhO9AHSa1qgeO6RUUNC+3gcbe1cS8zNOST0NdQqZ1eaOUfJNlD+Pesq40h4b5ogO/pQBY0ud4wCCe3NegaDfQTosjnbKO4HUVy0GjMunkYLSYGBU9qW060/fgj5sUAd1reoWs+ltDEru31ryy71p7aZ18kLIDjntXWaXqUN1OsagZ6c1Z1HwkmqTGTygMHkj0oAwdA1Ga+cBmB9eOleiWdvHDZBw5U+orFPhBLKwCWTESHkmprW/W0thaXhL443dxQBcvdOa6j3GeuF1GNoblkdt2CQDXVahqDRW5EDBgenNcjfmQqZHByD3oAnsZwB8/Sre9ZnCAjHpWC1wAgx3qaynxJuLc0AdddmBbLaQCQMVjixgkTdgiq89w8sYBJxmrdmWlKItAG94a0WBt0zZIHStafSYH6ZWnaavkWqqvepbi4ZRwKAKR0WEt8sgB96qT6LAuf3vPsKuG4bf04qvI7SyYAOO1AEf9mWyxqwdiehpLiCyhjD7TkHqTT5GCRsrDjGetZt0DNFgcKP1oAtPLE8ZZVXp19Kx7qUtLwelIrNGdu7jvUUxG4k9fWgB0UreYBnvRVXzQGXHBzRQB50wxK31NWEcAVEw/etkdzUoXPagBysc4FSgYAJNQb9tMeUnIoAtG6CNhahmuTJnJqsM0hAxQBNHIc8HApJiGPWogaTPOKAHI2w5Fb+jajHDCyt970J61gtC/lF8HbnBOKiQ8jB6UAeyeDNGj+122o3B+R+VWvWBJAqlbf/WlcADvXzho/i670+KOBcNEnQN2rfj8ZXzazaXkEnAwGT+HHvQB6dq+palHZMLK5ZZIyOG746iug0e9e7sIZpGDMRng5qhK1nf2CyMFMrLuIFSeGTBaMLaNVCOSQM9DQBvb2Ns+eMqcA15bo2vBbu4iv2/1TkBW7c169NCjxFenFeWfEnw0jr9ssAI7vP3xxu+tAF3VTDeWuIWBJ54PWuL1G2DQvv8AvKcc9q4+bWtQs9yid0Zcgrmucur+8upGeSWQkn+8aAN3UIbZ5tjyEHqcDpVmKezVFQM54wOK5+0glaEyFmzUNxK6PjcaANm9mg+8q59M0aVqCQXO4oCVUnpWC88r9Txip7API8iKCSwwKANafXT5m9I13Zz0rQvdWdlhuo0jywyc1h2+jT3DH+EAc57UXm20AQ4ZQML6UAdFYeJbmV1QmNMHj5a6Ca9tZ4lW/g8wnuvFeawM5cNHwSa9O0PTvt1lDzlsdKAINLsrOa9LRwyxhOmGrrra/uLVQohJXoS3XFZQlhs9RggYKp7+9auuataWUJVSpZhwBQBtQ6lZGJVZlEjfwk1i6vbabcMd3ykc5U15tD4iS5vn+1Zj28A5q3HrlubtGSQ7R1yetAFnW5ILJ9kG9vQnpWXqV6txahFUiRqu6jc293JuBG31FNtrKCZhkZ560Ac+kbNGowcg4NTxx7H711P9nwKwjVakbR41JbbnvQBgwkvtU5xXQ6PEgkX5l+uazZrbbkcKPaoYX8qQlHJoA9GheMjAYYAprMrMw6iuSs9QKcuxrQs9SVt/IB9M0AW7txHkAiqr3ZCjA/EVnXl7tnLhs/0rPl1EfNyDQBpXF2wALt3zVM3eSwB6nrWdNdeZxn5aoSSsknB4oA2nlJyxwcdaqy3PIwapx3fynJqF5twz3oAuGTdKpB7iiqUc2ZV+oooA5ZyfNbHqakDiopP9a31NFAAzZc1GW+Y80P60z+VADifejPXmmCloAfmlB5BHWogTmp4lyRQBt2Fzavp8kN1kSY+XHesJtquSvTPepLgqkfB+aqsU6OQJOvrQA6SXJxnFaOk34hBR/mDdPas++WKMBom4I5zVeKZV780Ael2HjGfTIAit5oxgA+lS2fj+6gvRcCFSV/hLcV50tzvZSc+mKtomcFTQB7ZoXxTvNRvYraW0ijMnAYNwK2NR1RruxmSVsuPmArwyxv0tby2dx9xgTiuvfxRDbXETPL5kTdgc8UAcze2t/qWpSN9mkLyOeiYFasPhOdJESaPYwG4g12un+Io9QAWyjVY4xk8YyavwGSZlnuFUHpx6UAcZY+HttqVc85PAFYOqeHvLlcksFA64616hZyo+9NoDA556GuV8cXphUCEIWzkkUAefT6aYsEscVWRmjlxECpHcmm3NzK7tukYg9s1U3lmPJ/OgDrrfUP8AR32BVkddrZPBqsscN4hjkdd31/lXPqxB5NWYXKEMuc0AdbougJ56RvhgxxnNeweFvDyWuw5G0DnmvJPCV1LNewox4BBNezwX6QabvUgY460AZPjbQtPY+fvaOYKcMvWvGfET3ljG0iXHnRBurD5h6V6zqGox6pIbcSKcDNeQ+NZFN21tESABhvrQBzz3fnHfJgP1OO9Pgnxk7qyH3ISD2709ZT0z+tAG4l66j5HNaenarIhAZiRXLRycnBqxFLjFAHpelamk0qbsntXSORztJxivJrG7khdWRuc13FvqRnt1Qn5sZNAD9Xbacr/OshJDzn1qW+uAzgE81SkcdaAH3N2ynap6elJb3rK55rPmb5sk1GGy3DUAbrXBeJuRzWY7ncetJE5wOc4pJm596AF83GQTUUkpIOaiLYJOeajL55oAf5hB609ZSR1qqze9KjUAXI2/eJz3FFV4m/ep9RRQBmSxv5j/ACN1PamFHx91vyoooAa0b/3G/KozG/8Acb8qKKAFET5+635UrRPk/I35UUUANET5+435VMiuo+63X0oooAq3u/B+Vvyqid4xhGz9KKKAHlZWjztc49qiEchI+R8fSiigC5EjAD5Hz9KtwNKCfkPPtRRQBYELNl2Vs/SkYcj5GOPaiigDsPC18Fg8tUZWDAEY6iu+E7lIwCdpHpRRQBUlMiFzGDyetcz4uhkGGKNh0yeO9FFAHnksbhmBRsfSoxEQc7Gz9KKKAE2ybuEb8qkUSjGEb8qKKAOn8Leek6tsbOcdK9F8Rap9i0WONBmR1GRRRQBxukasDfqyq4Y9Rg1x+u3Ly6ncvtblzjiiigDJdXwcxtn6VDtbP+rb8qKKAHxxvydjflVhI3wCEb8qKKANKzVldcoxH0ro4mZF3BWGBxxRRQBVnlZp/utnvxTWd2zhT+VFFAFOTzcn5W/KowX/ALrZ+lFFAE1vI6nlWx9KsSBnG4BvyoooAqMHycq2fpRtb+635UUUABRj/C35UgVx/C35UUUAWLaNvNT5G6jtRRRQB//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Severe pancreatic duct changes with dilation of the main pancreatic duct and of the primary and secondary branches.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: ERCP in Paediatric Practice: Diagnosis and Treatment, Isis Medical Media LTD, Oxford University Press, UK 1997. Copyright &copy; 1997 Oxford University Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f9_33_9759=[""].join("\n");
var outline_f9_33_9759=null;
